SVM-light Version V5.01-TK-1.5
5 # kernel type
3 # kernel parameter -d 
1 # kernel parameter -g 
1 # kernel parameter -s 
1 # kernel parameter -r 
empty# kernel parameter -u 
0.4 # kernel parameter -L 
1 # kernel parameter -T 
S # kernel parameter -C 
1 # kernel parameter -F 
0 # kernel parameter -S 
0.400000 # kernel parameter -M 
3 # kernel parameter -N 
S # kernel parameter -V 
S # kernel parameter -W 
0 # kernel parameter -U 
4253 # highest feature index 
560 # number of training documents 
362 # number of support vectors plus 1 
0.99961707 # threshold b, each following line is a SV (starting with alpha*y)
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (BACKGROUND)))(CC (&))(NP (NNS (AIMS))))(: (:))(S (NP (NP (NN (Androgen))(NN (effect))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(VP (VBP (remain))(SBAR (S (NP (JJ (controversial))(NN (androgen))(NN (ablation))(NN (therapy))(NN (treat))(NNP (HCC)))(ADVP (RB (also)))(VP (VBP (lead))(NP (JJ (inconsistent))(NN (result))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 86:D01.268.556.435 104:C04.557.470.200.025.255 891:D27.505.696.399.472.161 892:D27.505.696.399.472.161  |ES| 5:1 10:1 14:1 19:1 75:1 91:1 101:1 104:1 130:1 254:1 303:1 304:1 441:1 1046:1 1090:1 1777:1 1778:1 1852:1 2181:1 3153:1 3154:1 3155:1  |EV| 
-2.208185055207550817613082472235  |BT| (NP (NP (JJ (Desmoplakin))(NN (act))(NN (tumor))(NN (suppressor))(NN (inhibition))(NN (Wnt/beta-catenin))(NN (signaling))(NN (pathway))(JJ (human))(NN (lung))(NN (cancer)))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249 975:D12.776.220.790.500  |ES| 7:1 18:1 19:1 36:1 103:1 195:1 246:1 302:1 328:1 383:1 700:1 3438:1  |EV| 
-4.1931826621266736765392124652863  |BT| (S (NP (DT (The))(JJ (monoclonal))(NN (antibody))(NN (CH12)))(VP (VBZ (augments))(NP (NP (JJ (5-fluorouracil-induced))(NN (growth))(NN (suppression))(JJ (hepatocellular))(NN (carcinoma))(NN (xenograft)))(VP (VBG (expressing))(NP (JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor))(NN (variant))(CD (III))))))) |ET|  |BS| 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 1094:D12.776.124.125.900 1095:A10.272.497  |ES| 19:1 102:1 184:1 185:1 186:1 265:1 303:1 304:1 691:1 810:1 990:1 1365:1 2281:1 2453:1 2611:1 3815:1 3816:1 3817:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(VP (VBP (result))(VP (VBP (provide))(NP (JJ (direct))(NN (evidence))(JJ (decorin-mediated))(NN (inhibition))(JJ (colorectal))(NN (cancer))(NN (growth))(NN (migration))(NN (interaction))(NN (stabilization))(NN (E-cadherin)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625  |ES| 2:1 17:1 18:1 19:1 38:1 101:1 102:1 103:1 514:1 618:1 711:1 1537:1 1538:1 1891:1 2267:1 3785:1 3786:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NP (NN (Dehydroepiandrosterone)))(PRN (-LRB- (-LRB-))(NP (NN (DHEA)))(-RRB- (-RRB-))))(, (,))(NP (JJ (major))(NN (precursor))(NN (androgen))(NN (estrogen)))(, (,)))(NP (NP (JJ (several))(JJ (beneficial))(NN (effect))(JJ (immune))(NN (system)))(, (,))(NP (NN (memory))(NN (function)))(, (,))(S (VP (VBG (modulating))(NP (NP (NN (effect))(NN (diabetes)))(, (,))(NP (NN (obesity)))(, (,))(NP (NN (chemical))(NN (carcinogenesis)))))))) |ET|  |BS| 33:C04.697.098 564:C18.654.726.500 726:C18.452.394.750 740:D04.808.054.079.429.625 889:D27.505.696.399.472.277 892:D27.505.696.399.472.161 899:F02.463.425.540 900:A15.382  |ES| 2:1 10:1 14:1 19:1 33:1 75:1 207:1 262:1 462:1 593:1 984:1 2009:1 2010:1 2124:1 2435:1 2633:1 3154:1 3166:1 3167:1 3168:1 3169:1 3170:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (BACKGROUND/AIMS)))(: (:))(NP (NP (JJ (Several))(NN (study)))(VP (VBD (reported))(NP (NP (NP (NP (NP (NN (efficacy))(NN (combination))(NN (therapy))(NN (interferon)))(PRN (-LRB- (-LRB-))(NP (NN (IFN)))(-RRB- (-RRB-))))(NN (alpha))(NN (5-fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))) |ET|  |BS| 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 617:D12.644.276.374.440 618:E02.186  |ES| 10:1 14:1 19:1 104:1 130:1 131:1 303:1 304:1 441:1 530:1 993:1 1836:1 2302:1 2303:1 2304:1 2305:1 2306:1 2307:1 2308:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (BACKGROUND/AIMS)))(: (:))(NP (NP (DT (The))(NN (success))(NN (sorafenib))(NN (treatment)))(VP (VBD (advanced))(SBAR (S (NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(VP (VBD (focused))(NP (NN (interest))(NN (role))(NN (Ras))(NN (signaling))(NN (malignancy)))))))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 52:E02 69:G02.111.087.800 104:C04.557.470.200.025.255  |ES| 10:1 14:1 19:1 31:1 49:1 104:1 195:1 303:1 304:1 441:1 546:1 691:1 997:1 1775:1 2063:1 2302:1 2309:1 2310:1 2311:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(NP (NP (NNP (Magnolol))(, (,))(NN (plant))(NN (lignan)))(NP (VBN (isolated))(NN (bark))(NN (seed))(NN (cone))(NN (Magnolia))(NN (officinalis)))(, (,))(VP (VBN (shown))(NP (JJ (chemopreventive))(NN (effect))(JJ (chemically-induced))(NN (skin))(NN (cancer))(NN (development)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 328:B01.650 619:D02.455.426.559.847.117.159.205 620:B01.650.940.800.575.100.680.500 621:D02.455.426.559.389.140.450 622:A08.675.650.850.625.670.100 623:A08.186.211.730.885.287.500 624:D27.505.696.706.018 625:A06.407.071.140 626:A05.810.453.324 627:A18.024.500.750  |ES| 2:1 18:1 19:1 35:1 75:1 104:1 237:1 1046:1 1098:1 1653:1 1946:1 2233:1 2312:1 2313:1 2314:1 2315:1 2316:1 2317:1 2318:1 2319:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NNP (Brucine))(NN (alkaloid))(VBN (derived))(NN (seed))(NNS (Strychnos)))(NP (JJ (nux-vomica))(NNP (Linn))))) |ET|  |BS| 52:E02 104:C04.557.470.200.025.255 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 629:E02.190.488 630:Z01.252.474.164 631:D03.132  |ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 1721:1 2315:1 2320:1 2321:1 2322:1 2323:1 2324:1 2325:1 2326:1 2327:1 2328:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (S (NP (NP (NP (JJ (Caffeic))(NN (acid))(NN (phenethyl))(NN (ester)))(PRN (-LRB- (-LRB-))(NP (NN (CAPE)))(-RRB- (-RRB-))))(, (,))(NP (JJ (natural))(NN (component)))(NP (NN (propolis)))(, (,)))(VP (VBP (show))(S (NP (JJ (anticarcinogenic))(NN (property)))(VP (NP (VBN (modified))(JJ (resistant))(NN (hepatocyte))(NN (model)))(S (NP (VBN (administered))(NN (initiation))(NN (promotion))(NN (hepatocarcinogenesis))(NN (process))))))))(: (;))(RB (however))(, (,))(NP (NP (NN (information))(NN (mechanism)))(VP (VBG (underlying))(S (NP (NN (chemoprotection)))(ADJP (VBN (limited))))))) |ET|  |BS| 262:A11.436.348 632:D05.750.078.840.762  |ES| 2:1 10:1 14:1 19:1 72:1 162:1 217:1 333:1 427:1 429:1 435:1 637:1 638:1 841:1 900:1 1021:1 1275:1 1387:1 1909:1 2131:1 2329:1 2330:1 2331:1 2332:1 2333:1 2334:1 2335:1 2336:1 2337:1 2338:1 2339:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Elevated))(NN (expression))(JJ (coactivator-associated))(NN (arginine))(NN (methyltransferase))(CD (1)))(VP (VBN (associated))(NP (JJ (early))(NN (hepatocarcinogenesis))))) |ET| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NP (NP (NN (dioscin))(NN (show))(JJ (excellent))(JJ (protective))(NN (effect)))(JJ (ethanol-induced))(NN (liver))(NN (injury)))(S (VP (VBG (ameliorating))(NP (NP (JJ (ethanol-induced))(JJ (oxidative))(NN (stress)))(, (,))(NP (JJ (mitochondrial))(NN (function)))(, (,)))(NP (NP (JJ (inflammatory))(NP (NN (cytokine)))(NN (production)))(, (,))(NP (NN (apoptosis))(NN (liver))(NN (steatosis)))(, (,))))))(VP (VBD (developed))(NP (JJ (new))(NN (drug))(NN (treatment))(JJ (ethanol-induced))(NN (liver))(NN (injury))(NN (future))))) |ET|  |BS| 39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241  |ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1  |EV| 
-0.021324114977858243946684524416924  |BT| (S (NP (VBN (Increased))(NN (expression))(NN (cyclooxygenase-2))(NN (protein))(NN (rat))(NN (hepatocarcinogenesis)))(VP (VBD (caused))(ADJP (ADJP (JJ (choline-deficient)))(, (,))(NP (NP (NN (L-amino))(JJ (acid-defined))(NN (diet))(JJ (chemopreventive))(NN (efficacy))(JJ (specific))(NN (inhibitor)))(, (,))(NP (NN (nimesulide))))))) |ET|  |BS| 7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125  |ES| 2:1 4:1 19:1 61:1 115:1 380:1 540:1 849:1 900:1 1212:1 1946:1 2188:1 2190:1 2191:1 2304:1 2506:1 3183:1 3186:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNS (CONCLUSIONS)))(: (:))(S (NP (DT (This))(NN (study)))(VP (VBZ (demonstrates))(NP (JJ (synergistic))(NN (antitumor))(NN (activity))(NN (combination))(NN (dovitinib))(NN (oxaliplatin))(NN (colon))(NN (cancer))(JJ (different))(NN (RAS-RAF))(NN (status)))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550  |ES| 18:1 19:1 104:1 113:1 131:1 239:1 399:1 414:1 416:1 530:1 807:1 2012:1 2244:1 2541:1 2542:1 2543:1 2544:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NNP (Celecoxib)))(, (,))(NP (NP (JJ (selective))(NN (cyclooxygenase-2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(NP (NN (inhibitor)))(, (,)))(NP (JJ (effective))(JJ (chemopreventive))(NN (colon))(NN (cancer))(JJ (nonsteoroidal))(JJ (antiinflammatory))(NN (drug)))(VP (VBD (approved))(NP (NP (NNP (FDA))(JJ (adjuvant))(NN (therapy))(NN (patient)))(JJ (familial))(JJ (adenomatous))(NN (polyposis))))) |ET|  |BS| 3:C04.557.470.035.215.100 50:M01.643 52:E02 349:D27.505.519.389.310.500 633:I01.409.418.750.600.650.760 683:D27.505.519.389.310 684:D02.065.884.247 685:D27.505.696.477.067 686:D27.505.954.158 687:D26.650.064  |ES| 2:1 10:1 14:1 18:1 19:1 57:1 58:1 61:1 76:1 113:1 120:1 130:1 191:1 380:1 854:1 1639:1 1749:1 1946:1 2343:1 2475:1 2476:1 2477:1 2478:1 2479:1  |EV| 
-2.6977848664400880807079374790192  |BT| (S (NP (DT (The))(JJ (anti-tumor))(NN (effect))(NN (thymoquinone)))(ADVP (RB (also)))(VP (VP (VBD (investigated))(NP (NN (tumor))(NN (xenograft))(NN (mouse))(NN (model))(NN (colon))))(, (,))(NP (NN (prostate))(, (,))(JJ (pancreatic))(NN (lung))(NN (cancer))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 34:A05.360.444.575 46:A03.556.124.526.356 92:E04.936.764 93:A01.941.875 608:A03.734  |ES| 2:1 5:1 7:1 18:1 19:1 52:1 72:1 75:1 77:1 113:1 265:1 328:1 403:1 467:1 691:1 3677:1 3796:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (VP (NP (NNP (Digital)))(VBG (karyotyping))(VP (VBZ (identifies))(NP (NN (thymidylate))(NN (synthase))(NN (amplification))(NN (mechanism))(NN (resistance))(NN (5-fluorouracil))(JJ (metastatic))(JJ (colorectal))(NN (cancer))(NN (patient)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430  |ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Critical))(NN (function))(NN (ADAM9))(NN (mouse))(NN (prostate))(NN (cancer)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500  |ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (injection))(NN (N-diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(VP (VBP (initiate))(NP (NN (hepatocarcinogenesis))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 554:D02.654.442.200  |ES| 10:1 14:1 19:1 785:1 900:1 1875:1 3231:1 3595:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (CD (2012))(NN (case))(NN (report))))(, (,))(VP (VBN (described))(NP (NP (NN (breakthrough)))(VP (VBG (finding))(NP (NP (CD (two))(JJ (advanced))(NNP (HCC))(NN (patient)))(, (,))(NP (S (NP (CD (one)))(VP (VBD (achieved))(SBAR (S (NP (JJ (complete))(NN (remission))(NN (liver))(NN (tumor)))(VP (VBD (normalized))(NP (NP (NN (alpha-fetoprotein))(NN (level)))(, (,))(PP (IN (along))(NP (JJ (complete))(NN (remission))(NN (lung))(NN (metastasis))))))))))(, (,))(NP (JJ (concomitant))(NN (use))(NN (thalidomide))(NN (cyproheptadine))))))))) |ET|  |BS| 50:M01.643 104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 275:C23.888 405:V03.100 406:V03.100 515:C04.588.274.623 747:D02.455.426.559.847.181.384.340 748:D12.776.124.790.106.092 749:D02.241.223.805.810.800  |ES| 2:1 7:1 19:1 120:1 172:1 244:1 249:1 328:1 417:1 441:1 634:1 806:1 836:1 927:1 933:1 934:1 997:1 1010:1 1659:1 1681:1 2491:1 2661:1 2662:1 2663:1 2664:1 2665:1 2666:1 2667:1 2668:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NNP (UNLABELLED)))(: (:))(S (NP (JJ (Epidemiological))(NNS (data)))(VP (VBP (associate))(NP (NP (NN (coffee))(NN (consumption)))(NP (JJR (lower))(NN (prevalence))(JJ (chronic))(NN (liver))(NN (disease))))(VP (VBD (reduced))(NP (NP (NN (risk))(JJ (elevated))(NN (liver))(NN (enzyme))(NN (level)))(PRN (-LRB- (-LRB-))(NP (NN (gamma))(NN (glutamyl))(NN (transpeptidase))(NN (alanine))(NN (aminotransferase)))(-RRB- (-RRB-)))))))(, (,)))(VP (VBD (advanced))(NP (NP (NN (liver))(NN (disease))(NN (complication)))(, (,))(NP (JJ (hepatocellular))(NN (carcinoma)))))) |ET|  |BS| 60:E05.318.308.985.525.750 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 648:D08.811.913.050.200.500 649:E01.370.225.124.200 650:C06.552 651:H02.403.720.500 652:D20.215.784.249  |ES| 2:1 10:1 14:1 19:1 104:1 117:1 171:1 179:1 249:1 303:1 304:1 452:1 756:1 793:1 836:1 997:1 998:1 1790:1 2266:1 2384:1 2385:1 2386:1 2387:1 2388:1 2389:1 2390:1 2391:1 2392:1 2393:1 2394:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Magnolol)))(VP (MD (could))(ADVP (RB (potentially)))(NP (JJ (safe))(JJ (potent))(JJ (anticarcinogenic))(NN (agent))(NN (skin))(NN (cancer))))) |ET|  |BS| 778:D27.505.954.444  |ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1  |EV| 
-4.2015042725533930934034287929535  |BT| (S (NP (NNP (Dovitinib)))(VP (VBZ (demonstrates))(NP (JJ (antitumor))(JJ (antimetastatic))(NN (activity))(NN (xenograft))(NN (model))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255  |ES| 19:1 72:1 265:1 303:1 304:1 399:1 2244:1 2245:1 2541:1 3449:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (Inhibition))(NP (NN (c-Jun))(JJ (NH2-terminal))(NN (kinase))(NN (switch)))(NN (Smad3))(NN (signaling))(NN (oncogenesis))(NN (tumor)))(: (-))(NP (NN (suppression))(NN (rat))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 43:F01.145.544 69:G02.111.087.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 771:D08.811.913.696.620.682.700.567.374  |ES| 19:1 195:1 303:1 304:1 470:1 849:1 1686:1 2453:1 2703:1 2708:1 2709:1 2710:1 2711:1 2712:1  |EV| 
-4.3630251136214326379558769986033  |BT| (S (PP (IN (In))(NP (JJ (medium-term))(NN (carcinogenesis))(NN (test))(NN (rat))))(, (,))(NP (NP (ADJP (CD (2.0))(NN (%)))(NN (KA)))(VP (ADVP (RB (orally)))(VBN (given))(NP (NN (F344/DuCrj))(NN (rat))(CD (4))(NN (week))(NN (initiation))(NN (period))))(, (,)))(VP (VBD (followed))(NP (NP (NN (combination))(JJ (partial))(NN (hepatectomy))(NN (treatment))(NN (hepatocarcinogenesis))(NN (promoter)))(, (,))(NP (NP (NN (phenobarbital)))(PRN (-LRB- (-LRB-))(NP (NN (PB)))(-RRB- (-RRB-))))))) |ET|  |BS| 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200 756:D03.383.742.698.253.650 776:G01.910.645 849:G08.686.785.760.769.490.500 914:L01.178 928:E04.210.556 1205:E05.940.150  |ES| 2:1 10:1 14:1 19:1 29:1 83:1 207:1 244:1 319:1 369:1 530:1 546:1 637:1 783:1 849:1 900:1 1418:1 2685:1 2725:1 3130:1 3215:1 3272:1 3273:1 3496:1 4224:1 4225:1 4226:1 4227:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Cytochrome))(NN (P450))(NN (1A2)))(VP (VBZ (Metabolizes))(S (NP (NN (17beta-Estradiol)))(VP (VB (Suppress))(NP (JJ (Hepatocellular))(NN (Carcinoma))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 705:D08.244.453.040.443 706:D04.808.365.415.248  |ES| 19:1 1241:1 2151:1 2548:1 2549:1 2550:1 2551:1 2552:1 2553:1  |EV| 
4.3916130581683914257951073523145  |BT| (SINV (S (NP (JJ (Overall))(NN (analysis)))(VP (VBD (indicated))(SBAR (S (NP (NN (pterostilbene)))(VP (VBD (reduced))(NP (NN (colon))(NN (tumor))(NN (multiplicity))(JJ (non-invasive))(NN (adenocarcinoma))))))))(, (,))(VP (VBD (lowered))(S (VP (VBG (proliferating))(NP (NN (cell))(JJ (nuclear))(NN (antigen))))))(VP (VBD (downregulated))(NP (NN (expression))(NN (beta-catenin))(NN (cyclin))(NN (D1))))) |ET|  |BS| 23:D12.776.091.249 51:C04.588.274.476.411.307.180 84:C04.557.470.200.025 215:D12.644.360.262.150.100 696:V02.270.500 768:D12.776.660.740  |ES| 2:1 7:1 19:1 60:1 94:1 113:1 115:1 255:1 426:1 452:1 661:1 743:1 744:1 1030:1 1256:1 1361:1 1541:1 2428:1 2858:1 2863:1 2864:1 2865:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (VP (ADVP (RB (Here)))(VBP (show))(SBAR (S (NP (NP (JJ (ATP-binding))(NN (cassette))(NN (member))(NN (B5)))(PRN (-LRB- (-LRB-))(NP (NN (ABCB5)))(-RRB- (-RRB-))))(VP (VBZ (identifies))(NP (NP (JJ (therapy-refractory))(NN (tumor))(NN (cell))(JJ (colorectal))(NN (cancer))(NN (patient)))(PP (VBG (following))(NP (NP (NN (fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-)))))))))(: (-))(S (NP (VBN (based))(NN (chemoradiation))(NN (therapy)))(VP (VBP (provide))(NP (NP (NN (evidence)))(JJ (functional))(NN (role))(NN (ABCB5))(JJ (colorectal))(NN (cancer))(NN (5-FU))(NN (resistance))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 50:M01.643 52:E02 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 1004:E02.095.147  |ES| 7:1 10:1 14:1 17:1 18:1 19:1 31:1 38:1 94:1 120:1 130:1 400:1 415:1 429:1 711:1 769:1 1094:1 1610:1 2308:1 2895:1 2919:1 3505:1 3506:1 3507:1 3508:1 3509:1 3510:1 3511:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (IN (Unlike))(NP (NN (celecoxib))))(, (,))(NP (NN (sulindac)))(VP (VBD (proved))(NP (ADJP (RB (highly))(JJ (effective)))(NN (colon))(NN (tumor))(NN (prevention))(NN (15-PGDH))(NN (KO))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 684:D02.065.884.247  |ES| 2:1 7:1 19:1 52:1 113:1 133:1 626:1 869:1 1474:1 1639:1 2179:1 2807:1 2849:1 3882:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (ADJP (RB (Orally))(VBN (administered)))(NN (lycopene)))(VP (VBZ (attenuates))(NP (NP (JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(NN (rat)))(VP (VBG (modulating))(NP (NP (NN (Nrf-2)))(: (/))(NP (NN (HO-1))(NN (Akt/mTOR))(NN (pathway)))))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534  |ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (DT (The))(NN (blockade))(NN (5-LOX)))(VP (VP (VBZ (inhibits))(NP (NN (colon))(NN (cancer))(NN (cell))(NN (proliferation)))(ADVP (FW (vitro))(FW (vivo))))(SBAR (S (VP (MD (may))(VP (VB (prove))(NP (JJ (beneficial))(JJ (chemopreventive))(NN (therapy))(NN (colon))(NN (cancer))))))))) |ET|  |BS| 52:E02 122:C14.280.383 183:G04.299.233.750 548:D08.811.682.664.500.848  |ES| 18:1 19:1 94:1 113:1 130:1 216:1 299:1 378:1 491:1 615:1 691:1 984:1 1946:1 2669:1 3390:1 3797:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (DT (All))(NN (result)))(VP (VBD (revealed))(NP (NP (NN (pterostilbene))(JJ (effective))(NN (antitumor))(NN (agent)))(NP (RB (well))(NP (JJ (inhibitory))(NN (effect))(NN (down-regulation))(JJ (inflammatory))(NN (iNOS))(NN (COX-2))(NN (gene)))(NN (expression))(NN (up-regulation))(NN (apoptosis))(NN (mouse))(NN (colon))))(, (,))(S (VP (VBG (suggesting))(NP (NP (NP (NN (pterostilbene)))(JJ (novel))(JJ (functional))(NN (agent)))(ADJP (JJ (capable))(S (VP (VBG (preventing))(NP (JJ (inflammation-associated))(NN (colon))(NN (tumorigenesis))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248  |ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBD (demonstrated))(NP (NP (NN (alantolactone)))(, (,))(NP (NN (sesquiterpene))(NN (lactone)))(, (,))(NP (NP (JJ (potential))(NN (activity))(JJ (triple-negative))(NN (breast))(NN (cancer))(NN (MDA-MB-231))(NN (cell))(JJ (suppressing))(NN (signal))(NN (transducer))(NN (activator))(NN (transcription))(CD (3)))(PRN (-LRB- (-LRB-))(NP (NN (STAT3)))(-RRB- (-RRB-))))(NP (NN (signaling))(NN (pathway)))))) |ET|  |BS| 41:A11 69:G02.111.087.800 160:C04.588.180.788 209:G02.111.087.847 250:E07.305.812 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 761:G02.111.087.800 762:D02.455.849.765 763:Z01.542.248.540 764:D02.540  |ES| 2:1 10:1 14:1 18:1 19:1 23:1 26:1 94:1 131:1 195:1 244:1 251:1 383:1 399:1 487:1 827:1 859:1 860:1 861:1 862:1 1175:1 1307:1 2250:1 2686:1 2687:1 2688:1 2689:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (Despite))(NP (JJ (recent))(JJ (therapeutic))(NN (advance))))(, (,))(NP (NP (NN (response))(NN (rate))(NN (chemotherapy))(NN (patient)))(JJ (metastatic))(NN (colon))(NN (cancer)))(VP (VBP (remain))(NP (NP (NP (QP (RB (approximately))(CD (50)))(NN (%)))(NP (NN (fluoropyrimidine))))(, (,))(NP (NN (5-fluorouracil))(-LRB- (-LRB-))(NN (5-FU))(-RRB- (-RRB-))))(, (,))(S (VP (VBG (continuing))(VP (VB (serve))(NP (NN (foundation))(JJ (chemotherapeutic))(NN (agent))(NN (treatment))(NN (disease)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 50:M01.643 52:E02 113:C04.697.650 151:E02.319 288:C23.550.288 560:D03.383.742.698.875.404 660:D27.505.954.248 709:N03.219.483.311  |ES| 2:1 10:1 14:1 18:1 19:1 41:1 113:1 120:1 337:1 368:1 369:1 494:1 495:1 532:1 541:1 546:1 550:1 659:1 728:1 998:1 1762:1 1843:1 2181:1 2307:1 2308:1 2558:1 2559:1 2560:1 2561:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNS (Effects)))(VP (VBD (baked))(S (NP (NP (NP (NN (PP)))(PRN (-LRB- (-LRB-))(NP (ADJP (CD (20))(NN (%)))(NN (wt/wt)))(-RRB- (-RRB-))))(NN (colon))(NNS (CSCs)))(ADVP (RB (also)))(VP (VBN (tested))(NP (FW (vivo))(NN (mouse))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 556:C11.768.175 1126:Z01.639.760.590.715  |ES| 5:1 10:1 14:1 19:1 52:1 78:1 113:1 369:1 378:1 1870:1 1966:1 2533:1 2988:1 3461:1 3941:1 3942:1 4155:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NNP (Gemcitabine)))(, (,))(NP (JJ (current))(JJ (standard-of-care))(NN (chemotherapy))(JJ (pancreatic))(NN (cancer)))(, (,))(NP (JJ (limited))(JJ (clinical))(NN (benefit))))) |ET|  |BS| 151:E02.319  |ES| 2:1 18:1 19:1 84:1 175:1 467:1 495:1 2131:1 2617:1 2618:1 2619:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(NP (DT (These))(VBP (result))(NP (VBN (suggested))(NN (TFA))(VBD (protected))(ADJP (NN (mouse))(JJ (CCl4-induced))(ADJP (NN (liver))(NN (injury))(JJ (antioxidant)))(NN (stress))(JJ (antiinflammatory)))(NN (effect))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217  |ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Consistent))(NN (finding))(, (,))(JJ (ABCB5-expressing))(NN (tumor))(NN (cell))(NN (population)))(RRC (ADVP (RB (also)))(NP (NN (treatment))(ADJP (JJ (refractory))(S (VP (VBD (exhibited))(NP (NN (resistance))(JJ (5-FU-induced))(NN (apoptosis))(JJ (colorectal))(NN (cancer))(NN (xenograft))(NN (model))(NN (5-FU))(NN (monotherapy)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 52:E02 92:E04.936.764 93:A01.941.875 175:J01.897.280.500.269 275:C23.888 560:D03.383.742.698.875.404 829:M01.686 966:N01.600  |ES| 2:1 5:1 7:1 17:1 18:1 19:1 72:1 89:1 94:1 265:1 546:1 609:1 927:1 1094:1 2023:1 2308:1 3379:1 3395:1 3396:1 3397:1 3398:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(VBP (result)))(VP (VBP (indicate))(SBAR (S (NP (NP (NN (administration))(NN (resveratrol)))(UCP (CC (either))(NP (JJ (early))(JJ (advanced))(NN (stage))(NN (hepatocarcinogenesis)))(ADJP (RB (equally))(JJ (effective)))))(VP (VBZ (involves))(NP (NP (NN (activation)))(NP (JJ (apoptotic))(NN (pathway))(NN (male))(NNP (Wistar))(NN (rat))))))))) |ET|  |BS| 39:G04.299.139.160 723:B01.050.150.900.649.865.635.505.700.900  |ES| 19:1 39:1 101:1 225:1 383:1 658:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1479:1 1639:1 1673:1 1712:1 2223:1 2575:1 2603:1 2854:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (Zinc-finger))(NN (protein))(CD (331)))(, (,))(NP (JJ (novel))(JJ (putative))(NN (tumor))(NN (suppressor)))(, (,)))(VP (VBZ (suppresses))(NP (NN (growth))(NN (invasiveness))(JJ (gastric))(NN (cancer))))) |ET|  |BS| 7:D12.776 45:G07.700.320.249 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 1131:G02.111.570.820.709.600.040.985  |ES| 2:1 4:1 7:1 18:1 19:1 86:1 102:1 686:1 700:1 891:1 918:1 3954:1 3955:1 3956:1  |EV| 
-0.20241187241001057373068761080503  |BT| (FRAG (ADVP (RB (Collectively)))(, (,))(NP (NP (NNS (data)))(SBAR (IN (along))(S (NP (JJ (negative))(NN (genotoxicity)))(VP (VBP (demonstrate))(SBAR (S (NP (NP (NN (oxyfluorfen)))(PRN (-LRB- (-LRB-))(NP (ADJP (QP (JJR (>))(CD (98)))(NN (%)))(NN (purity)))(-RRB- (-RRB-))))(ADJP (JJ (potential)))(VP (VBP (induce))(S (NP (NN (mouse))(NN (liver))(NN (tumor)))(ADJP (JJ (nongenotoxic)))))))(, (,))(NP (NP (JJ (mitogenic))(NNP (MOA))(JJ (clear))(NN (threshold)))(VP (VBD (predicted))(NP (JJ (carcinogenic))(JJ (human))(JJ (relevant))(NN (exposure))(NN (level)))))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 515:C04.588.274.623 575:V02.050 953:D27.505.519.593.624  |ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 243:1 249:1 369:1 449:1 502:1 793:1 827:1 836:1 865:1 1466:1 1872:1 1953:1 2666:1 3336:1 3337:1 3338:1 3339:1 3340:1 3341:1 3342:1 3343:1 3344:1 3345:1 3346:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(S (ADVP (RB (Collectively)))(, (,))(VP (VBP (result))(VP (VBP (suggest))(SBAR (S (NP (NN (curcumin)))(VP (VBZ (potentiates))(NP (NP (JJ (antitumor))(NN (effect))(NN (radiation))(NN (therapy)))(JJ (colorectal))(NN (cancer))(VBG (suppressing))(NP (NN (NF-kappaB))(JJ (NF-kappaB-regulated))(NN (gene))(NN (product))))(, (,))(NP (VBG (leading))(NN (inhibition))(NN (proliferation))(NN (angiogenesis)))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745  |ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1  |EV| 
-0.41193764206488481249834876507521  |BT| (S (S (VP (VBG (Using))(NP (JJ (protein-protein))(NN (interaction))(NN (screening)))))(, (,))(VP (VBD (found))(SBAR (S (NP (NN (FOXO3a)))(VP (VBD (interacted))(NP (NN (ER-alpha))(NN (ER-beta))(NN (protein))(JJ (human))(NN (breast))(NN (carcinoma))(NN (cell))(NN (line))(NN (MCF-7)))(, (,))(S (VP (VBG (suggesting))(VP (VBZ (exists))(NP (NN (crosstalk))(NN (FOXO3a))(NN (ER))(NN (signaling))(NN (pathway))(JJ (estrogen-dependent))(NN (breast))(NN (cancer))(NN (cell))))))))))) |ET|  |BS| 7:D12.776 126:G02.111.087.800 148:G12.425.143.281 432:A11.251.210.190.630 889:D27.505.696.399.472.277 1110:D12.776.826.750.350.174 1111:D12.776.826.750.350.262 1112:D23.125  |ES| 2:1 4:1 18:1 19:1 23:1 36:1 37:1 94:1 195:1 224:1 264:1 304:1 383:1 618:1 741:1 1009:1 1188:1 1484:1 1719:1 3361:1 3362:1 3363:1 3886:1 3887:1 3888:1 3889:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Phyllanthus))(NN (urinaria)))(VP (VBZ (ameliorates))(NP (NN (severity))(JJ (nutritional))(FW (steatohepatitis))(FW (vitro))(FW (vivo))))) |ET|  |BS| 508:C06.552.241 813:B01.650.940.800.575.100.350.622  |ES| 19:1 216:1 378:1 1473:1 1791:1 2875:1 2876:1 2877:1 2878:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (DT (The))(NN (potency))(JJ (nifuroxazide))(NN (breast))(NN (cancer)))(VP (VBN (assessed))(ADVP (FW (vitro))(FW (vivo)))))) |ET| 18:1 19:1 23:1 216:1 378:1 691:1 2796:1 2820:1 3823:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Administration))(NN (HMGB1))(NN (release))(NN (inhibitor))(NN (ethyl))(NN (pyruvate)))(, (,))(VP (VBP (affect))(NP (NP (JJ (p53-mediated))(JJ (hepatic))(NN (apoptosis)))(, (,))(VP (ADVP (RB (substantially)))(VBD (prevented))(NP (JJ (carcinogen-induced))(NN (cirrhosis))(NN (tumorigenesis))(NN (rat))(NN (liver))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 357:C06.552.630 433:F01.470.047 585:D12.644.276.087.371 589:E02.204.125 662:C23.550.355  |ES| 2:1 19:1 78:1 89:1 380:1 836:1 838:1 849:1 1199:1 1486:1 1944:1 2164:1 2165:1 2346:1 2417:1 2418:1 2419:1 2420:1 2421:1  |EV| 
-3.5348492423815969232236966490746  |BT| (S (PP (IN (In))(NP (JJ (current))(NN (study))))(, (,))(NP (NN (serial))(NN (microPET))(NN (imaging)))(VP (VBD (used))(VP (VB (evaluate))(NP (NP (JJ (iodine-124-labeled))(NN (iodo-azomycin-galactoside)))(PRN (-LRB- (-LRB-))(NP (-LRB- (-LRB-))(CD (124))(-RRB- (-RRB-))(NN (I-IAZG)))(-RRB- (-RRB-))))))(PRN (-LRB- (-LRB-))(NP (JJ (4.2-day))(JJ (physical))(NN (half-life)))(-RRB- (-RRB-)))(S (NP (NN (hypoxia))(NN (imaging))(NN (agent)))(NP (CD (17))(NN (MCa))(NN (breast))(NN (tumor))(CD (six))(NN (FSaII))(NNS (fibrosarcomas)))(VP (VBN (implanted))(NP (NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 375:Z01.639.100 967:D01.248.497.158.490 1002:C04.588.180 1011:C23.888.852.079 1017:E01.370.350 1018:C04.557.450.565.590.350 1019:A07.231.114.228.550 1020:G01.910.405 1021:E01.370.600 1022:V02.690  |ES| 2:1 7:1 10:1 14:1 19:1 23:1 52:1 131:1 175:1 244:1 476:1 728:1 890:1 930:1 1781:1 2474:1 3559:1 3560:1 3561:1 3562:1 3563:1 3564:1 3565:1 3566:1 3567:1 3568:1 3569:1 3570:1 3571:1 3572:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NNS (data)))(VP (VBD (indicated))(NP (NP (NN (silymarin))(JJ (therapeutic))(NN (effect)))(NP (JJ (early))(NN (stage))(NN (liver))(NN (damage))))(, (,))(S (VP (VBG (reversing))(NP (NP (JJ (fatty))(NN (change)))(VP (VBG (recovering))(NP (NN (liver))(NN (histopathology))(JJ (dose-dependent))(NN (manner))))))))) |ET|  |BS| 242:A03.620 801:D03.383.663.283.266.450.268.777  |ES| 2:1 19:1 75:1 200:1 541:1 658:1 793:1 836:1 1128:1 1129:1 1541:1 1668:1 1848:1 2070:1 2740:1 2821:1 2822:1 2823:1 2824:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (5-aza-dC))(NN (treatment)))(ADVP (RB (markedly)))(VP (VBD (decreased))(NP (NP (NN (atherosclerosis))(NN (development))(NN (Ldlr)))(-LRB- (-LRB-))(PRN (: (-))(: (/))(: (-)))(-RRB- (-RRB-))(NN (mouse)))(NP (PP (IN (without))(NP (NN (change))(NN (body))(NN (weight))))(, (,))(NP (NN (plasma))(NN (lipid))(NN (profile)))(, (,))(NP (NN (macrophage))(NN (cholesterol))(NN (level))(NN (plaque))(NN (lipid))(NN (content)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 52:E02 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821 653:C23.888.144 654:D02.145.150 655:D04.808.247.222.284 656:C07.793.208.377 657:A12.207.152.693 658:A11.329.372 659:D10  |ES| 2:1 10:1 14:1 19:1 35:1 45:1 52:1 200:1 202:1 249:1 546:1 1195:1 1711:1 1794:1 1804:1 1981:1 2395:1 2396:1 2397:1 2398:1 2399:1 2400:1 2401:1 2402:1 2403:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NP (NP (NN (dioscin))(NN (show))(JJ (excellent))(JJ (protective))(NN (effect)))(JJ (ethanol-induced))(NN (liver))(NN (injury)))(S (VP (VBG (ameliorating))(NP (NP (JJ (ethanol-induced))(JJ (oxidative))(NN (stress)))(, (,))(NP (JJ (mitochondrial))(NN (function)))(, (,)))(NP (NP (JJ (inflammatory))(NP (NN (cytokine)))(NN (production)))(, (,))(NP (NN (apoptosis))(NN (liver))(NN (steatosis)))(, (,))))))(VP (VBD (developed))(NP (JJ (new))(NN (drug))(NN (treatment))(JJ (ethanol-induced))(NN (liver))(NN (injury))(NN (future))))) |ET|  |BS| 39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241  |ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (PRP$ (Our))(VP (VBP (result))(VP (VBP (demonstrate))(S (VP (NN (resveratrol))(VP (VB (potentiate))(NP (JJ (anti-tumor))(NN (effect))(NN (5-FU))(NN (CRC))(NN (cell))(NN (chemosensitizing)))(, (,))(S (VP (VBG (inhibiting))(NP (NNP (EMT))(NN (phenotype)))(PP (IN (via))(NP (NN (up-regulation))(JJ (intercellular))(NN (junction))(NN (down-regulation))(NN (NF-kappaB))(NN (pathway))))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 41:A11 80:G05.695 85:G02.111.087.225 122:C14.280.383 142:I01.880.604 210:D12.776.260.600 560:D03.383.742.698.875.404 1054:A11.284.149.165.420  |ES| 2:1 19:1 75:1 94:1 101:1 236:1 245:1 257:1 383:1 502:1 596:1 658:1 714:1 880:1 896:1 1712:1 1759:1 2075:1 2308:1 3677:1 3678:1 3679:1 3680:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Erlotinib)))(ADVP (RB (also)))(VP (VBD (decreased))(NP (NN (hepatocyte))(NN (proliferation))(NN (liver))(NN (injury))))) |ET|  |BS| 242:A03.620 262:A11.436.348  |ES| 5:1 19:1 202:1 299:1 836:1 1909:1 2416:1 2596:1  |EV| 
-1.0737220013299406673468183726072  |BT| (NP (NP (DT (These))(S (VP (VBG (finding))(VP (VB (provide))(NP (NP (JJ (important))(NN (information))(NN (interaction)))(PP (IN (among))(NP (NP (VBG (transforming))(NN (growth))(NN (factor))(NN (beta)))(, (,))(NP (NN (BMP)))(, (,))(NP (NN (Wnt))(NN (signaling))(NN (pathway))(NN (progression))(NN (CRC))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 147:G02.149.115.800.925 503:D12.644.276.374.687 1099:D12.644.276.954.200  |ES| 2:1 19:1 48:1 102:1 185:1 195:1 245:1 383:1 618:1 711:1 792:1 877:1 902:1 927:1 1372:1 1772:1 1972:1 2338:1 3855:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (S (ADVP (RB (Notably)))(, (,))(NP (JJ (adeno-XAF1))(NN (treatment)))(ADVP (RB (significantly)))(VP (VBD (inhibited))(NP (NN (tumor))(NN (growth)))(, (,))(ADVP (NP (ADJP (RB (strongly))(VBN (enhanced)))(NN (antitumor))(NN (activity))(NN (TRAIL))(JJ (gastric))(NN (cancer))(NN (xenograft))(NN (model)))(FW (vivo)))(, (,))(NP (RB (significantly))(JJ (prolonged))(NN (survival))(NN (time))(JJ (animal))(NN (bearing))(NN (tumor))(NN (xenograft)))))) |ET|  |BS| 8:C04 19:B01.050 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875 96:I03.784 122:C14.280.383 322:G01.910 455:B01.050.150.900.649.147.890  |ES| 2:1 7:1 18:1 19:1 46:1 72:1 86:1 102:1 124:1 265:1 274:1 365:1 378:1 385:1 399:1 546:1 635:1 1081:1 1584:1 1695:1 2244:1 2798:1 2799:1 2800:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(VP (VBN (Taken))(ADVP (RB (together)))(, (,))(S (VP (VBG (finding))(VP (VB (identify))(S (NP (NN (mechanism))(NN (ABT-100))(NN (function)))(VP (VBP (show))(NP (NP (NN (efficacy))(NN (ABT-100))(JJ (chemopreventive))(NN (agent)))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))) |ET|  |BS| 104:C04.557.470.200.025.255 375:Z01.639.100  |ES| 2:1 19:1 33:1 104:1 162:1 239:1 303:1 304:1 429:1 728:1 832:1 927:1 1537:1 1538:1 1946:1 2304:1 2538:1  |EV| 
-2.8027341628579449661629041656852  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(S (NP (NN (Alcohol))(NN (consumption)))(VP (VBZ (promotes))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))))) |ET|  |BS| 104:C04.557.470.200.025.255 904:F01.145.317.269  |ES| 10:1 14:1 19:1 104:1 298:1 303:1 304:1 441:1 1046:1 2387:1 3962:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NNS (Data)))(VP (VBN (obtained))))(VP (VBP (suggest))(S (NP (NN (contribution))(NN (SphK/S1P))(NN (system)))(NP (JJ (related))(NN (signaling))(NN (pathway))(JJ (protective))(NN (effect))(NN (melatonin))(NN (hepatocarcinogenesis)))))) |ET|  |BS| 126:G02.111.087.800 707:D03.438.473.914.481  |ES| 19:1 75:1 195:1 383:1 419:1 493:1 593:1 796:1 900:1 1224:1 1360:1 2554:1 2555:1 2556:1  |EV| 
-0.12348151662249051696562673896551  |BT| (S (NP (NN (Apoptosis))(JJ (signal-regulating))(NN (kinase))(CD (1)))(VP (VBZ (inhibits))(NP (NP (NN (hepatocarcinogenesis)))(VP (VBG (controlling))(NP (JJ (tumor-suppressing))(NN (function))(JJ (stress-activated))(JJ (mitogen-activated))(NN (protein))(NN (kinase))))))) |ET|  |BS| 8:C04 122:C14.280.383 478:D08.811.913.696.620.682.700.567 938:D08.811.913.696.620.682.700.559.500  |ES| 4:1 19:1 33:1 98:1 470:1 615:1 900:1 2220:1 3291:1 3292:1 3293:1 3294:1 3295:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (Modulation))(NN (energy))(JJ (metabolic))(NN (enzyme))(NN (expression))(JJ (N-nitrosodiethylamine-mediated))(NN (hepatocarcinogenesis))(JJ (Chinese))(NN (herb)))(, (,))(NP (NNP (Huqi))(NNP (San)))) |ET|  |BS| 554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500  |ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1  |EV| 
-3.7208525145449584670132026076317  |BT| (S (NP (NN (Regrowth))(JJ (5-fluorouracil-treated))(JJ (human))(NN (colon))(NN (cancer))(NN (cell)))(VP (VBD (prevented))(NP (NP (NN (combination))(NN (interferon))(NN (gamma)))(, (,))(NP (NN (indomethacin)))(, (,))(NP (NN (phenylbutyrate)))))) |ET|  |BS| 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 795:D03.438.473.420 1033:D12.644.276.374.440.893 1068:D02.241.223.651  |ES| 2:1 18:1 19:1 36:1 94:1 113:1 530:1 1944:1 2305:1 2389:1 2792:1 3735:1 3736:1 3737:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Metformin)))(VP (VBZ (inhibits))(NP (JJ (early))(NN (stage))(JJ (diethylnitrosamineinduced))(NN (hepatocarcinogenesis))(NN (rat))))) |ET|  |BS| 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450  |ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Diosmin)))(VP (VBZ (abrogates))(VP (ADVP (RB (chemically)))(VBN (induced))(NN (hepatocarcinogenesis))(PP (IN (via))(NP (NP (NN (alleviation))(JJ (oxidative))(NN (stress)))(, (,))(NP (JJ (hyperproliferative))(JJ (inflammatory))(NN (marker))(JJ (murine))(NN (model)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 158:D23.101 715:D03.383.663.283.266.450.260.222 716:G03.495.710  |ES| 2:1 19:1 72:1 412:1 534:1 596:1 627:1 900:1 2430:1 2522:1 2579:1 2580:1 2581:1 2582:1 2583:1 2584:1  |EV| 
-0.41137856962399155236198566854  |BT| (S (NP (NNS (Effects)))(VP (VBP (magnolol))(NP (NP (JJ (UVB-induced))(NN (skin))(NN (cancer))(NN (development))(NN (mouse)))(JJ (possible))(NN (mechanism))(NN (action))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 742:G03.787  |ES| 18:1 19:1 35:1 52:1 162:1 1359:1 2013:1 2319:1 2526:1 2752:1 3461:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Branched-chain))(NN (amino))(NN (acid))(-LRB- (-LRB-))(NN (BCAA))(-RRB- (-RRB-)))(, (,))(S (VP (VB (improve))(NP (NN (insulin))(NN (resistance)))))(, (,))(VP (VBD (inhibited))(NP (NP (JJ (obesity-related))(NN (colon))(NN (carcinogenesis))(JJ (rodent))(NN (model)))(, (,))(S (ADVP (RB (also)))(VP (VBD (reduced))(NP (NN (incidence))(JJ (hepatocellular))(NN (carcinoma))(JJ (obese))(NN (patient))(NN (liver))(NN (cirrhosis)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 50:M01.643 104:C04.557.470.200.025.255 122:C14.280.383 357:C06.552.630 434:E05.318.308.985.525.375 514:B01.050.150.900.649.865 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500  |ES| 2:1 5:1 10:1 14:1 19:1 72:1 113:1 120:1 207:1 303:1 304:1 365:1 452:1 836:1 1094:1 1199:1 1275:1 1511:1 2173:1 2189:1 2360:1 2364:1 2465:1 2466:1 2467:1 2468:1  |EV| 
-2.779053991906948795076459646225  |BT| (S (VP (VBN (Dysregulated))(SBAR (S (NP (JJ (Kruppel-like))(NN (factor))(CD (4))(NN (vitamin))(NN (D))(NN (receptor))(NN (signaling)))(VP (VBP (contribute))(NP (NN (progression))(JJ (hepatocellular))(NN (carcinoma)))))))) |ET|  |BS| 16:C23.550.291.656 69:G02.111.087.800 104:C04.557.470.200.025.255 982:D12.776.826.535  |ES| 19:1 48:1 185:1 186:1 195:1 303:1 304:1 318:1 319:1 450:1 2591:1 2592:1 3460:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (NN (Magnolol))(NNS (pretreatments)))(VP (VBP (prevent))(S (NP (JJ (UVB-induced))(NN (skin))(NN (cancer))(NN (development)))(VP (VBG (enhancing))(NP (NN (apoptosis)))(, (,))(S (VP (VBG (causing))(NP (NN (cell))(NN (cycle))(NN (arrest))(NN (G2/M))(NN (phase)))))))(, (,))(S (VP (VBG (affecting))(NP (JJ (various))(NN (signaling))(NN (pathway)))))))) |ET|  |BS| 39:G04.299.139.160 126:G02.111.087.800 702:G04.299.134.109.750  |ES| 2:1 18:1 19:1 35:1 89:1 94:1 104:1 195:1 239:1 383:1 601:1 602:1 733:1 1096:1 1491:1 2312:1 2319:1 2525:1 2526:1 2527:1 2528:1 2529:1 2530:1  |EV| 
-4.3916130581683914257951073523145  |BT| (SINV (NP (NP (JJ (Hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (CD (one))(JJ (common))(NN (cancer)))(ADVP (RB (worldwide)))(, (,))(VP (VBD (caused)))(NP (NP (NP (NNP (Hepatitis))(NNP (C))(NN (virus)))(PRN (-LRB- (-LRB-))(NP (NN (HCV)))(-RRB- (-RRB-))))(NN (hepatotoxin)))) |ET|  |BS| 104:C04.557.470.200.025.255 550:B04.450.410  |ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (DNA))(NN (microarray))(NN (analysis)))(VP (VBN (used))))(VP (VBP (analyze))(NP (NP (JJ (transcriptional))(NN (profile))(NN (HCT116))(JJ (colorectal))(NN (cancer))(NN (cell)))(VP (VBN (treated))(NP (NP (NP (NN (5-fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NN (oxaliplatin))(VBN (selected))(NN (resistance))(NN (agent))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 198:D13.444.308 209:G02.111.087.847 560:D03.383.742.698.875.404 717:A11.251.210.190.380 718:E05.588.570  |ES| 10:1 14:1 17:1 18:1 19:1 94:1 476:1 559:1 566:1 661:1 666:1 728:1 913:1 1094:1 1099:1 1711:1 2307:1 2308:1 2543:1 2585:1 2586:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Latexin)))(VP (VBP (exhibit))(NP (NN (tumor))(NN (suppressor))(JJ (potential))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 104:C04.557.470.200.025.255 175:J01.897.280.500.269 206:G05.360.340.024.340.375.249  |ES| 7:1 19:1 303:1 304:1 587:1 700:1 827:1 2720:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (Up-regulation))(JJ (several))(NN (miR-1))(NN (target)))(PP (VBG (including))(NP (NP (NN (FoxP1)))(, (,))(NP (NN (MET)))(, (,))(NP (NN (HDAC4))(JJ (primary))(JJ (human))(NNS (HCCs))(NP (NN (down-regulation))(NN (expression))(JJ (5-AzaC-treated))(NN (HCC))(NN (cell)))))))(VP (VBP (suggest))(NP (NN (role))(NN (hepatocarcinogenesis))))) |ET|  |BS| 15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880  |ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1  |EV| 
-2.3123336854932858841493725776672  |BT| (S (ADVP (RB (Herein)))(, (,))(VP (VBD (found))(SBAR (IN (whereas))(S (VP (VBG (sparing))(NP (NP (JJ (normal))(NP (JJ (human))(NN (colon))(JJ (mucosal))(JJ (epithelial))(NN (cell))))(, (,))(NP (NN (EPLE))))(VP (ADVP (RB (selectively)))(VBD (inhibited))(NP (NN (proliferation))(NN (CRC))(NN (cell))(NN (line)))(ADVP (RB (well)))(NP (JJ (primary))(NN (tumor))(NN (cell))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 41:A11 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 122:C14.280.383 183:G04.299.233.750 302:A10.615.550  |ES| 2:1 7:1 19:1 36:1 37:1 94:1 113:1 118:1 127:1 245:1 264:1 299:1 344:1 365:1 372:1 428:1 787:1 2489:1 3521:1 3522:1 3523:1  |EV| 
-4.3916130581683914257951073523145  |BT| (FRAG (NP (NNS (CONCLUSIONS))(: (:)))(NP (NN (Pitavastatin))(JJ (effective))(VBG (inhibiting))(NP (JJ (early))(NN (phase))(JJ (obesity-related))(NN (liver))(NN (tumorigenesis))))(, (,))(ADVP (RB (therefore)))(, (,))(NP (MD (may))(NP (JJ (useful))(NN (chemoprevention))(NN (liver))(NN (cancer))(JJ (obese))(NN (individual))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 122:C14.280.383 242:A03.620 253:E02.319.162 493:M01 564:C18.654.726.500  |ES| 2:1 18:1 19:1 78:1 104:1 218:1 239:1 491:1 836:1 870:1 880:1 1036:1 1128:1 1639:1 2467:1 2468:1 2512:1 2529:1 3387:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (AIRmax)))(ADVP (RB (also)))(NP (JJ (susceptible))(NN (AIRmin))(NN (colon))(NN (cancer)))(VP (VP (VBD (induced))(NP (NP (QP (CD (2))(CD (7)))(JJ (weekly))(NNS (dos)))(ADJP (ADJP (JJ (1,2-dimethylhydrazine)))(PRN (-LRB- (-LRB-))(NP (NN (DMH)))(-RRB- (-RRB-)))))(, (,))(S (VP (VBG (showing))(NP (NP (ADJP (RB (significantly))(JJR (higher)))(NN (number))(JJ (colonic))(JJ (aberrant))(NN (crypt))(NN (focus)))(PRN (-LRB- (-LRB-))(NP (NN (ACF)))(-RRB- (-RRB-))))(NP (CD (150))(NN (day))(NN (DMH))(NN (treatment))))))(PRN (-LRB- (-LRB-))(S (NP (NN (P)))(VP (JJ (=))(NP (CD (0.01)))))(-RRB- (-RRB-))))(NP (ADJP (RB (significantly))(JJR (higher)))(NN (number))(NN (tumor))(VBG (affecting))(NP (NP (JJR (larger))(JJ (intestinal))(NN (area)))(CD (300-475))(NN (day))))) |ET|  |BS| 8:C04 46:A03.556.124.526.356 52:E02 292:Z01 433:F01.470.047 824:C04.834.020 1177:A03.556.124.526  |ES| 2:1 5:1 7:1 10:1 14:1 18:1 19:1 109:1 113:1 124:1 148:1 170:1 311:1 315:1 412:1 546:1 581:1 646:1 677:1 899:1 988:1 1431:1 1725:1 2201:1 2530:1 2642:1 2643:1 2653:1 2913:1 2914:1 4074:1 4075:1 4076:1 4077:1 4078:1 4079:1 4080:1 4081:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Garlic))(NN (oil)))(VP (VBD (attenuated))(NP (NP (JJ (nitrosodiethylamine-induced))(NN (hepatocarcinogenesis)))(VP (VBG (modulating))(NP (JJ (metabolic))(NN (activation))(NN (detoxification))(NN (enzyme))))))) |ET|  |BS| 554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811  |ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Melatonin)))(VP (VBD (improved))(SBAR (S (NP (NN (survival))(NN (rate)))(VP (ADVP (RB (successfully)))(VBD (attenuated))(NP (NN (liver))(NN (injury))))))(, (,))(VP (VBN (shown))(NP (NN (histopathology))))(, (,))(VP (VBD (decreased))(NP (NP (NN (level))(NN (serum))(NN (transaminase)))(NP (VBN (reduced))(NN (expression))(JJ (placental))(NN (glutathione))(NN (S-transferase))))))) |ET|  |BS| 242:A03.620 707:D03.438.473.914.481 779:E05.318.308.985.550.900 780:D08.811.913.225.500 781:D08.811.913.477.700 782:A12.207.152.846 783:A16.710  |ES| 2:1 19:1 41:1 115:1 202:1 237:1 249:1 274:1 452:1 808:1 836:1 2410:1 2416:1 2738:1 2739:1 2740:1 2741:1 2742:1 2743:1 2744:1 2745:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Loss))(NN (metallothionein)))(VP (VBZ (predisposes))(NP (NN (mouse))(JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(VBG (activating))(NN (NF-kappaB))(NN (target))(NN (gene))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670  |ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1  |EV| 
-1.4315982286929056499502621591091  |BT| (FRAG (NP (NP (DT (The))(NN (copper))(NN (chelator))(NN (trientine))(JJ (antiangiogenic))(NN (effect)))(NP (JJ (hepatocellular))(NN (carcinoma)))(, (,))(NP (ADVP (RB (possibly)))(NN (inhibition))(NN (interleukin-8))(NN (production))))) |ET|  |BS| 12:Z01.542.049 43:F01.145.544 104:C04.557.470.200.025.255 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195  |ES| 2:1 19:1 75:1 103:1 303:1 304:1 691:1 1548:1 2677:1 3801:1 3802:1 3803:1 3804:1 3805:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(NP (NP (JJ (Regular))(NN (aspirin))(NN (use))(NN (diagnosis))(JJ (colorectal))(NN (cancer)))(VP (VBD (associated))(NP (NP (JJR (lower))(NN (risk))(JJ (colorectal))(JJ (cancer-specific))(JJ (overall))(NN (mortality)))(, (,))(PP (ADVP (RB (especially)))(IN (among))(NP (JJ (individual))(NN (tumor)))))(S (VP (VBP (overexpress))(NP (NN (COX-2)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 493:M01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 696:V02.270.500  |ES| 2:1 7:1 17:1 18:1 19:1 76:1 104:1 117:1 169:1 171:1 345:1 1037:1 1372:1 1659:1 1882:1 2487:1 2508:1 2509:1 2510:1 2511:1 2512:1 2513:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (NN (study))))(, (,))(VP (VBD (determined))(NP (NP (JJ (combined))(NN (effect))(NN (celecoxib)))(, (,))(NP (NN (COX-2))(NN (inhibitor)))(, (,)))(PP (IN (along))(NP (NP (NP (NN (exisulind)))(PRN (-LRB- (-LRB-))(NP (NN (sulindac))(NN (sulfone/Aptosyn)))(-RRB- (-RRB-))))(JJ (low))(NNS (dos))(NN (prostate))(NN (cancer)))))) |ET|  |BS| 349:D27.505.519.389.310.500 684:D02.065.884.247  |ES| 2:1 10:1 14:1 18:1 19:1 75:1 76:1 77:1 131:1 164:1 244:1 380:1 531:1 869:1 1582:1 2653:1 2666:1 2807:1 3575:1 3576:1  |EV| 
-2.9727829815594759566010907292366  |BT| (NP (NP (NP (NN (BTG3))(NN (tumor))(NN (suppressor))(NN (gene))(NN (promoter))(NN (demethylation)))(, (,))(NP (NN (histone))(NN (modification))(NN (cell))(NN (cycle))(NN (arrest)))(NP (NN (genistein))(JJ (renal))(NN (cancer))))) |ET|  |BS| 206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375  |ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NN (finding)))(VP (VBP (suggest))(NP (NN (rimonabant))(ADJP (JJ (able))(S (VP (VBP (inhibit))(NP (NP (JJ (colorectal))(NN (cancer))(NN (cell))(NN (growth))(JJ (different))(NN (stage))(NN (colon))(NN (cancer))(NN (pathogenesis)))(VP (VBG (inducing))(NP (JJ (mitotic))(NN (catastrophe))(NN (vitro))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 122:C14.280.383 385:F02.784.629.131  |ES| 17:1 18:1 19:1 94:1 102:1 113:1 216:1 414:1 501:1 658:1 720:1 796:1 927:1 1129:1 1370:1 1864:1 2831:1 2832:1 2833:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (Sulindac))(NN (reversal))(JJ (15-PGDH-mediated))(NN (resistance))(NN (colon))(NN (tumor))(NN (chemoprevention))(NNS (NSAIDs)))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500  |ES| 7:1 19:1 113:1 870:1 1094:1 2965:1 2966:1 3770:1 3771:1  |EV| 
-1.5147634258028119802474975585938e-08  |BT| (S (NP (NP (VBG (Transforming))(NN (growth))(NN (factor-beta))(NN (adaptor)))(, (,))(NP (NN (beta2-spectrin)))(, (,)))(VP (VBZ (modulates))(S (NP (NN (cyclin))(JJ (dependent))(NN (kinase))(CD (4)))(VP (VB (reduce))(NP (NN (development))(JJ (hepatocellular))(NN (cancer))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 503:D12.644.276.374.687 1106:D08.811.913.696.620.682.700.646.500.875 1107:D12.776.124.875  |ES| 2:1 18:1 19:1 35:1 102:1 303:1 319:1 321:1 470:1 606:1 743:1 1773:1 2361:1 3877:1 3878:1 3879:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Liver))(NN (cell))(NN (proliferation)))(VP (VBD (increased))(ADVP (RB (significantly)))(NP (NP (NN (liver))(NN (tumor))(JJ (tamoxifen-treated))(NN (rat)))(NP (ADJP (CD (12))(NN (month)))(NN (treatment))(NN (recovery))(NN (period)))))) |ET|  |BS| 52:E02 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 775:E02.760.058 776:G01.910.645  |ES| 7:1 19:1 47:1 94:1 124:1 299:1 546:1 836:1 849:1 1120:1 2721:1 2722:1 2723:1 2724:1 2725:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (ADVP (RB (Importantly)))(, (,))(NP (NN (cotreatment))(JJ (low))(NNS (dos))(NP (NP (NNS (oligoamines))(NN (DNA))(NN (methyltransferase))(NN (inhibitor)))(ADVP (RB (highly)))))(VP (VBZ (induces))(SBAR (S (NP (NN (reexpression)))(ADVP (RB (aberrantly)))(VP (VBD (silenced))(SBAR (S (NP (NN (SFRP2))(NN (gene)))(VP (VBP (result))(NP (NP (JJ (significant))(NN (inhibition))(NN (growth)))(VBN (established))(NN (tumor))(JJ (human))(NN (colon))(NN (tumor))(NN (model)))(FW (vivo)))))))))) |ET|  |BS| 6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240  |ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(JJ (present))(NN (study)))(VP (VBP (identify))(S (NP (NP (JJ (chemopreventive))(JJ (potential))(NN (pterostilbene))(JJ (colonic))(NN (tumor))(NN (formation)))(NN (end))(NN (point)))(VP (VB (evaluate))(NP (JJ (mechanistic))(NN (action))(NN (pterostilbene))(NN (colon))(NN (carcinogenesis))))))) |ET|  |BS| 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 225:E05.337 742:G03.787  |ES| 7:1 19:1 43:1 113:1 131:1 207:1 658:1 677:1 827:1 832:1 890:1 1307:1 1890:1 1946:1 2013:1 2121:1 2428:1 2834:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Past))(NN (study)))(VP (VBN (shown))(VP (VBD (amplified))(NP (NP (NP (JJ (insulin-like))(NN (growth))(NN (factor))(CD (1)))(PRN (-LRB- (-LRB-))(NP (NN (IGF1)))(-RRB- (-RRB-))))(: (/))(NP (NP (NP (NP (NN (IGF1))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (IGF1-R)))(-RRB- (-RRB-))))(NN (signalling))(JJ (important))(NN (role)))(NP (NP (NP (JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(NP (NN (development)))))(, (,))(NP (NN (progression))(NN (resistance))(NN (treatment))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 16:C23.550.291.656 52:E02 518:D08.811.913.696.620.682.725.400.185 598:D12.644.276.937.400 599:M01.526.799.500  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 31:1 35:1 48:1 98:1 102:1 131:1 185:1 186:1 237:1 245:1 546:1 902:1 1094:1 2093:1 2198:1 2208:1 2437:1 3697:1 3698:1 3699:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (METHODOLOGY/PRINCIPAL))(NNS (FINDINGS)))(: (:))(NP (NP (JJ (Pancreatic))(NN (cancer))(NN (cell))(NN (line)))(VP (VBN (treated))(NP (NN (resveratrol))))))) |ET|  |BS| 52:E02 94:A11.251.210  |ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Pamidronate)))(VP (VBD (induced))(NP (JJ (anti-proliferative))(, (,))(NP (JJ (apoptotic))(, (,))(NP (JJ (anti-migratory))(NN (effect))(JJ (hepatocellular))(NN (carcinoma))))))) |ET|  |BS| 39:G04.299.139.160 104:C04.557.470.200.025.255  |ES| 2:1 19:1 75:1 303:1 304:1 412:1 2223:1 3694:1 3695:1 3696:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (DT (These)))(VP (VBP (result))(VP (VBP (suggest))(SBAR (S (NP (NN (inflexinol)))(VP (VBZ (inhibits))(NP (NN (colon))(NN (cancer))(NN (cell))(NN (growth)))(PP (IN (via))(NP (NP (NN (induction)))(NP (NP (JJ (apoptotic))(NN (cell))(NN (death))(NN (inactivation))(NN (NF-kappaB)))(NP (NP (JJ (direct))(NN (modification))(NN (cysteine))(NN (residue)))(NP (NN (p50))(NN (subunit))(NN (NF-kappaB))))))))))))) |ET|  |BS| 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383 210:D12.776.260.600 583:D12.776.813 643:D02.886.030.230  |ES| 18:1 19:1 94:1 101:1 102:1 113:1 411:1 596:1 615:1 714:1 736:1 792:1 796:1 1314:1 1891:1 2110:1 2223:1 2373:1 2374:1 2375:1 2376:1 2377:1  |EV| 
-3.5129071809406013926491141319275  |BT| (S (PP (IN (In))(NP (NN (HepG2))(NN (cell))))(, (,))(S (S (NP (NN (transfection))(NN (RARgamma)))(VP (VBD (enhanced))))(, (,))(IN (whereas))(S (NP (NN (downregulation))(NN (RARgamma))(NN (expression))(NN (siRNA))(NN (approach)))(VP (VBD (impaired)))))(, (,))(NP (NN (effect))(NN (RA))(VBG (inducing))(NN (expression))(NN (alpha-fetoprotein))(, (,))(NN (protein))(NN (marker))(NN (hepatocarcinogenesis)))) |ET|  |BS| 85:G02.111.087.225 112:D12.776.097.820 117:D13.150.650.700 158:D23.101 217:E05.393.350.810 748:D12.776.124.790.106.092 1015:A11.251.860.180.432  |ES| 2:1 4:1 19:1 75:1 94:1 115:1 244:1 351:1 372:1 385:1 534:1 595:1 746:1 900:1 911:1 1864:1 2003:1 2665:1 3481:1 3556:1 3557:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Garcinol)))(VP (VBZ (suppresses))(NP (JJ (inflammation-associated))(NN (colon))(NN (carcinogenesis))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 53:C06.405.205.265  |ES| 19:1 52:1 113:1 207:1 686:1 1849:1 2612:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Acylglycerol))(NN (kinase)))(VP (VBZ (promotes))(NP (NN (cell))(NN (proliferation))(NN (tumorigenicity))(NN (breast))(NN (cancer)))(PP (IN (via))(NP (NN (suppression))(NN (FOXO1))(NN (transcription))(NN (factor)))))) |ET|  |BS| 183:G04.299.233.750 209:G02.111.087.847  |ES| 18:1 19:1 23:1 94:1 185:1 298:1 299:1 300:1 470:1 487:1 596:1 2453:1 3263:1 3264:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (NP (DT (The))(JJ (present))(NN (work)))(VP (VBZ (provides))(NP (NP (JJ (novel))(NNS (data)))(PP (VBG (concerning))(NP (JJ (preventive))(NN (action))(NN (glycerol))(NN (development))(NN (liver))(NN (cancer)))))))(VP (VBZ (represents))(NP (ADJP (RB (economically))(JJ (feasible)))(NN (intervention))(NN (treat))(JJ (high-risk))(NN (individual)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 61:E05.318.740.600.800 259:D12.776.395.240.150.500 445:I03.946 493:M01 697:D02.033.800.421 698:I01.261  |ES| 18:1 19:1 35:1 104:1 106:1 691:1 793:1 815:1 836:1 891:1 1090:1 1307:1 1546:1 1645:1 1882:1 1883:1 2013:1 2512:1 2514:1 2515:1 2516:1 2517:1 2518:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (azoxymethane-treated))(NN (rat))(NN (model))(JJ (experimental))(NN (colon))(NN (carcinogenesis))))(, (,))(NP (NN (sulindac))(NN (treatment)))(ADVP (RB (markedly)))(VP (VBD (induced))(NP (NP (NNP (Csk))(JJ (corresponding))(NN (increase))(JJ (inhibitory))(NN (phosphorylation))(NN (Src)))(PRN (-LRB- (-LRB-))(NP (NN (Tyr))(PRN (-LRB- (-LRB-))(CD (527))(-RRB- (-RRB-)))(-RRB- (-RRB-))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 52:E02 95:E05.599 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500  |ES| 2:1 10:1 14:1 19:1 40:1 72:1 113:1 207:1 244:1 263:1 412:1 546:1 849:1 869:1 2396:1 2429:1 2793:1 3426:1 3674:1 4230:1 4231:1 4232:1 4233:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(JJ (previous))(NN (study)))(VP (VBD (demonstrated))(SBAR (S (NP (NP (JJ (garlic))(NN (oil)))(PRN (-LRB- (-LRB-))(NP (NN (GO)))(-RRB- (-RRB-))))(VP (MD (could))(VP (VB (prevent))(NP (JJ (NDEA-induced))(NN (hepatocarcinogenesis))(NN (rat)))(, (,))(NP (NP (VBG (underlying))(NN (mechanism)))(VP (ADVP (RB (fully)))(VBN (understood)))))))))) |ET|  |BS| 239:F02.463.188.357 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200  |ES| 2:1 10:1 14:1 19:1 131:1 162:1 435:1 658:1 733:1 849:1 889:1 900:1 908:1 979:1 1175:1 1819:1 2614:1 2835:1 2836:1 2837:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (DT (These))(NN (observation)))(VP (VBP (suggest))(SBAR (S (NP (JJR (safer))(JJ (efficacious))(NN (sulindac))(NN (derivative)))(VP (VBD (developed))(NP (NP (JJ (colorectal))(NN (cancer))(NN (chemoprevention)))(VP (VBG (targeting))(NP (NN (PDE5)))(VP (ADVP (RB (possibly)))(NP (JJ (cGMP-degrading))(NNS (isozymes))))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 251:D02.455.426.559.847.486.875 253:E02.319.162 429:N04.761.559.590.900 430:E05.581.249 993:D08.811.348 1100:D03.438.759.646.454.160 1101:N06.850.135.060.075  |ES| 17:1 18:1 19:1 190:1 616:1 792:1 796:1 869:1 870:1 1165:1 1477:1 1548:1 2813:1 3858:1 3859:1 3860:1 3861:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (DT (The))(NN (effect))(NN (folate))(NN (transporter))(NN (gene))(NN (ablation))(NN (colon))(NN (carcinogenesis)))(VP (VBD (evaluated))(NP (NP (CD (8))(CD (38))(NN (week)))(JJ (post-azoxymethane))(NN (injection))(JJ (wild-type))(JJ (heterozygous))(NN (mouse))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530  |ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Connexin))(CD (32))(NN (luteolin))(NN (play))(JJ (protective))(NN (role)))(JJ (non-alcoholic))(NN (steatohepatitis))(NN (development))(JJ (related))(NN (hepatocarcinogenesis))(NN (rat)))) |ET|  |BS| 15:F01.829.316.616 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 704:D03.383.663.283.266.450.260.555  |ES| 19:1 31:1 35:1 238:1 419:1 493:1 849:1 900:1 1791:1 2069:1 2545:1 2546:1 2547:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Dietary))(NN (lycopene))(NN (tomato))(NN (extract))(NN (supplementation)))(VP (VBP (inhibit))(NP (JJ (nonalcoholic))(JJ (steatohepatitis-promoted))(NN (hepatocarcinogenesis))(NN (rat))))) |ET|  |BS| 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 509:C06.552.241.519 595:G07.203.650.240  |ES| 19:1 849:1 900:1 1097:1 1370:1 1796:1 2496:1 2562:1 2566:1 2567:1 2568:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(VP (VBP (result))(VP (VBP (suggest))(SBAR (S (NP (NN (ADAM9)))(VP (VBZ (contributes))(NP (NN (pathogenesis))(NN (prostate))(NN (cancer)))(ADVP (RB (potentially)))(ADVP (RB (also)))(NP (NN (carcinoma)))(, (,))(S (VP (VBG (raising))(SBAR (S (NP (NN (possibility))(NN (ADAM9)))(VP (MD (might))(NP (JJ (good))(NN (target))(NN (antitumor))(NN (drug)))))))))))))) |ET|  |BS| 265:C04.557.470.200 369:E02.319.300  |ES| 2:1 5:1 18:1 19:1 77:1 101:1 160:1 191:1 304:1 343:1 501:1 773:1 796:1 798:1 845:1 1318:1 1537:1 1538:1 2244:1 3211:1 3212:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (PRP$ (Our))(VP (VBP (result))(VP (VBP (demonstrate)))(, (,))(NP (ADVP (JJ (first))(NN (time)))(, (,))(NP (NP (NP (ADJP (NN (elaiophylin))(JJ (novel)))(NN (autophagy))(NN (inhibitor)))(, (,))(NP (NP (JJ (significant))(NN (antitumor))(NN (efficacy)))(JJ (single))(NP (NN (agent))(NN (combination))(JJ (human))(JJ (ovarian))(NN (cancer))(NN (cell)))))(, (,))(VP (VBG (establishing))(NP (JJ (potential))(NN (treatment))(JJ (ovarian))(NN (cancer))(NN (compound))))))))) |ET|  |BS| 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 259:D12.776.395.240.150.500 322:G01.910 390:G04.299.139.399 660:D27.505.954.248 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725  |ES| 2:1 18:1 19:1 36:1 94:1 101:1 135:1 380:1 502:1 530:1 546:1 658:1 728:1 816:1 827:1 891:1 1081:1 1317:1 1763:1 2244:1 2304:1 2433:1 2845:1 2846:1 2847:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Intake))(NNS (isoflavones)))(SBAR (S (NP (VBN (derived))(NN (soybean))(NN (product)))(VP (MD (may))(VP (VB (impact))(NP (NN (prostate))(NN (cancer))(NN (risk))))))))) |ET|  |BS| 61:E05.318.740.600.800 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400  |ES| 18:1 19:1 77:1 171:1 491:1 675:1 1721:1 3541:1 3597:1 3598:1 3599:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NNS (data)))(VP (VBD (indicated))(SBAR (S (NP (NN (nifuroxazide)))(VP (MD (may))(ADVP (RB (potentially)))(NP (JJ (therapeutic))(NN (agent))(NN (growth))(NN (metastasis))(NN (breast))(NN (cancer)))))))) |ET|  |BS| 52:E02 113:C04.697.650  |ES| 18:1 19:1 23:1 102:1 491:1 541:1 658:1 728:1 773:1 793:1 806:1 1541:1 2820:1  |EV| 
-0.28197646704768430936383083462715  |BT| (S (NP (DT (A))(JJ (novel))(JJ (CYR61-triggered))(`` (`))(NN (CYR61-alphavbeta3))(NN (integrin))(NN (loop)))('' ('))(VP (VBZ (regulates))(NP (NN (breast))(NN (cancer))(NN (cell))(NN (survival))(NN (chemosensitivity))(NN (activation))(NN (ERK1/ERK2))(NN (MAPK))(NN (signaling))(NN (pathway))))) |ET|  |BS| 69:G02.111.087.800 108:G04.299.316 116:D08.811.913.696.620.682.700.567.249.750 126:G02.111.087.800 259:D12.776.395.240.150.500 573:N05.715.350.200.650 919:D08.811.913.696.620.682.700.567.249.500 920:D12.776.543.750.705.408  |ES| 18:1 19:1 23:1 69:1 94:1 195:1 225:1 248:1 274:1 383:1 386:1 603:1 809:1 891:1 1489:1 3241:1 3242:1 3243:1 3244:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Ethanol))(NN (consumption))(NN (cause))(JJ (serious))(NN (liver))(NN (injury)))(PP (VBG (including))(NP (NN (cirrhosis))(JJ (hepatocellular))(NN (carcinoma)))))) |ET|  |BS| 73:N05.715.350.200 104:C04.557.470.200.025.255 242:A03.620 357:C06.552.630 662:C23.550.355 904:F01.145.317.269  |ES| 19:1 303:1 304:1 561:1 836:1 1199:1 1779:1 2387:1 2416:1 3178:1 3179:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Nitric))(JJ (oxide-releasing))(NN (aspirin))(NN (indomethacin))(JJ (potent))(NN (inhibitor))(NN (colon))(NN (cancer))(JJ (azoxymethane-treated))(NN (rat)))(: (:))(NP (NN (effect))(JJ (molecular))(NN (target))))) |ET|  |BS| 52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420  |ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1  |EV| 
-0.89958223240796542086172848939896  |BT| (NP (NNS (defensins))(NP (NP (NN (matrilysin)))(, (,))(S (ADVP (RB (highly)))(VP (VBN (overexpressed))(NP (NN (colon))(NN (cancer))))))) |ET|  |BS| 937:D08.811.277.656.300.480.525.700.250 1089:D12.644.050.200  |ES| 2:1 18:1 19:1 25:1 113:1 626:1 3289:1 3806:1  |EV| 
-4.3724034775933660057489760220051  |BT| (NP (NP (NP (NNP (UNLABELLED)))(: (:))(NP (NP (DT (The))(NN (Wnt/beta-catenin))(NN (pathway)))(VP (VBN (implicated))(NP (NP (NN (pathogenesis))(JJ (hepatocellular))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))) |ET|  |BS| 23:D12.776.091.249 147:G02.149.115.800.925  |ES| 10:1 14:1 18:1 19:1 104:1 302:1 303:1 383:1 441:1 501:1 691:1 977:1 2266:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NNP (Brucine)))(, (,))(NP (NN (alkaloid))(NN (seed))))(VP (VBZ (Strychnos))(NP (JJ (nux-vomica))(NNP (Linn))))) |ET|  |BS| 12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 631:D03.132 681:G04.299.283 682:D12.776.260.103.625  |ES| 2:1 19:1 31:1 63:1 94:1 98:1 104:1 185:1 303:1 304:1 383:1 514:1 806:1 2315:1 2320:1 2321:1 2322:1 2323:1 2472:1 2473:1 2474:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Compound))(NN (Astragalus)))(NP (FW (Salvia))(FW (miltiorrhiza))(NN (extract)))(VP (VBZ (suppresses))(NP (NP (JJ (hepatocellular))(NN (carcinoma))(NN (progression)))(VP (VBG (inhibiting))(NP (NN (fibrosis))(NN (PAI-1))(NN (mRNA))(NN (transcription))))))) |ET|  |BS| 16:C23.550.291.656 104:C04.557.470.200.025.255 111:D13.444.735.544 122:C14.280.383 209:G02.111.087.847 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 690:D12.644.861.695.500 691:C23.550.355  |ES| 19:1 48:1 303:1 304:1 325:1 487:1 686:1 880:1 949:1 2492:1 2493:1 2494:1 2495:1 2496:1 2497:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNP (Sorafenib)))(VP (VBZ (sensitizes))(NP (JJ (hepatocellular))(ADJP (NN (carcinoma))(NN (cell))(JJ (physiological)))(JJ (apoptotic))(NN (stimulus))))) |ET|  |BS| 39:G04.299.139.160 104:C04.557.470.200.025.255 230:G04  |ES| 19:1 94:1 303:1 304:1 2062:1 2223:1 2730:1 3210:1 3762:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (ADVP (RB (However)))(, (,))(NP (NN (investigation))(JJ (protective))(NN (effect))(NN (betaine))(NN (hepatocarcinogenesis))))) |ET|  |BS| 225:E05.337 743:D02.092.877.883.077  |ES| 2:1 19:1 75:1 433:1 493:1 900:1 1497:1 2636:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (Signal))(NN (transducer))(NN (activator))(NN (transcription))(CD (3)))(PRN (-LRB- (-LRB-))(NP (NN (STAT3)))(-RRB- (-RRB-))))(VP (VBZ (mediates))(NP (NN (pathogenesis))(NN (colon))(NN (cancer))(NN (substrate))(NN (PTK6))))) |ET|  |BS| 209:G02.111.087.847 250:E07.305.812  |ES| 10:1 14:1 18:1 19:1 113:1 251:1 487:1 501:1 755:1 860:1 861:1 862:1 1041:1 2960:1 3757:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NNP (Myrtenal)))(, (,))(NP (JJ (natural))(NN (monoterpene)))(, (,)))(VP (VBZ (down-regulates))(SBAR (S (NP (NN (TNF-alpha))(NN (expression)))(VP (VBZ (suppresses))(NP (JJ (carcinogen-induced))(JJ (hepatocellular))(NN (carcinoma))(NN (rat)))))))) |ET|  |BS| 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 351:A17.360 758:D02.455.849.575 789:D12.644.276.374.500.800 790:D12.644.276.374.750  |ES| 2:1 19:1 115:1 303:1 304:1 686:1 849:1 2333:1 2421:1 2683:1 2773:1 2774:1 2775:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Glycine))(NN (soya))(NN (diet)))(ADVP (RB (synergistically)))(VP (VBZ (enhances))(SBAR (S (NP (JJ (suppressive))(NN (effect))(NN (tamoxifen)))(VP (VBZ (inhibits))(NP (NP (JJ (tamoxifen-promoted))(NN (hepatocarcinogenesis)))(JJ (7,12-dimethylbenz))(PRN (-LRB- (-LSB-))(NP (NN (alpha)))(-RRB- (-RSB-)))(JJ (anthracene-induced))(NN (rat))(JJ (mammary))(NN (tumor))(NN (model)))))))) |ET|  |BS| 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 408:C04.588.531 595:G07.203.650.240 596:E02.642.249 640:D02.455.426.559.389.150.700.900 1001:B01.650.940.800.575.100.401.750 1002:C04.588.180 1003:D12.125.481  |ES| 7:1 19:1 72:1 75:1 615:1 849:1 900:1 1356:1 1373:1 1378:1 1836:1 1974:1 2191:1 2248:1 2371:1 3349:1 3499:1 3500:1 3501:1 3502:1 3503:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(VP (VBD (examined))(NP (NN (effect))(NN (pioglitazone))(NN (lung))(NN (cancer))(NN (development))(JJ (carcinogen-induced))(NN (lung))(NN (adenocarcinoma))(NP (NP (JJ (squamous))(NN (cell))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (SCC)))(-RRB- (-RRB-))))))) |ET|  |BS| 279:D27.888.569.100 929:C04.557.470.200.400  |ES| 10:1 14:1 18:1 19:1 35:1 75:1 94:1 255:1 304:1 324:1 328:1 843:1 1067:1 2421:1 3897:1 3898:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (JJ (Dietary))(NN (intake))(NN (pterostilbene)))(, (,))(NP (NN (constituent))(NN (blueberry)))(, (,)))(VP (VBZ (inhibits))(NP (NN (beta-catenin/p65))(JJ (downstream))(NN (signaling))(NN (pathway))(NN (colon))(NN (carcinogenesis))(NN (rat))))) |ET|  |BS| 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249  |ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Lycopene))(JJ (active))(JJ (chemopreventive))(NN (agent))(NN (offer))(NN (protection))(JJ (DEN-induced))(NN (hepatocarcinogenesis)))(VP (VBG (inhibiting))(NP (NN (NF-kappaB))(NN (mTOR))(NN (pathway))))) |ET|  |BS| 122:C14.280.383 210:D12.776.260.600  |ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1  |EV| 
-1.1126667922348900674478500150144  |BT| (NP (NP (NP (NP (NNP (Neurotensin))(NN (receptor-1)))(PRN (-LRB- (-LRB-))(NP (NN (NTR-1)))(-RRB- (-RRB-))))(NP (JJ (overexpressed))(NN (colon))(NN (cancer))(NN (colon))(NN (cancer))(NN (cell))(NN (line))))) |ET|  |BS| 94:A11.251.210 1048:D12.776.543.750.100.550  |ES| 10:1 14:1 18:1 19:1 25:1 94:1 113:1 264:1 3656:1 3657:1 3658:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NP (NN (5-Fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (common))(JJ (chemotherapeutic))(NN (agent)))(VP (VBN (used))(NP (NP (NP (NN (treatment))(JJ (colorectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (CRC)))(-RRB- (-RRB-))))(, (,))(NP (JJ (inadequate))(NN (response))(NN (rate)))(: (;))(VP (VBG (highlighting))(NP (NN (need))(NN (novel))))))))(VP (VBD (improved))(NP (NN (treatment))(NNS (regimen))(NN (patient))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 259:D12.776.395.240.150.500 284:N03.349.380.420 532:E02.183 560:D03.383.742.698.875.404 660:D27.505.954.248  |ES| 2:1 10:1 14:1 17:1 18:1 19:1 41:1 120:1 217:1 245:1 476:1 494:1 546:1 655:1 728:1 891:1 1762:1 1881:1 2308:1 2404:1 2407:1 2408:1 2409:1 2410:1  |EV| 
-2.4658414013250649077235721051693  |BT| (S (NP (NN (Curcumin)))(VP (VBZ (sensitizes))(NP (NP (JJ (human))(JJ (colorectal))(NN (cancer))(NN (xenograft))(JJ (nude))(NN (mouse))(NN (gamma-radiation)))(VP (VBG (targeting))(NP (JJ (nuclear))(JJ (factor-kappaB-regulated))(NN (gene))(NN (product))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335  |ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNS (RESULTS))(: (:)))(S (NP (NN (Nestin))(NN (expression)))(ADVP (RB (significantly)))(VP (VBD (associated))(NP (NP (JJ (poor))(NN (survival))(NN (patient))(JJ (triple-negative))(NN (breast))(NN (cancer)))(PRN (-LRB- (-LRB-))(S (NP (NN (P)))(VP (JJ (=))(NP (CD (0.01)))))(-RRB- (-RRB-))))))) |ET|  |BS| 50:M01.643 96:I03.784 159:I01.880.735.634 160:C04.588.180.788 1047:D05.750.078.593.540  |ES| 10:1 14:1 18:1 19:1 23:1 26:1 104:1 115:1 120:1 124:1 169:1 274:1 311:1 315:1 545:1 581:1 710:1 3650:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNP (Sorafenib))(NN (increase))(NN (survival))(NN (rate))(NN (patient)))(VP (VBD (advanced))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))) |ET|  |BS| 50:M01.643 104:C04.557.470.200.025.255 779:E05.318.308.985.550.900  |ES| 10:1 14:1 19:1 40:1 41:1 120:1 274:1 303:1 304:1 441:1 997:1 3210:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PRP$ (Our))(VP (VBP (result))(ADVP (RB (clearly)))(VP (VBP (indicate))(SBAR (S (NP (JJ (sulfated))(NN (polysaccharide))(NNP (U.))(NN (lactuca)))(VP (VBD (exert))(NP (JJ (marked))(NN (chemoprevention))(JJ (DENA-initiated))(NN (hepatocarcinogenesis))(NN (inhibition))(JJ (abnormal))(NN (cell))(NN (proliferation))(NN (induction))(NN (apoptosis))))))))) |ET|  |BS| 39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 253:E02.319.162 554:D02.654.442.200 803:D01.248.497.158.845 804:D09.698  |ES| 19:1 89:1 94:1 101:1 103:1 299:1 658:1 736:1 870:1 900:1 1229:1 1479:1 2802:1 2838:1 2839:1 2840:1 2841:1 2842:1 2843:1 2844:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Pharmacogenetic))(NN (approach))(NN (capecitabine))(NN (5-fluorouracil))(NN (selection)))(SBAR (S (NP (VBN (combined))(NN (oxaliplatin))(JJ (first-line))(NN (chemotherapy)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 151:E02.319 375:Z01.639.100 560:D03.383.742.698.875.404 810:D03.383.742.680.245.500.425 811:H01.158.273.343.750 812:G05.355.800  |ES| 17:1 18:1 19:1 164:1 495:1 911:1 997:1 2307:1 2490:1 2543:1 2872:1 2873:1 2874:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(S (NP (NP (JJ (Hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(ADVP (RB (rapidly)))(VP (VBG (increasing))(NP (NP (NN (cancer)))(WHNP (WHNP (WP$ (whose))(JJ (known))(NN (risk))(NN (factor)))(NP (JJ (chronic))(NN (ethanol))(NN (abuse))))(, (,))(NP (JJ (viral))(NN (hepatitis))(NN (infection)))(, (,))(NP (NN (aflatoxin))(NN (exposure))))))) |ET|  |BS| 104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 1137:D03.383.663.283.119 1138:C02.440.420 1139:C25.775.100.250 1140:C06.552.380 1141:C02  |ES| 2:1 10:1 14:1 18:1 19:1 104:1 171:1 185:1 304:1 441:1 556:1 715:1 919:1 1046:1 1790:1 1953:1 2048:1 2151:1 2214:1 2362:1 3424:1 3440:1 3969:1 3974:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Branched-chain))(NN (amino))(NN (acid))(-LRB- (-LRB-))(NN (BCAA))(-RRB- (-RRB-)))(, (,))(VP (VB (improve))(NP (NP (NN (protein))(NN (malnutrition))(NN (patient))(NN (liver))(NN (cirrhosis)))(, (,))(S (VP (VB (reduce))(NP (NN (risk))(JJ (hepatocellular))(NN (carcinoma))(NN (patient))(NN (obesity)))))))) |ET|  |BS| 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 564:C18.654.726.500 639:D12.125.070 943:C18.654.521.719.500  |ES| 2:1 4:1 10:1 14:1 19:1 120:1 171:1 303:1 304:1 836:1 1199:1 1275:1 2010:1 2189:1 2360:1 2361:1 2465:1 2466:1 3307:1  |EV| 
-2.2626868168387055391121975844726  |BT| (UCP (ADVP (RB (Here)))(, (,))(NP (NP (NN (report))(NN (identification))(JJ (hepatic))(NNS (microRNAs)))(SBAR (S (NP (VBN (dysregulated))(JJ (early))(NN (stage))(S (VP (VBG (feeding))(NP (NP (NP (NN (C57BL/6))(NN (mouse))(JJ (choline-deficient))(NN (amino))(JJ (acid-defined)))(-LRB- (-LRB-))(JJ (CDAA))(-RRB- (-RRB-))(NN (diet)))(ADJP (VBN (known)))))))(VP (VBP (promote))(FRAG (NP (NP (JJ (nonalcoholic))(NN (steatohepatitis)))(PRN (-LRB- (-LRB-))(NP (NN (NASH)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (hepatocarcinogenesis))(CD (84))(NN (week))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 374:F01.393.446 509:C06.552.241.519 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125  |ES| 2:1 10:1 14:1 19:1 52:1 400:1 409:1 417:1 556:1 679:1 783:1 838:1 900:1 1128:1 1129:1 1259:1 1791:1 1796:1 2188:1 2189:1 2190:1 2191:1 2192:1 2942:1 3065:1 3184:1 3469:1 3517:1 3518:1  |EV| 
4.3916130581683914257951073523145  |BT| (SINV (ADVP (RB (Here)))(VP (VBN (aimed)))(VP (VBP (determine))(NP (NP (NN (mechanism))(NN (action))(NN (DHEA)))(, (,))(NP (NP (NN (comparison))(NN (vitamin))(NN (E)))(, (,))(NP (JJ (chemically-induced))(JJ (hepatocellular))(NN (carcinoma))(NN (model))(NN (rat))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 740:D04.808.054.079.429.625 741:D03.383.663.283.909 742:G03.787  |ES| 2:1 19:1 72:1 74:1 162:1 303:1 304:1 400:1 844:1 849:1 2013:1 2085:1 2233:1 2591:1 2633:1 2634:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NN (Hepatocyte))(NP (NP (CD (I))(NN (kappaB))(NN (kinase))(NN (beta)))(PRN (-LRB- (-LRB-))(NP (NN (IKK))(NN (beta)))(-RRB- (-RRB-))))(VBZ (inhibits))(NP (NP (NN (hepatocarcinogenesis)))(VP (VBG (suppressing))(NP (NP (NP (NN (accumulation))(JJ (reactive))(NN (oxygen))(NN (specie)))(PRN (-LRB- (-LRB-))(NP (NN (ROS)))(-RRB- (-RRB-))))(NN (liver))(NN (damage)))))(, (,))(SBAR (IN (whereas))(S (NP (NN (JNK1))(NN (activation)))(VP (VBZ (promotes))(NP (NP (NN (ROS))(NN (accumulation)))(, (,))(NP (NN (liver))(NN (damage)))(, (,))(NP (NN (carcinogenesis)))))))) |ET|  |BS| 33:C04.697.098 122:C14.280.383 242:A03.620 262:A11.436.348 635:D08.811.913.696.620.682.700.494 636:D01.339.431  |ES| 2:1 10:1 14:1 19:1 207:1 225:1 298:1 372:1 470:1 615:1 836:1 900:1 1848:1 1972:1 2120:1 2250:1 2349:1 2350:1 2351:1 2352:1 2353:1 2354:1 2355:1 2356:1 2357:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NN (study)))(VP (VBZ (demonstrates))(NP (NP (NN (inhibition))(NN (cell))(NN (proliferation))(NN (regulation)))(SBAR (S (NP (JJ (inflammatory))(NN (marker)))(VP (MD (may))(, (,))(ADVP (JJS (least))(NN (part)))(, (,))(S (VP (VBG (underlying))(NP (NN (mechanism))(JJ (related))(NN (liver))(NN (tumor))(NN (inhibition))(NN (diosmin))))))))))) |ET|  |BS| 41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222  |ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(VBP (suggest))(NP (NN (inosine))(CD (5)))('' ('))(: (-))(NP (NP (NN (monophosphate))(NN (dehydrogenase))(NN (inhibitor)))(, (,))(VP (ADVP (RB (already)))(VBN (used))(NP (NN (treatment))(NN (disease)))))(, (,))(VP (MD (may))(NP (VBN (used))(JJ (potential))(NN (differentiation))(NN (therapy))(NN (drug))(NN (control))(NN (prostate))(NN (cancer))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 74:G04.299.151 288:C23.550.288 1128:D08.811.682.047.820.450 1129:E02.319  |ES| 2:1 18:1 19:1 77:1 130:1 191:1 215:1 289:1 380:1 476:1 491:1 546:1 796:1 827:1 843:1 998:1 3085:1 3944:1 3945:1 3946:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (VBD (investigated))(NP (JJ (anticancer))(NN (activity))(JJ (tolfenamic))(NN (acid))(JJ (human))(JJ (colorectal))(NN (cancer))(NN (cell))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 55:B01.050.150.900.649.801.400.112.400.400  |ES| 2:1 17:1 18:1 19:1 36:1 94:1 131:1 244:1 399:1 403:1 1275:1 1307:1 1880:1 2598:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Hyperactive))(NN (EGFR))(NN (signaling))(NN (Stat3))(NN (Jak-Stat3))(NN (activity)))(ADVP (RB (together)))(VP (VBP (promote))(SBAR (S (NP (NP (JJ (ovarian))(NN (cancer))(NN (progression))(NN (cisplatin))(NN (resistance)))(ADVP (RB (therefore))))(VP (VBP (represent))(NP (NP (NN (target)))(VP (VBG (preventing))(NP (NN (development))(NN (cisplatin))(NN (resistance))(JJ (recurrent))(NN (disease))(NN (cisplatin))(NN (therapy))(JJ (ovarian))(NN (cancer)))))))))) |ET|  |BS| 16:C23.550.291.656 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 288:C23.550.288 496:C23.550.291.937 498:D01.210.375 745:C10.597.350.350  |ES| 18:1 19:1 35:1 48:1 130:1 160:1 187:1 195:1 218:1 399:1 679:1 799:1 998:1 1094:1 1538:1 1753:1 1761:1 1763:1 1937:1 2645:1 2646:1 2647:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (PRP$ (Our))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (NN (Raloxifene))(JJ (potent))(NN (IL-6))(: (/))(NN (GP130))(NN (inhibitor)))(VP (MD (may))(VP (VB (chemoprevention))(NP (NP (NN (agent))(NN (liver))(NN (cancer)))(VP (VBG (targeting))(NP (JJ (persistent))(NN (STAT3))(NN (signaling)))))))))))) |ET|  |BS| 69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775  |ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Bortezomib)))(VP (VBZ (induces))(SBAR (S (NP (NP (JJ (tumor-specific))(NN (cell))(NN (death)))(NN (growth))(NN (inhibition))(JJ (hepatocellular))(NN (carcinoma)))(VP (VBZ (improves))(NP (NN (liver))(NN (fibrosis)))))))) |ET|  |BS| 8:C04 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 134:G04.299.139 675:D01.029.260.110.500 676:C06.552.630  |ES| 19:1 94:1 102:1 103:1 214:1 303:1 304:1 411:1 836:1 949:1 2460:1 2463:1 2464:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Tamoxifen))(JJ (non-steroidal))(JJ (anti-estrogenic))(NN (drug)))(NP (ADJP (RB (widely))(JJ (used)))(NN (treatment))(NN (prevention))(NN (breast))(NN (cancer))(NN (woman))))(: (;))(FRAG (ADVP (RB (however)))(, (,))(NP (NP (NN (evidence))(NN (tamoxifen))(JJ (hepatocarcinogenic))(NN (rat)))(, (,))(NP (NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 52:E02 67:D26 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 641:D27.505.696.399.472.277.540 642:M01.975  |ES| 2:1 18:1 19:1 23:1 38:1 52:1 191:1 217:1 476:1 546:1 849:1 1387:1 1474:1 2366:1 2367:1 2368:1 2369:1 2370:1 2371:1 2372:1  |EV| 
-2.1433809839909194749907328514382  |BT| (S (S (NP (NP (NN (RNA))(NN (interference))(JJ (knockdown))(NN (DRD2))(NN (inhibition))(JJ (pharmacologic))(NN (antagonist)))(PRN (-LRB- (-LRB-))(NP (NN (pimozide))(NN (haloperidol)))(-RRB- (-RRB-))))(VP (VBD (reduced))(NP (NN (proliferation))(JJ (pancreatic))(NN (cancer))(NN (cell)))))(, (,))(VP (VBD (induced))(NP (NP (JJ (endoplasmic))(NN (reticulum))(NN (stress))(NN (apoptosis)))(, (,))(NP (VBN (reduced))(NN (cell))(NN (migration)))))) |ET|  |BS| 39:G04.299.139.160 43:F01.145.544 156:G05.355.315.203.374.790 183:G04.299.233.750 362:D12.776.543.750.069.300.400.500 681:G04.299.283 1059:H01.158.703 1069:D02.522.352.506 1070:D03.438.103.732 1071:G04.434  |ES| 2:1 10:1 14:1 18:1 19:1 89:1 94:1 103:1 299:1 412:1 452:1 464:1 467:1 514:1 515:1 516:1 1210:1 1271:1 2522:1 3742:1 3743:1 3744:1 3745:1 3746:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (DT (The))(JJ (potential))(NN (utility))(NN (acetyltanshinone))(NN (IIA))(NN (treatment))(JJ (HER2-overexpressed))(NN (breast))(NN (cancer)))(: (:))(NP (NP (NN (Induction))(NN (cancer))(NN (cell))(NN (death)))(VP (VBG (targeting))(NP (JJ (apoptotic))(JJ (metabolic))(NN (signaling))(NN (pathway))))))) |ET|  |BS| 33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553  |ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Constitutive))(NN (activation))(NN (Wnt/beta-catenin))(NN (pathway)))(VP (VBN (implicated))(NP (JJ (primary))(NN (cause))(NN (colon))(NN (cancer))))) |ET|  |BS| 23:D12.776.091.249 147:G02.149.115.800.925  |ES| 18:1 19:1 113:1 225:1 302:1 344:1 383:1 977:1 1779:1 3399:1  |EV| 
-2.4849896192352431967265147250146  |BT| (NP (NP (NN (Amelioration))(JJ (free))(NN (fatty))(JJ (acid-induced))(NN (fatty))(NN (liver))(NN (quercetin-3-O-beta-D-glucuronide))(NN (modulation))(NN (peroxisome))(JJ (proliferator-activated))(JJ (receptor-alpha/sterol))(JJ (regulatory))(JJ (element-binding))(JJ (protein-1c))(NN (signaling)))) |ET|  |BS| 69:G02.111.087.800 242:A03.620 533:D03.383.663.283.266.450.284.777 536:D12.776.826.239.500 576:D12.776.260.103.500.750.500 1133:D10.251.310  |ES| 19:1 195:1 836:1 1801:1 1817:1 1887:1 1945:1 2070:1 2599:1 3958:1 3960:1 4082:1 4083:1 4084:1 4085:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Chemopreventive))(NN (evaluation))(NN (Tephrosia))(NN (purpurea))(JJ (N-nitrosodiethylamine-induced))(NN (hepatocarcinogenesis))(NNP (Wistar))(NN (rat)))) |ET|  |BS| 225:E05.337 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890  |ES| 19:1 849:1 900:1 2503:1 2603:1 2948:1 3972:1 3994:1 3995:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Nitidine))(NN (chloride)))(VP (VBZ (inhibits))(NP (NP (JJ (hepatocellular))(NN (carcinoma))(NN (cell)))(NN (growth)))(NP (FW (vivo))(NN (suppression))(NN (JAK1/STAT3))(NN (signaling))(NN (pathway))))) |ET|  |BS| 41:A11 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 122:C14.280.383 126:G02.111.087.800 794:D08.811.913.696.620.682.725.124.100  |ES| 19:1 94:1 102:1 195:1 303:1 304:1 378:1 383:1 615:1 2453:1 2787:1 2788:1 2789:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (PRP$ (Our))(VP (VBP (result))(NP (NN (show))(NN (enzastaurin))(JJ (effective))(JJ (chemopreventive))(NN (agent))(NN (mouse))(NN (model))(JJ (sporadic))(NN (colon))(NN (cancer)))(SBAR (S (ADVP (RB (significantly)))(VP (VBZ (reduces))(NP (NP (NN (tumor))(NN (initiation))(NN (progression)))(VP (VBG (inhibiting))(NP (NN (expression))(JJ (proproliferative))(NN (gene))))))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 16:C23.550.291.656 122:C14.280.383 155:G05.355.310  |ES| 7:1 9:1 18:1 19:1 48:1 52:1 72:1 101:1 113:1 115:1 124:1 142:1 429:1 637:1 658:1 725:1 728:1 880:1 1639:1 1946:1 2855:1 2856:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNP (Chemoprevention))(NNP (Diethylnitrosamine-Initiated))(NNP (Phenobarbital-Promoted))(NNP (Hepatocarcinogenesis))(NNP (Rats))(NNP (Sulfated))(NNP (Polysaccharides))(NNP (Aqueous))(NN (Extract))(NNP (Ulva))(NN (lactuca)))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 554:D02.654.442.200 756:D03.383.742.698.253.650 803:D01.248.497.158.845 804:D09.698 1184:B01.650.940.150.900  |ES| 19:1 1959:1 2842:1 3664:1 4097:1 4098:1 4099:1 4100:1 4101:1 4102:1 4103:1 4104:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNP (Coffee)))(VP (VBZ (reduces))(NP (NP (NN (liver))(NN (damage))(NN (rat))(NN (model))(NN (steatohepatitis)))(: (:))(NP (VBG (underlying))(NN (mechanism))(NN (role))(NNS (polyphenols))(NNS (melanoidins)))))) |ET|  |BS| 15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249  |ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1  |EV| 
-3.1958428682744397519854828715324  |BT| (FRAG (NP (NNP (Boswellia))(NNP (serrata))(NN (resin))(NN (extract)))(VBZ (alleviates))(NP (NP (NN (azoxymethane)))(PRN (-LRB- (-LRB-))(NP (NN (AOM)))(-RRB- (-RRB-))))(: (/))(NP (NP (NN (dextran))(NN (sodium))(NN (sulfate)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (colon))(NN (tumorigenesis)))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 942:D05.750.078.840.490  |ES| 10:1 14:1 19:1 78:1 113:1 406:1 407:1 409:1 1993:1 1994:1 2496:1 3301:1 3302:1 3303:1 3304:1 3305:1 3306:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (K-Ras))(NN (mutation))(NN (treatment))(NN (outcome))(JJ (colorectal))(NN (cancer))(NN (patient)))(VP (VBG (receiving))(NP (JJ (exclusive))(NN (fluoropyrimidine))(NN (therapy))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800  |ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Inhibitory))(NN (effect))(JJ (oleanolic))(NN (acid))(JJ (hepatocellular))(NN (carcinoma)))(PP (IN (via))(NP (NP (JJ (ERK-p53-mediated))(NN (cell))(NN (cycle))(NN (arrest)))(NP (JJ (mitochondrial-dependent))(NN (apoptosis))))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 772:D02.455.849.919.530.733 773:G04.299.134.109  |ES| 19:1 75:1 89:1 94:1 303:1 304:1 596:1 601:1 602:1 1275:1 2713:1 2714:1 2715:1 2716:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Natural))(NN (product))(NN (pectolinarigenin)))(VP (VBZ (inhibits))(NP (NN (osteosarcoma))(NN (growth))(NN (metastasis)))(PP (IN (via))(NP (JJ (SHP-1-mediated))(NN (STAT3))(NN (signaling))(NN (inhibition)))))) |ET|  |BS| 43:F01.145.544 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383 447:C04.557.450.565.575.650 793:D20.215  |ES| 19:1 102:1 103:1 195:1 251:1 596:1 615:1 675:1 806:1 1562:1 2780:1 2785:1 2786:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (S (NP (JJ (Diethylnitrosamine-induced))(NN (hepatocarcinogenesis)))(VP (VBD (suppressed))(NP (NN (lecithin)))))(: (:))(S (NP (NN (retinol))(JJ (acyltransferase-deficient))(NN (mouse)))(ADVP (RB (primarily)))(NP (NP (JJ (retinoid))(NN (action)))(NP (ADVP (RB (immediately)))(NP (NN (carcinogen))(NN (administration))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 554:D02.654.442.200 711:D02.455.326.271.665.202.495  |ES| 19:1 52:1 104:1 307:1 900:1 1970:1 2013:1 2125:1 2569:1 2570:1 2571:1 2572:1 2573:1 2574:1 2575:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (Disruption))(NN (Ptk6))(NN (decrease))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080  |ES| 19:1 52:1 78:1 113:1 295:1 2533:1 3444:1 3445:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (VBN (shown))(NN (diosmin)))(VP (VBZ (attenuates))(SBAR (S (NP (NP (NN (2-AAF)))(VP (VBD (induced))(NP (NP (NP (JJ (hepatic))(NN (toxicity))(JJ (early))(NN (tumor))(NN (promotion))(NN (marker)))(PRN (-LRB- (-LRB-))(NP (NP (NN (ODC)))(, (,))(NP (NN (PCNA))(NN (Ki67))))(-RRB- (-RRB-))))(, (,))(NP (JJ (chemopreventive))(NN (efficacy))(NN (DEN))))))(VP (VBD (initiated))(NP (JJ (2-AAF))(VBN (promoted))(NN (hyper-proliferation))(NN (hepatocarcinogenesis))(NNP (Wistar))(NN (rat)))))))) |ET|  |BS| 376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740  |ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (ADVP (RB (Here)))(, (,))(VP (VBP (provide))(NP (NP (NP (NN (evidence))(NN (periostin))(, (,))(NN (protein))(JJ (structural))(NN (sequence))(NN (homology))(JJ (TGF-beta-inducible))(NN (gene)))(, (,))(NP (NN (beta))(NN (ig-h3)))(, (,)))(VP (VBN (upregulated))(NP (JJ (colorectal))(NN (cancer))(NN (liver))(NN (metastasis)))))(, (,))(VP (MD (may))(VP (VB (play))(NP (NN (role)))(S (VP (VBG (promoting))(NP (NN (growth))(NN (tumor))))))))) |ET|  |BS| 4:C04.588.274.476.411.307 6:G05.360.340.024.340 8:C04 15:F01.829.316.616 45:G07.700.320.249 79:I03.450.642.693 112:D12.776.097.820 113:C04.697.650 242:A03.620 503:D12.644.276.374.687 1005:G02.111.810  |ES| 2:1 4:1 7:1 9:1 17:1 18:1 19:1 31:1 38:1 102:1 125:1 238:1 293:1 400:1 491:1 711:1 806:1 836:1 881:1 1972:1 3512:1 3513:1 3514:1 3515:1 3516:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (CONCLUSION))(: (:)))(VP (VP (VBN (Taken))(ADVP (RB (together))))(, (,))(SBAR (S (NP (NNS (data))(VBP (show))(NN (Akt))(NN (inhibitor))(NN (AZD5363)))(VP (VBZ (synergizes))(SBAR (S (NP (JJ (lysosomotropic))(NN (inhibitor))(NN (autophagy))(NN (chloroquine)))(VP (VBP (induce))(NP (NN (apoptosis))(NN (delay))(NN (tumor))(NN (progression))(NN (prostate))(NN (cancer))(NN (model))(JJ (resistant))(NN (monotherapy))(NN (AZD5363)))(, (,))(S (VP (VBG (providing))(NP (NP (JJ (new))(JJ (therapeutic))(NN (approach)))(RRC (ADVP (RB (potentially)))(NP (JJ (translatable))(NN (patient))))))))))))))) |ET|  |BS| 8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180  |ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(VP (VBD (found))(SBAR (S (NP (NP (NN (treatment))(JJ (COX2-overexpressing))(NN (HT29))(JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (fisetin)))(PRN (-LRB- (-LRB-))(NP (CD (30-120))(NN (microM)))(-RRB- (-RRB-))))(VP (VBD (resulted))(SBAR (S (NP (NP (NN (induction))(NN (apoptosis)))(, (,))(NP (NP (NN (downregulation))(NN (COX2))(NN (protein))(NN (expression)))(PP (IN (without))(S (VP (VBG (affecting))(NP (NN (COX1))))))))(VP (VBD (inhibited))(NP (NN (secretion))(NN (prostaglandin))(NN (E2))))))))))) |ET|  |BS| 7:D12.776 39:G04.299.139.160 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 122:C14.280.383 792:A11.251.210.190.475 1118:D10.251.355.255.550.250.200 1119:D08.811.600.720.500 1120:A12.200  |ES| 2:1 4:1 10:1 14:1 18:1 19:1 36:1 37:1 89:1 94:1 113:1 115:1 365:1 546:1 594:1 595:1 736:1 843:1 1195:1 2084:1 2530:1 2978:1 3017:1 3685:1 3904:1 3905:1 3906:1 3907:1 3908:1 3909:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Administration))(NNP (SP600125))(NN (acetaminophen)))(VP (VBD (protected))(NP (NP (NP (NN (Jnk)))(PRN (-LRB- (-LRB-))(NP (NN (Deltahepa)))(-RRB- (-RRB-))))(NN (control))(NN (mouse))(NN (liver))(NN (injury))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 242:A03.620 661:D02.065.199.092.040  |ES| 10:1 14:1 19:1 52:1 289:1 836:1 2346:1 2411:1 2412:1 2413:1 2414:1 2415:1 2416:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Epidemiological))(NN (study)))(VP (VBP (indicate))(NP (JJ (adequate))(JJ (dietary))(NN (folate))(JJ (protective))(NN (colon))(NN (cancer)))(, (,))(SBAR (IN (although))(S (NP (NN (mechanism)))(VP (VBP (remain))(ADJP (RB (largely))(JJ (elusive)))))))) |ET|  |BS| 224:D03.438.733.631.400 595:G07.203.650.240 722:E05.318.760.500  |ES| 2:1 18:1 19:1 113:1 131:1 162:1 493:1 777:1 778:1 1479:1 1592:1 2181:1 2384:1 2593:1 2594:1 2595:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (NN (conclusion))))(, (,))(NP (NN (simvastatin)))(VP (VBD (inhibited))(NP (NP (NN (colon))(NN (cancer))(NN (development))(NN (induction)))(NN (apoptosis))(NN (suppression))(NN (angiogenesis))))) |ET|  |BS| 39:G04.299.139.160 122:C14.280.383 754:D02.455.426.559.847.638.400.900  |ES| 2:1 18:1 19:1 35:1 89:1 113:1 244:1 365:1 736:1 1284:1 2453:1 2502:1 2679:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (ADVP (RB (However)))(, (,))(NP (JJ (molecular))(NN (mechanism))(NN (progesterone))(NN (action))(NN (breast))(NN (cancer)))(ADVP (RB (still)))(VP (VBP (remain))(ADJP (JJ (elusive))))) |ET|  |BS| 742:G03.787 1010:D04.808.745.745.654.829  |ES| 2:1 18:1 19:1 23:1 161:1 162:1 433:1 776:1 777:1 2013:1 2181:1 3536:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(ADVP (RB (previously)))(VP (VBD (showed))(SBAR (S (NP (NP (NP (NP (JJ (anthocyanin-containing))(JJ (baked))(JJ (purple-fleshed))(NN (potato)))(PRN (-LRB- (-LRB-))(NP (NN (PP)))(-RRB- (-RRB-))))(NN (extract)))(PRN (-LRB- (-LRB-))(NP (NN (PA)))(-RRB- (-RRB-))))(VP (VBD (suppressed))(SBAR (S (NP (JJ (early))(JJ (advanced))(JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (proliferation)))(VP (VBD (induced))(NP (NP (NN (apoptosis)))(, (,))(NP (NP (NN (effect))(NN (colon))(NNS (CSCs)))(ADJP (VBN (known))))))))))))) |ET|  |BS| 39:G04.299.139.160 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 183:G04.299.233.750 556:C11.768.175 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087 1126:Z01.639.760.590.715 1127:Z01.107.757.656  |ES| 2:1 10:1 14:1 18:1 19:1 36:1 75:1 89:1 94:1 113:1 132:1 299:1 307:1 412:1 556:1 843:1 997:1 1128:1 1527:1 1966:1 2439:1 2440:1 2496:1 3940:1 3941:1 3942:1 3943:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (ESE-1))(: (/))(NN (EGR-1))(NN (pathway)))(VP (VBP (play))(NP (NN (role)))(NP (ADJP (JJ (tolfenamic))(JJ (acid-induced)))(NP (NN (apoptosis))(JJ (colorectal))(NN (cancer))(NN (cell)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 39:G04.299.139.160 41:A11 79:I03.450.642.693  |ES| 17:1 18:1 19:1 31:1 89:1 94:1 238:1 383:1 2597:1 2598:1 2599:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Methyl))(NN (antcinate))(NN (A))(NN (Antrodia))(NN (camphorata)))(VP (VBZ (induces))(NP (NP (NN (apoptosis))(JJ (human))(NN (liver))(NN (cancer))(NN (cell))(JJ (oxidant-mediated))(NN (cofilin)))(: (-))(NP (JJ (Bax-triggered))(JJ (mitochondrial))(NN (pathway)))))) |ET|  |BS| 39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 573:N05.715.350.200.650 786:B01.300.179.120.174.070 787:D27.720.642  |ES| 18:1 19:1 36:1 69:1 89:1 94:1 214:1 383:1 836:1 2004:1 2753:1 2754:1 2755:1 2756:1 2757:1 2758:1 2759:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Nuclear))(NN (Maspin))(NN (expression)))(NP (ADJP (RB (highly))(JJ (predictive)))(NN (5-FU))(NN (chemotherapy))(NN (response))(NN (patient)))(VP (VBD (advanced))(NP (NN (stage))(NN (colon))(NN (cancer))))) |ET|  |BS| 50:M01.643 151:E02.319 560:D03.383.742.698.875.404  |ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (GP73)))(PRN (-LRB- (-LRB-))(PRN (: (-))(: (/))(: (-)))(-RRB- (-RRB-))))(, (,))(NP (NN (GP73))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-)))(-RRB- (-RRB-))(, (,))(NP (NP (NN (GP73))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-)))(NN (mouse)))(VP (VBN (given))(NP (NN (injection))(NN (diethylnitrosamine))))))(S (VP (VBP (induce))(NP (NN (liver))(NN (injury)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 242:A03.620 554:D02.654.442.200  |ES| 2:1 10:1 14:1 19:1 29:1 44:1 45:1 51:1 52:1 243:1 785:1 836:1 1952:1 2416:1 4174:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (CONCLUSION))(: (:)))(PP (IN (In))(NP (NN (summary))))(, (,))(S (VP (VBG (finding))(VP (VB (provide))(NP (NP (JJ (preclinical))(NN (evidence)))(VP (VBG (supporting))(NP (NN (evaluation))(NN (agent))(NN (DMAPT))(NN (gemcitabine))(NN (prevention))(NN (treatment))(JJ (pancreatic))(NN (cancer))))))))) |ET|  |BS| 52:E02 225:E05.337  |ES| 2:1 18:1 19:1 38:1 104:1 244:1 467:1 490:1 546:1 711:1 728:1 927:1 1472:1 1474:1 1494:1 1882:1 2503:1 2504:1 2505:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (ADVP (RB (However)))(, (,))(NP (NNP (Sorafenib))(NN (treatment)))(ADVP (RB (transiently)))(VP (VBD (inhibited))(SBAR (S (NP (NN (cell))(NN (cycle))(NN (progression)))(VP (VBD (resulted))(SBAR (S (NP (JJ (mitotic))(NN (catastrophe)))(VP (VBD (enhanced))(NP (JJ (non-apoptotic))(NN (liver))(NN (injury))(NN (regeneration))))))))))) |ET|  |BS| 16:C23.550.291.656 39:G04.299.139.160 52:E02 122:C14.280.383 353:G04.299.134 925:G10.261.326.520  |ES| 2:1 19:1 48:1 94:1 365:1 385:1 433:1 546:1 594:1 601:1 720:1 836:1 2416:1 2833:1 3210:1 3260:1 3614:1 4213:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(NP (DT (These))(VBP (result))(NP (VBN (suggested))(NN (TFA))(VBD (protected))(ADJP (NN (mouse))(JJ (CCl4-induced))(ADJP (NN (liver))(NN (injury))(JJ (antioxidant)))(NN (stress))(JJ (antiinflammatory)))(NN (effect))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217  |ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Quantitative))(NN (analysis))(JJ (basic))(NN (fibroblast))(NN (growth))(NN (factor))(JJ (vascular))(JJ (endothelial))(NN (growth))(NN (factor)))(NP (JJ (human))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 1067:D12.644.276.624.120  |ES| 17:1 18:1 19:1 36:1 102:1 185:1 661:1 1251:1 2213:1 3092:1 3732:1 3733:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Embelin)))(VP (VBZ (inhibits))(NP (NP (NN (chemical))(JJ (carcinogen-induced))(NN (colon))(NN (carcinogenesis)))(, (,))(NP (NP (NN (effect)))(ADJP (RB (partially))(JJ (dependent)))(NN (presence))(JJ (functional))(NN (PPARgamma)))(, (,))(NP (NP (VBG (indicating))(NN (PPARgamma))(JJ (necessary))(NN (signaling))(NN (pathway)))(VBN (involved))(NN (antitumor))(NN (activity))(JJ (normal))(NN (organism)))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 279:D27.888.569.100 719:D12.776.826.239.588  |ES| 2:1 19:1 75:1 113:1 118:1 195:1 207:1 321:1 346:1 383:1 399:1 415:1 615:1 774:1 1351:1 2124:1 2236:1 2244:1 2421:1 2587:1 2588:1 2589:1 2590:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Nifuroxazide)))(VP (VBZ (induces))(SBAR (S (NP (NN (apoptosis)))(VP (VBZ (impairs))(NP (JJ (pulmonary))(NN (metastasis))(NN (breast))(NN (cancer))(NN (model)))))))) |ET|  |BS| 10:A01.236 39:G04.299.139.160 113:C04.697.650 182:A04.411  |ES| 18:1 19:1 23:1 72:1 89:1 214:1 806:1 948:1 2729:1 3659:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Glycyrrhizic))(NN (Acid)))(NP (VBN (used))(NN (treat))(JJ (chronic))(NN (hepatitis))))(, (,))(S (VP (VBG (inhibiting))(NP (NN (penetration))(NN (hepatitis))(NN (A))(NN (virus))(NNS (hepatocytes)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 122:C14.280.383 262:A11.436.348 734:D02.455.849.919.530.466 735:B04.450.420.410 736:C06.552.380.350  |ES| 2:1 19:1 69:1 476:1 880:1 894:1 1090:1 1422:1 1790:1 2048:1 2625:1 2626:1 2627:1  |EV| 
-0.46188398397680430207401514053345  |BT| (S (NP (NN (Honokiol)))(VP (VP (VBZ (activates))(NP (JJ (AMP-activated))(NN (protein))(NN (kinase))(NN (breast))(NN (cancer))(NN (cell)))(PP (IN (via))(NP (JJ (LKB1-dependent))(NN (pathway)))))(VP (VBZ (inhibits))(NP (NN (breast))(NN (carcinogenesis)))))) |ET|  |BS| 10:A01.236 33:C04.697.098 41:A11 122:C14.280.383 1009:D08.811.913.696.620.682.700.085  |ES| 4:1 18:1 19:1 23:1 94:1 207:1 301:1 383:1 470:1 596:1 615:1 3533:1 3534:1 3535:1  |EV| 
-1.5034483017404909332981333136559  |BT| (NP (NP (ADVP (RB (However)))(PRN (, (,))(NP (JJ (Ptk6-null))(NN (mouse)))(ADVP (RB (also)))(NP (JJ (resistant))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis)))))) |ET|  |BS| 29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080  |ES| 2:1 5:1 19:1 52:1 78:1 113:1 427:1 433:1 2533:1 4212:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Great))(NN (interest)))(VP (VBD (focused))(NP (NN (chemoprevention))(JJ (colonic))(NN (carcinogenesis))(JJ (oral))(NN (administration)))(NP (NP (NP (JJ (ursodeoxycholic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (UDCA)))(-RRB- (-RRB-))))(NN (administration)))(VP (ADVP (RB (reportedly)))(VBZ (reduces))(NP (NN (incidence))(NN (colon))(NN (cancer))(NN (animal))(NN (experiment)))))) |ET|  |BS| 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 253:E02.319.162 434:E05.318.308.985.525.375 737:D04.808.105.225.272.962 738:E05.017 739:E02.319.267.100  |ES| 10:1 14:1 18:1 19:1 46:1 113:1 142:1 207:1 677:1 870:1 1051:1 1275:1 1511:1 2310:1 2311:1 2575:1 2628:1 2629:1 2630:1 2631:1 2632:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (PP (IN (In))(NP (NN (study))))(, (,))(NP (NP (NP (NN (report))(NN (effect))(NN (resveratrol))(JJ (early))(JJ (advanced))(NN (stage))(NN (hepatocarcinogenesis))(NN (model))(NN (N-nitrosodiethylamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(: (-))(VBN (induced))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(JJ (male))(NNP (Wistar))(NN (rat))))) |ET|  |BS| 104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900  |ES| 2:1 10:1 14:1 19:1 72:1 75:1 131:1 244:1 303:1 304:1 409:1 417:1 441:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1712:1 1875:1 2602:1 2603:1  |EV| 
-3.878951422424336215044604614377  |BT| (S (NP (NP (NN (Downregulation))(JJ (tumor-suppressor))(NN (miR-16)))(PP (IN (via))(NP (JJ (progestin-mediated))(JJ (oncogenic))(NN (signaling)))))(VP (VBZ (contributes))(NP (NN (breast))(NN (cancer))(NN (development))))) |ET|  |BS| 69:G02.111.087.800 85:G02.111.087.225 206:G05.360.340.024.340.375.249 279:D27.888.569.100 981:D27.505.696.399.472.858  |ES| 18:1 19:1 23:1 35:1 195:1 296:1 596:1 845:1 953:1 1156:1 3456:1 3457:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NP (JJ (Polyinosinic-polycytidylic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (Poly))(NN (I))(: (:))(NN (C)))(-RRB- (-RRB-))))(NN (IFN-gamma))(NN (treatment)))(VP (VBD (inhibited))(NP (NN (liver))(NN (fibrosis))(JJ (pair-fed))(JJ (ethanol-fed))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383 663:C16.320.565.398.500.330.500 676:C06.552.630 751:D02.033.375 815:D13.695.578.550.560.600 816:G01.358.500.505.300  |ES| 10:1 14:1 19:1 52:1 104:1 365:1 546:1 836:1 949:1 1275:1 1955:1 2350:1 2883:1 2884:1 2885:1 2886:1 2887:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION))(: (:)))(S (NP (PRP$ (Our))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (NN (garcinol)))(VP (MD (may))(VP (VB (merit))(S (NP (JJ (clinical))(NN (investigation))(NN (chemoprophylactic))(NN (food))(NN (help)))(VP (VB (prevent))(NP (JJ (colitis-associated))(NN (colon))(NN (cancer)))))))))))) |ET|  |BS| 53:C06.405.205.265 225:E05.337 680:G07.203.300  |ES| 18:1 19:1 84:1 101:1 104:1 113:1 410:1 491:1 658:1 733:1 796:1 1497:1 1882:1 2470:1 3371:1 3372:1 3373:1 3374:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (DT (This))(NN (research)))(VP (VBZ (provides))(NP (NN (evidence))(NN (tea)))(, (,))(NP (ADVP (RB (particularly)))(NP (VBN (administered))(NN (combination))(NN (sulindac)))(, (,))(NP (PP (ADJP (RB (highly))(JJ (effective)))(S (VP (VBG (inhibiting))(NP (NP (NP (JJ (intestinal))(NN (neoplasia))(NN (male))(NN (Apc)))(PRN (-LRB- (-LRB-))(NP (NN (min)))(-RRB- (-RRB-))))(NN (mouse)))(PP (IN (via))(NP (JJ (direct))(JJ (indirect))(NN (effect))(NN (beta-catenin/APC))(NN (pathway))))))))))) |ET|  |BS| 3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644  |ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(NP (JJ (Chronic))(NP (NP (NN (ethanol))(NN (consumption))(NN (increase))(NN (risk))(JJ (hepatic))(NN (cirrhosis))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))) |ET|  |BS| 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 904:F01.145.317.269  |ES| 10:1 14:1 19:1 40:1 104:1 171:1 303:1 304:1 441:1 838:1 1046:1 1199:1 2387:1 3440:1 3967:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (BACKGROUND)))(CC (&))(NP (NNS (AIMS))))(: (:))(S (NP (JJ (Chronic))(NN (alcohol))(NN (drinking)))(VP (VBZ (accelerates))(NP (NP (NN (liver))(NN (fibrosis))(NN (patient)))(JJ (viral))(NN (hepatitis)))(VP (ADVP (RB (fully)))(VBD (explained))(NP (JJ (ethanol-enhanced))(NN (liver))(NN (damage))))))) |ET|  |BS| 50:M01.643 242:A03.620 676:C06.552.630 751:D02.033.375 904:F01.145.317.269 1136:B04.450  |ES| 19:1 104:1 120:1 529:1 836:1 889:1 949:1 1046:1 1777:1 1778:1 1848:1 2048:1 3710:1 3967:1 3968:1 3969:1 3970:1 3971:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Cryptotanshinone)))(VP (VBZ (inhibits))(NP (NP (JJ (constitutive))(NN (signal))(NN (transducer))(NN (activator))(NN (transcription))(CD (3))(NN (function)))(VP (VBG (blocking))(NP (NN (dimerization))(NN (DU145))(NN (prostate))(NN (cancer))(NN (cell))))))) |ET|  |BS| 41:A11 122:C14.280.383 209:G02.111.087.847 250:E07.305.812 970:E06.658.453.560.100 971:G02.149.250  |ES| 18:1 19:1 33:1 77:1 94:1 487:1 604:1 615:1 859:1 860:1 861:1 862:1 3420:1 3421:1 3422:1 3423:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Decorin-mediated))(NN (inhibition))(JJ (colorectal))(NN (cancer))(NN (growth))(NN (migration)))(NP (VBN (associated))(NN (E-cadherin))(NN (vitro))(NN (mouse))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625  |ES| 17:1 18:1 19:1 52:1 102:1 103:1 169:1 216:1 514:1 2267:1 2557:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (PRP$ (Our))(NNS (data)))(VP (VBP (demonstrate))(SBAR (S (NP (NN (coffee))(NN (consumption)))(VP (VBZ (protects))(SBAR (S (NP (NN (liver))(NN (damage)))(VP (VBD (caused))(NP (JJ (high-fat))(NN (diet)))))))))))) |ET|  |BS| 242:A03.620 652:D20.215.784.249 694:G07.203.650.240.267  |ES| 19:1 104:1 502:1 658:1 793:1 836:1 1848:1 1863:1 1882:1 2191:1 2386:1 2387:1 2506:1 2507:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Survivin))(NN (overexpression)))(VP (VBN (associated))(NP (NP (JJ (poor))(NN (prognosis))(JJ (human))(JJ (gastric))(NN (cancer)))(, (,))(NP (NN (target))(JJ (gastric))(NN (cancer))(NN (therapy)))))) |ET|  |BS| 52:E02 55:B01.050.150.900.649.801.400.112.400.400 159:I01.880.735.634 163:E01.789  |ES| 2:1 18:1 19:1 36:1 86:1 130:1 152:1 160:1 169:1 544:1 545:1 3779:1  |EV| 
-1.9695396453762441524304449558258  |BT| (S (ADVP (RB (Hence)))(, (,))(NP (NN (chloroform)))(VP (VBD (prevented))(SBAR (S (NP (NN (hypomethylation)))(VP (VBD (increased))(NP (NP (NN (mRNA)))(NN (expression))(NN (c-myc))(NN (gene))(NN (promotion))(NN (liver))(NN (tumor))(NN (DCA)))(, (,))(S (VP (VBG (enhancing))(NP (JJ (DCA-promotion))(NN (kidney))(NN (tumor)))))))))) |ET|  |BS| 111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224  |ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NP (NN (Aspirin)))(PRN (-LRB- (-LSB-))(NP (NP (JJ (acetylsalicylic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (ASA)))(-RRB- (-RRB-))))(-RRB- (-RSB-))))(VP (VBN (shown))(VP (VBP (prevent))(NP (NN (CRC))))))(: (;))(S (ADVP (RB (however)))(, (,))(NP (JJ (epigenetic))(NN (mechanism))(NN (action)))(VP (VBP (remain))(ADJP (JJ (unknown)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203  |ES| 2:1 10:1 14:1 19:1 162:1 217:1 237:1 245:1 733:1 1275:1 1373:1 1378:1 1387:1 1603:1 2013:1 2181:1 2182:1 2449:1 2450:1 2451:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Epidemiological))(NN (evidence)))(VP (VBZ (suggests))(S (NP (NN (vitamin))(NN (D)))(VP (MD (may))(VP (VB (play))(NP (NP (NN (role)))(VP (VBG (inhibiting))(NP (NN (development))(NN (colon))(NN (prostate))(NN (cancer)))))))))) |ET|  |BS| 15:F01.829.316.616 46:A03.556.124.526.356 79:I03.450.642.693 122:C14.280.383 651:H02.403.720.500 720:D04.808.247.222.474 721:D04.808.812.768  |ES| 18:1 19:1 31:1 35:1 38:1 77:1 113:1 238:1 331:1 491:1 880:1 2384:1 2591:1 2592:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Hepatocellular))(NN (carcinoma)))(VP (VBD (found))(NP (CD (four))(CD (five))(NN (rat))(CD (12))(NN (month))(NN (tamoxifen))(NN (treatment))))) |ET|  |BS| 52:E02 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900  |ES| 19:1 37:1 304:1 546:1 770:1 849:1 1120:1 2151:1 2371:1 2723:1 4188:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (ADVP (RB (Additionally)))(, (,))(VP (VBD (reported))(SBAR (S (NP (NN (tamoxifen)))(VP (MD (may))(VP (VB (cause))(NP (NP (NP (JJ (non-alcoholic))(NN (fatty))(NN (liver))(NN (disease)))(PRN (-LRB- (-LRB-))(NP (NN (NAFLD)))(-RRB- (-RRB-))))(NP (JJ (human))(JJ (experimental))(NN (animal)))))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 1175:B01.050.050.199  |ES| 2:1 10:1 14:1 19:1 36:1 46:1 263:1 491:1 836:1 993:1 998:1 1779:1 2069:1 2070:1 2371:1 2609:1 4068:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Hepatoprotective))(NN (effect))(NN (tamoxifen))(NN (steatosis))(JJ (non-alcoholic))(NN (steatohepatitis))(NN (mouse))(NN (model)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 509:C06.552.241.519 640:D02.455.426.559.389.150.700.900  |ES| 19:1 52:1 72:1 75:1 1791:1 2069:1 2371:1 2678:1 3504:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Bromelain-containing))(NN (food))(CC (and/or))(NN (bromelain)))(VP (MD (may))(VP (VB (represent))(NP (JJ (good))(NN (candidate))(JJ (colorectal))(NN (cancer))(NN (chemoprevention)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 253:E02.319.162 679:D08.811.277.656.262.500.096 680:G07.203.300  |ES| 17:1 18:1 19:1 149:1 491:1 799:1 870:1 1243:1 1318:1 2469:1 2470:1 2471:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (JJ (Kruppel-like))(NN (factor))(CD (9)))(PRN (-LRB- (-LRB-))(NP (NN (KLF9)))(-RRB- (-RRB-))))(VP (VBZ (prevents))(NP (JJ (colorectal))(NN (cancer))(NN (inhibition))(JJ (interferon-related))(NN (signaling))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375  |ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NP (JJ (Epidermal))(NN (growth))(NN (factor))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (EGFR)))(-RRB- (-RRB-))))(NN (tyrosine))(NN (kinase))(NN (inhibitor))(NN (erlotinib)))(VP (VBP (show))(SBAR (S (NP (JJ (potent))(NP (NP (NN (antitumor))(NN (activity))(JJ (non-small-cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-))))(NN (cell))(NN (line)))(VP (VBD (approved))(NP (NNP (Food))(NNP (Drug))(NNP (Administration))(JJ (second))(JJ (third))(NN (line))(NN (treatment))(NN (NSCLC)))))))) |ET|  |BS| 52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875  |ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1  |EV| 
-1.2469448331233934368356131017208  |BT| (S (NP (NN (OBJECTIVE))(: (:)))(NP (NP (NN (Vitamin))(NN (D)))(PRN (-LRB- (-LRB-))(NP (CD (3)))(-RRB- (-RRB-))))(VP (VBN (upregulated))(NP (NP (NN (protein))(CD (1))(PRN (-LRB- (-LRB-))(NP (NN (VDUP1)))(-RRB- (-RRB-))))(NP (NP (JJ (potent))(NN (tumour))(NN (suppressor)))(SBAR (WHNP (WP$ (whose))(NN (expression)))(S (ADVP (RB (dramatically)))(VP (VBD (reduced))(NP (NP (JJ (various))(NN (type))(JJ (human))(NN (cancer)))(, (,))(PP (VBG (including))(NP (JJ (gastric))(NN (cancer)))))))))))) |ET|  |BS| 55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 415:F01.658.500 1050:D12.776.157.125.050.060 1051:D04.808.247.222.159 1052:D12.776.641.750  |ES| 2:1 4:1 10:1 14:1 18:1 19:1 22:1 36:1 86:1 98:1 104:1 115:1 125:1 452:1 543:1 561:1 645:1 700:1 862:1 919:1 1011:1 1096:1 1417:1 2592:1 3665:1 3666:1  |EV| 
-3.3585472512465344152587931603193  |BT| (NP (NP (NP (JJ (Altered))(NN (gene))(NN (expression))(NN (DNA))(NN (repair)))(: (-))(NP (NP (NN (cell))(JJ (proliferation-associated))(NNS (proteins/enzymes)))(VP (VBN (examined))(NP (NN (process))(JJ (tamoxifen-induced))(NN (hepatocarcinogenesis))(JJ (female))(JJ (Sprague-Dawley))(NN (rat))))))) |ET|  |BS| 155:G05.355.310 640:D02.455.426.559.389.150.700.900 642:M01.975 730:D08.811 769:B01.050.150.900.649.865.635.505.700.750 1134:G02.111.087.219 1135:D12.776.543  |ES| 9:1 19:1 94:1 115:1 324:1 638:1 666:1 849:1 900:1 971:1 1404:1 2707:1 3963:1 3964:1 3965:1 3966:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(NP (NN (Silibinin))(NN (target))(NN (beta-catenin))(NN (IGF-1Rbeta))(NN (pathway))(JJ (chemopreventive))(NN (efficacy))(JJ (azoxymethane-induced))(NN (colon))(NN (carcinogenesis))(NN (A/J))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937  |ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNS (Glucans))(JJ (edible))(NN (mushroom))(NN (Pleurotus))(NN (pulmonarius)))(VP (VBP (inhibit))(NP (JJ (colitis-associated))(NN (colon))(NN (carcinogenesis))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 731:B01.300.179.100.650 732:D05.750.078.562 733:B01.300.179.100  |ES| 19:1 52:1 113:1 207:1 410:1 1370:1 2620:1 2621:1 2622:1 2623:1 2624:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Loss))(NN (Dicer)))(ADVP (RB (primarily)))(VP (VBZ (impairs))(SBAR (S (NP (NN (hepatocyte))(NN (survival)))(VP (VBP (promote))(NP (NN (hepatocarcinogenesis))(NN (cooperation))(JJ (additional))(JJ (oncogenic))(NN (stimulus)))))))) |ET|  |BS| 96:I03.784 262:A11.436.348 279:D27.888.569.100  |ES| 19:1 274:1 679:1 900:1 953:1 980:1 1788:1 1909:1 1960:1 1970:1 2728:1 2729:1 2730:1  |EV| 
-3.8077501706627998601106810383499  |BT| (NP (NP (CD (One))(JJ (reasonable))(NN (possibility))(JJ (attributable))(NN (hyperinsulinemia))(JJ (compensatory))(JJ (obesity-related))(NN (insulin))(NN (resistance)))) |ET|  |BS| 564:C18.654.726.500 678:C18.452.394.968.500 1053:C18.452.394.968  |ES| 19:1 343:1 654:1 1094:1 2364:1 2467:1 3668:1 3669:1 3670:1 3671:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Aliskiren)))(VP (VBZ (attenuates))(NP (NN (steatohepatitis))(NN (increase))(NN (turnover))(JJ (hepatic))(JJ (fat))(NN (mouse))(NN (fed))(NN (methionine))(NN (choline))(JJ (deficient))(NN (diet))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676 665:N04.452.677.680  |ES| 19:1 40:1 52:1 838:1 1504:1 1791:1 2050:1 2191:1 2422:1 2423:1 2424:1 2425:1 2426:1 2427:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Pravastatin)))(VP (VBZ (reduces))(NP (NN (lung))(NN (metastasis))(NN (rat))(JJ (hepatocellular))(NN (carcinoma)))(PP (IN (via))(NP (VBN (coordinated))(NN (decrease))(NN (MMP))(NN (expression))(NN (activity)))))) |ET|  |BS| 104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 817:D02.455.426.559.847.638.930 818:D08.811.277.656.300.480.525  |ES| 19:1 115:1 142:1 295:1 303:1 304:1 328:1 399:1 596:1 806:1 849:1 2890:1 2891:1 2892:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NNP (UNLABELLED)))(: (:))(NP (NP (NP (JJ (Antidiabetic))(NNS (thiazolidinediones)))(PRN (-LRB- (-LRB-))(NP (NN (TZD)))(-RRB- (-RRB-))))(PP (FW (vitro))(NP (NP (JJ (antiproliferative))(NN (effect))(JJ (epithelial))(NN (cancer)))(, (,))(PP (VBG (including))(NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))))) |ET|  |BS| 104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422  |ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1  |EV| 
4.3916130581683914257951073523145  |BT| (SINV (PP (IN (As))(NP (NN (wogonin))(ADJP (JJ (effective))(ADVP (FW (vitro))(FW (vivo))))))(, (,))(NP (JJ (novel))(S (VP (VBG (finding))(S (NP (JJ (open))(NN (possibility))(NN (wogonin))(JJ (effective))(ADJP (ADJP (JJ (therapeutic)))(CC (and/or))(ADJP (JJ (chemopreventive))))(NN (agent)))(ADJP (JJ (ER-positive))))(: (-))(NP (NP (JJ (negative))(NN (breast))(NN (cancer)))(, (,))(NP (RB (particularly))(JJ (aggressive))(JJ (hormonal))(JJ (therapy-resistant))(JJ (ER-negative))(NN (type)))))))) |ET|  |BS| 52:E02 162:F01.145.126.125 259:D12.776.395.240.150.500  |ES| 2:1 18:1 19:1 23:1 149:1 168:1 216:1 343:1 378:1 538:1 541:1 543:1 728:1 891:1 927:1 1045:1 1639:1 1654:1 1946:1 2380:1 2444:1 2445:1 2446:1 2447:1 2448:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (EX (There)))(NP (JJ (abundant))(JJ (epidemiological))(NN (evidence))(JJ (heavy))(NN (alcohol))(NN (intake)))(VP (VBZ (contributes))(NP (NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (development))))) |ET|  |BS| 104:C04.557.470.200.025.255 651:H02.403.720.500 904:F01.145.317.269  |ES| 10:1 14:1 19:1 35:1 38:1 303:1 304:1 441:1 767:1 845:1 1798:1 2563:1 3217:1 3710:1 4039:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (VBN (examined))(NN (effect))(NN (pitavastatin))(: (-))(NN (drug)))(VP (VBD (used))(S (NP (NN (treatment))(NN (hyperlipidemia)))(: (-))(NP (NP (NN (development))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(: (-))(VP (VBN (induced))(S (NP (NP (NN (liver))(JJ (preneoplastic))(NN (lesion))(NN (C57BL/KsJ-db/db)))(PRN (-LRB- (-LRB-))(NP (NN (db/db)))(-RRB- (-RRB-))))(NP (JJ (obese))(NN (mouse)))))))) |ET|  |BS| 52:E02 67:D26 242:A03.620 554:D02.654.442.200 593:B01.050.050.199.520.520.420 765:B01.050.150.900.649.865.635.505.500.550.530 766:C18.452.584.500.500  |ES| 2:1 10:1 14:1 19:1 35:1 52:1 75:1 131:1 191:1 244:1 324:1 409:1 476:1 546:1 836:1 1131:1 1307:1 1438:1 1875:1 1952:1 2468:1 2690:1 2691:1 2692:1 2693:1 2694:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NN (result)))(VP (VBD (showed))(NP (NN (cimetidine))(VBG (inhibiting))(NN (effect))(NN (hepatocarcinogenesis))))) |ET|  |BS| 12:Z01.542.049 122:C14.280.383 808:D02.078.370.200  |ES| 19:1 75:1 101:1 132:1 658:1 880:1 900:1 2857:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Chronic))(NN (exposure))(NN (toxaphene)))(VP (VBD (resulted))(NP (NN (increase))(NN (liver))(NN (tumor))(NN (B6C3F1))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 1149:D02.455.526.439.913  |ES| 7:1 19:1 40:1 52:1 594:1 836:1 1953:1 3967:1 3985:1 3986:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(VP (VBD (hypothesized))(S (NP (NN (PTK6))(NN (inhibition))(JJ (effective))(NN (strategy)))(VP (VBP (inhibit))(SBAR (S (NP (NP (NP (NP (NN (growth))(NN (survival))(NN (Her2)))(PRN (-LRB- (-LRB-))(CC (+))(-RRB- (-RRB-))))(NN (breast))(NN (cancer))(NN (cell)))(, (,))(PP (VBG (including))(NP (ADJP (RB (relatively))(JJ (resistant)))(NNP (Lapatinib))))(, (,)))(VP (VBN (targeted))(NP (NP (NP (NP (NN (therapy))(NN (Her2)))(PRN (-LRB- (-LRB-))(CC (+))(-RRB- (-RRB-))))(NN (breast))(NN (cancer)))(, (,))(NP (CC (either))(ADJP (RB (intrinsically))(VBN (acquired)))(JJ (continuous))(NN (drug))(NN (exposure))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 43:F01.145.544 45:G07.700.320.249 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 96:I03.784 122:C14.280.383  |ES| 2:1 10:1 14:1 16:1 18:1 19:1 23:1 39:1 94:1 102:1 103:1 130:1 191:1 274:1 427:1 561:1 843:1 1041:1 1044:1 1114:1 1370:1 1639:1 1750:1 1953:1 3059:1 3924:1 3925:1 3926:1 3927:1 3928:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Overexpression))(NN (Klotho)))(VP (VBZ (suppresses))(SBAR (S (NP (NN (liver))(NN (cancer))(NN (progression)))(VP (VBZ (induces))(S (NP (NN (cell))(NN (apoptosis)))(ADVP (RB (negatively)))(VP (VBG (regulating))(NP (JJ (wnt/beta-catenin))(NN (signaling))(NN (pathway)))))))))) |ET|  |BS| 16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925  |ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1  |EV| 
-1.9955611726600928079733421327546  |BT| (S (NP (NN (Expression))(NN (protein))(NN (kinase))(NN (C)))(VP (NNS (isoenzymes))(NP (JJ (colorectal))(NN (cancer))(NN (tissue))(JJ (differential))(NN (activation))(JJ (different))(NN (bile))(NN (acid))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 98:A10 992:D08.811.913.696.620.682.700.725 993:D08.811.348 994:D04.808.105  |ES| 4:1 17:1 18:1 19:1 225:1 272:1 316:1 414:1 470:1 1275:1 1621:1 1677:1 1955:1 3486:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(PP (IN (Since))(NP (NN (lymph))(NN (node))(NN (involvement))(JJ (important))(JJ (prognostic))(NN (factor))(NN (breast))(NN (cancer))(NN (patient))))(, (,))(NP (JJ (antimetastatic))(NN (activity))(NN (alpha-mangostin)))(VP (VBD (detected))(NP (NP (JJ (mammary))(NN (cancer)))(VP (VBG (carrying))(NP (NN (p53))(NN (mutation))(JJ (present))(NN (study)))))(VP (MD (may))(NP (JJ (specific))(JJ (clinical))(NN (application)))))) |ET|  |BS| 2:G05.360.340.024.340.375.249.385 18:G05.365.590 50:M01.643 247:G01.374.676.530 703:A10.549.400  |ES| 2:1 12:1 18:1 19:1 23:1 34:1 84:1 104:1 120:1 131:1 165:1 185:1 239:1 399:1 491:1 540:1 636:1 850:1 884:1 902:1 1007:1 1307:1 2245:1 2246:1 2248:1 2535:1 2536:1 2537:1  |EV| 
-1.0690895034426830534357577562332  |BT| (FRAG (ADVP (RB (However)))(, (,))(NP (NP (NN (action))(NN (compound))(JJ (ethanol-induced))(NN (liver))(NN (injury)))(ADJP (RB (still))(JJ (unknown))))) |ET|  |BS| 242:A03.620 751:D02.033.375  |ES| 2:1 19:1 433:1 776:1 836:1 2013:1 2182:1 2416:1 2433:1 2674:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NN (PURPOSE)))(: (:))(S (NP (JJ (Recent))(NN (study)))(VP (VBD (revealed))(S (NP (NP (JJ (branched-chain))(NN (amino))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (BCAA)))(-RRB- (-RRB-))))(VP (VB (reduce))(NP (NP (NP (NN (development))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (patient))(NN (obesity))(NN (hepatitis))(NN (C))(NN (virus))(NN (infection))(S (VP (VBG (improving))(NP (NP (NN (insulin))(NN (resistance)))(PRN (-LRB- (-LRB-))(NP (NN (IR)))(-RRB- (-RRB-)))))))))))) |ET|  |BS| 50:M01.643 104:C04.557.470.200.025.255 550:B04.450.410 564:C18.654.726.500 637:D06.472.699.587.200.500.625 638:C02.440.440 639:D12.125.070  |ES| 10:1 14:1 19:1 35:1 104:1 120:1 131:1 275:1 303:1 304:1 441:1 687:1 1094:1 1275:1 1422:1 1955:1 2010:1 2048:1 2189:1 2358:1 2359:1 2360:1 2361:1 2362:1 2363:1 2364:1 2365:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Peroxisome))(JJ (proliferator-activated))(NN (receptor-gamma)))(VP (VBZ (contributes))(NP (JJ (inhibitory))(NN (effect))(NN (Embelin))(NN (colon))(NN (carcinogenesis))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 719:D12.776.826.239.588  |ES| 19:1 75:1 113:1 207:1 845:1 1800:1 1801:1 2429:1 2587:1 2871:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NN (finding)))(ADVP (RB (also)))(VP (VBD (showed))(SBAR (S (NP (NP (JJ (myrtenal))(NNS (restrains))(NN (liver))(NN (cancer)))(VP (VBG (preventing))(NP (NN (DEN-PB)))))(VP (VBD (induced))(NP (NN (up-regulation))(NN (TNF-alpha))(NN (protein))(NN (expression))(NN (immunoblot)))))))) |ET|  |BS| 7:D12.776 122:C14.280.383 142:I01.880.604 789:D12.644.276.374.500.800 790:D12.644.276.374.750 802:E05.478.566.320  |ES| 4:1 5:1 18:1 19:1 115:1 132:1 412:1 658:1 836:1 896:1 927:1 1937:1 2682:1 2775:1 2828:1 2829:1 2830:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Essential))(NN (contribution))(NN (chemokine)))(, (,))(NP (NN (CCL3)))(, (,))(NP (NN (receptor)))(, (,))(NP (NN (CCR1)))(, (,))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (progression)))) |ET|  |BS| 16:C23.550.291.656 104:C04.557.470.200.025.255 313:D12.644.276.374.200  |ES| 2:1 19:1 48:1 186:1 303:1 304:1 1360:1 3476:1 3477:1 3478:1 3479:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBN (shown))(NP (NP (JJ (myrtenal))(, (,))(JJ (natural))(NN (monoterpene)))(, (,))(NP (VP (VBP (act))(SBAR (S (NP (JJ (antineoplastic))(NN (agent))(NN (diethylnitrosamine)))(VP (VBD (induced))(NP (JJ (phenobarbital))(VBN (promoted))(NP (JJ (experimental))(JJ (hepatocellular))(NN (carcinoma)))))))))))) |ET|  |BS| 81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575  |ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1  |EV| 
-1.1638344131006945758599613327533  |BT| (NP (NP (NN (INTERPRETATION)))(: (:))(S (S (NP (NN (Stimulation))(NN (survivin))(NN (expression))(NN (TCF/beta))(NN (catenin)))(VP (MD (might))(VP (VB (impose))(NP (NN (stem))(JJ (cell-like))(NN (phenotype)))(SBAR (S (NP (JJ (colonic))(NN (crypt))(NN (epithelium))(NN (coupling)))(VP (VBD (enhanced))(NP (NN (cell))(NN (proliferation))(NN (resistance))(NN (apoptosis)))))))))(, (,))(VP (VBP (contribute))(NP (JJ (molecular))(NN (pathogenesis))(JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 39:G04.299.139.160 46:A03.556.124.526.356 62:A10.272 80:G05.695 183:G04.299.233.750 308:A11.872  |ES| 2:1 17:1 18:1 19:1 89:1 94:1 104:1 115:1 161:1 173:1 236:1 299:1 385:1 450:1 501:1 677:1 798:1 1094:1 1106:1 2229:1 2913:1 3601:1 3602:1 3603:1 3604:1 3605:1 3606:1 3607:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Diet-induced))(NN (obesity))(NN (ethanol)))(VP (VBP (impair))(NP (NN (progression))(JJ (hepatocellular))(NN (carcinoma))(NN (mouse))(JJ (mesenteric))(NN (vein))(NN (injection))(NN (model))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 226:E02.319.267.530 564:C18.654.726.500 595:G07.203.650.240 596:E02.642.249 751:D02.033.375 976:A07.231.908.670.385  |ES| 19:1 48:1 52:1 72:1 303:1 304:1 785:1 2010:1 3439:1 3440:1 3441:1 3442:1 3443:1  |EV| 
-4.3916130581683914257951073523145  |BT| (FRAG (PP (IN (After))(NP (NP (JJ (3-month))(NN (recovery))(NN (period))(JJ (tamoxifen-treated))(NN (rat))(JJ (large))(NN (liver))(NN (tumor)))(PRN (-LRB- (-LRB-))(NP (NN (diameter))(CD (3))(NN (cm)))(-RRB- (-RRB-)))))) |ET|  |BS| 8:C04 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 776:G01.910.645 1151:C06.552.416  |ES| 7:1 10:1 14:1 19:1 836:1 849:1 862:1 1408:1 1409:1 2722:1 2724:1 2725:1 3265:1 4072:1 4073:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (NP (NN (CONCLUSION)))(: (:))(S (NP (DT (This))(NN (study)))(VP (VBZ (provides))(SBAR (S (NP (NN (evidence))(NN (saffron)))(VP (VBZ (exerts))(NP (JJ (significant))(JJ (chemopreventive))(NN (effect))(NN (liver))(NN (cancer))(NN (inhibition))(NN (cell))(NN (proliferation))(NN (induction))(NN (apoptosis))))))))) |ET|  |BS| 39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 624:D27.505.696.706.018 701:B01.650.940.800.575.100.549.500  |ES| 18:1 19:1 38:1 75:1 89:1 94:1 103:1 104:1 131:1 135:1 299:1 736:1 807:1 815:1 836:1 1882:1 1946:1 1977:1 2523:1  |EV| 
-3.2466654241427903571093338541687  |BT| (S (ADVP (FW (In))(FW (vivo)))(, (,))(NP (NP (NP (NN (nimbolide)))(PRN (-LRB- (-LRB-))(NP (CD (5))(CD (20))(NN (mg/kg))(NN (body))(NN (weight)))(-RRB- (-RRB-))))(, (,))(VP (VBN (injected))(ADVP (RB (intraperitoneally)))(NP (NN (tumor))(NN (inoculation))))(, (,)))(ADVP (RB (significantly)))(VP (VBD (decreased))(NP (NN (volume))(JJ (colorectal))(NN (cancer))(NN (xenograft))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 92:E04.936.764 93:A01.941.875 653:C23.888.144 1024:D20.215.894.200 1025:Z01.252.100.450 1026:Z01.252.474.651  |ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 124:1 202:1 244:1 265:1 378:1 578:1 1870:1 2398:1 2399:1 3584:1 3585:1 3586:1 3587:1 3588:1 3589:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Monensin)))(VP (VBZ (inhibits))(SBAR (S (NP (JJ (canonical))(NP (NN (Wnt))(NN (signaling))(JJ (human))(JJ (colorectal))(NN (cancer))(NN (cell))))(VP (VBZ (suppresses))(NP (NN (tumor))(NN (growth))(JJ (multiple))(JJ (intestinal))(NN (neoplasia))(NN (mouse)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 102:C04.588.274.476.411 122:C14.280.383 1043:D03.383.312.600  |ES| 7:1 17:1 18:1 19:1 36:1 52:1 94:1 102:1 109:1 195:1 615:1 640:1 649:1 686:1 877:1 3236:1 3648:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Claudin-1))(NN (overexpression))(JJ (intestinal))(JJ (epithelial))(NN (cell)))(VP (VBZ (enhances))(NP (NN (susceptibility))(JJ (adenamatous))(NN (polyposis))(JJ (coli-mediated))(NN (colon))(NN (tumorigenesis))))) |ET|  |BS| 3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100  |ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(VBP (result)))(VP (VBP (indicate))(SBAR (S (NP (NNP (Lrat))(NNP (KO))(NN (mouse)))(NP (DT (le))(JJ (susceptible))(JJ (DEN-induced))(NN (hepatocarcinogenesis)))(ADVP (RB (due)))(VP (VBD (increased))(NP (ADJP (NP (NN (retinoid))(NN (signaling)))(JJR (higher)))(NN (expression))(NN (p21)))(, (,))(SBAR (S (NP (NP (VBN (accompanied))(JJ (altered))(JJ (hepatic))(NN (level)))(JJ (DEN-activating))(NN (enzyme))(NNP (MGMT))(NNP (Lrat))(NNP (KO))(NN (mouse)))(ADVP (RB (also)))(VP (VBP (contribute))(SBAR (S (NP (VBN (decreased))(NN (cancer))(NN (initiation)))(VP (VBD (suppressed))(NP (NN (liver))(NN (tumor))(NN (development)))))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 515:C04.588.274.623 649:E01.370.225.124.200 711:D02.455.326.271.665.202.495 807:D08.811.913.555.500.800.650  |ES| 2:1 5:1 7:1 18:1 19:1 35:1 47:1 52:1 101:1 115:1 170:1 195:1 202:1 249:1 307:1 450:1 637:1 658:1 693:1 836:1 838:1 899:1 900:1 1135:1 1479:1 2388:1 2573:1 2735:1 2801:1 2848:1 2849:1 2850:1 2851:1 2852:1 2853:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Coffee)))(VP (VBZ (reduces))(NP (NP (NN (liver))(NN (damage))(NN (rat))(NN (model))(NN (steatohepatitis)))(: (:))(NP (VBG (underlying))(NN (mechanism))(NN (role))(NNS (polyphenols))(NNS (melanoidins)))))) |ET|  |BS| 15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249  |ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (NP (NP (JJ (Anti-tumor))(NN (effect)))(VBN (pegylated))(NN (interferon))(NN (rat))(NN (hepatocarcinogenesis))(NN (model)))) |ET|  |BS| 8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 617:D12.644.276.374.440  |ES| 19:1 72:1 75:1 849:1 900:1 2305:1 2442:1 2443:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NP (NN (BACKGROUND))(: (:)))(NP (NP (JJ (Chemopreventive))(NN (effect))(JJ (selective))(NN (cyclooxygenase-2)))(PRN (-LRB- (-LRB-))(NP (NN (COX-2)))(-RRB- (-RRB-))))(NN (inhibitor))(NN (JTE-522))(NN (diethylnitrosamine))(-LRB- (-LRB-))(NN (DEN))(-RRB- (-RRB-))(: (-)))(VBN (induced))(NN (hepatocarcinogenesis)))(VP (VBD (evaluated))(NP (NNP (Wistar))(NN (rat))))) |ET|  |BS| 225:E05.337 349:D27.505.519.389.310.500 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900  |ES| 10:1 14:1 19:1 61:1 75:1 76:1 104:1 380:1 409:1 780:1 849:1 900:1 1046:1 1749:1 1875:1 1952:1 2603:1 3972:1 3973:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBN (shown))(NP (NP (JJ (myrtenal))(, (,))(JJ (natural))(NN (monoterpene)))(, (,))(NP (VP (VBP (act))(SBAR (S (NP (JJ (antineoplastic))(NN (agent))(NN (diethylnitrosamine)))(VP (VBD (induced))(NP (JJ (phenobarbital))(VBN (promoted))(NP (JJ (experimental))(JJ (hepatocellular))(NN (carcinoma)))))))))))) |ET|  |BS| 81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575  |ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (ADVP (RBR (More))(RB (importantly)))(, (,))(NP (NP (NN (EPLE)))(VBN (hampered))(NN (tumor))(NN (development))(NN (CRC))(NN (xenograft))(NN (model)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 92:E04.936.764 93:A01.941.875  |ES| 2:1 7:1 19:1 35:1 72:1 245:1 265:1 2489:1 2767:1 2768:1 2769:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Natural))(NNS (polyphenols)))(VP (VBP (facilitate))(NP (NP (NN (elimination))(NN (HT-29))(JJ (colorectal))(NN (cancer))(NN (xenograft))(NN (chemoradiotherapy)))(: (:))(NP (NP (NN (Bcl-2)))(: (-))(NP (NN (superoxide))(NN (dismutase))(JJ (2-dependent))(NN (mechanism))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 56:D02.455.426.559.389.657.715 59:E02.186.079 92:E04.936.764 93:A01.941.875 792:A11.251.210.190.475  |ES| 17:1 18:1 19:1 104:1 146:1 147:1 154:1 156:1 162:1 265:1 1989:1 2780:1 2781:1 2782:1 2783:1 2784:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Loss))(NN (metallothionein)))(VP (VBZ (predisposes))(NP (NN (mouse))(JJ (diethylnitrosamine-induced))(NN (hepatocarcinogenesis))(VBG (activating))(NN (NF-kappaB))(NN (target))(NN (gene))))) |ET|  |BS| 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670  |ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1  |EV| 
-2.6124282852923670361633412539959  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(NP (VBN (shown))(NN (diosmin)))(VP (VBZ (attenuates))(SBAR (S (NP (NP (NN (2-AAF)))(VP (VBD (induced))(NP (NP (NP (JJ (hepatic))(NN (toxicity))(JJ (early))(NN (tumor))(NN (promotion))(NN (marker)))(PRN (-LRB- (-LRB-))(NP (NP (NN (ODC)))(, (,))(NP (NN (PCNA))(NN (Ki67))))(-RRB- (-RRB-))))(, (,))(NP (JJ (chemopreventive))(NN (efficacy))(NN (DEN))))))(VP (VBD (initiated))(NP (JJ (2-AAF))(VBN (promoted))(NN (hyper-proliferation))(NN (hepatocarcinogenesis))(NNP (Wistar))(NN (rat)))))))) |ET|  |BS| 376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740  |ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1  |EV| 
-3.5873223255998709646519273519516  |BT| (S (NP (PRP (We)))(VP (VBD (investigated))(SBAR (IN (whether))(S (NP (NN (lack))(NN (fucosylation))(JJ (consequent))(NN (loss))(NN (GDP-fucose))(NN (synthesis)))(VP (VBZ (contributes))(NP (NN (colon))(NN (carcinogenesis)))))))) |ET|  |BS| 20:G03.495 33:C04.697.098 46:A03.556.124.526.356 1125:D03.438.759.646.454.340.350.400  |ES| 19:1 32:1 113:1 207:1 221:1 252:1 403:1 843:1 845:1 3436:1 3937:1 3938:1 3939:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNS (CONCLUSIONS))(: (:)))(NP (NNP (Aliskiren)))(VP (VBZ (attenuates))(NP (NN (steatohepatitis))(NN (fibrosis))(NN (mouse))(NN (fed))(NN (MCD))(NN (diet))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 691:C23.550.355  |ES| 19:1 52:1 104:1 239:1 949:1 1791:1 2191:1 2422:1 2423:1 2426:1 2524:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (S (NP (JJ (Liver-specific))(NN (deletion))(NN (prohibitin))(CD (1)))(VP (VBP (result))(NP (JJ (spontaneous))(NN (liver))(NN (injury)))))(, (,))(NP (NP (NN (fibrosis)))(, (,))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 242:A03.620 306:G05.355.600.800 691:C23.550.355  |ES| 2:1 19:1 52:1 98:1 101:1 283:1 303:1 304:1 836:1 949:1 1059:1 2416:1 2726:1 2727:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (ADVP (RB (Overall)))(, (,))(VP (VBP (result))(NP (NN (support))(JJ (translational))(JJ (potential))(NN (silibinin))(JJ (colorectal))(NN (cancer))(NN (chemoprevention))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 145:G02.111.087.675.871 253:E02.319.162 696:V02.270.500 809:L01.178.682.920  |ES| 2:1 17:1 18:1 19:1 101:1 827:1 870:1 1364:1 2635:1 2858:1 2866:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(NP (NN (Silibinin))(NN (target))(NN (beta-catenin))(NN (IGF-1Rbeta))(NN (pathway))(JJ (chemopreventive))(NN (efficacy))(JJ (azoxymethane-induced))(NN (colon))(NN (carcinogenesis))(NN (A/J))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937  |ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (PP (IN (Among))(NP (NNS (others))))(, (,))(NP (NN (bladder))(, (,))(NN (lung))(, (,))(NN (colon))(, (,))(NN (breast))(NN (cancer))(VBN (associated))(NN (4-ABP))))) |ET|  |BS| 46:A03.556.124.526.356 182:A04.411 933:A05.810.890  |ES| 2:1 18:1 19:1 23:1 113:1 169:1 328:1 564:1 1000:1 3281:1 3282:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NNP (Prevention))(NN (rat))(NN (liver))(NN (fibrosis))(NN (carcinogenesis))(NN (coffee))(NN (caffeine)))) |ET|  |BS| 33:C04.697.098 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175  |ES| 19:1 207:1 836:1 849:1 949:1 2386:1 2898:1 2899:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNP (Cryptotanshinone)))(ADVP (RB (rapidly)))(VP (VBD (inhibited))(NP (NN (STAT3))(NN (Tyr705))(NN (phosphorylation))(NN (DU145))(NN (prostate))(NN (cancer))(NN (cell))(NN (growth))(NN (cell)))(NP (CD (96))(NN (hour))(NN (treatment))))) |ET|  |BS| 41:A11 45:G07.700.320.249 52:E02 82:D12.644.360.024.342.300 122:C14.280.383 972:G02.111.087.677  |ES| 18:1 19:1 77:1 94:1 102:1 251:1 365:1 546:1 3420:1 3423:1 3424:1 3425:1 3426:1 3427:1 3428:1  |EV| 
-2.2912990617458035558229312300682  |BT| (S (NP (NN (Inhibition))(NN (autophagy)))(VP (VBZ (potentiates))(NP (JJ (antitumor))(NN (effect))(NN (multikinase))(NN (inhibitor))(NN (sorafenib))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 43:F01.145.544 104:C04.557.470.200.025.255 390:G04.299.139.399  |ES| 19:1 75:1 303:1 304:1 380:1 1317:1 2063:1 2244:1 2499:1 2703:1 3592:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (JJ (current))(NN (study))))(, (,))(VP (VBD (investigated))(SBAR (IN (whether))(S (NP (NP (JJ (ursodeoxycholic))(NN (acid)))(PRN (-LRB- (-LRB-))(NP (NN (UDCA)))(-RRB- (-RRB-))))(VP (VBP (inhibit))(NP (NP (JJ (colitis-related))(NN (mouse))(NN (colon))(NN (carcinogenesis)))(VBN (compared))(NN (effect))(NN (sulfasalazine)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 737:D04.808.105.225.272.962 755:D02.065.884.730  |ES| 2:1 10:1 14:1 19:1 50:1 52:1 75:1 113:1 131:1 175:1 207:1 221:1 244:1 403:1 1275:1 1370:1 2630:1 2631:1 2680:1 2681:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (DT (The))(JJ (objective))(NN (study)))(VP (VBD (determine))(SBAR (S (NP (NP (NP (NP (JJ (chemopreventive))(NN (activity))(JJ (Korean))(JJ (red))(NN (ginseng))(NN (extract)))(PRN (-LRB- (-LRB-))(NP (NN (KRG)))(-RRB- (-RRB-))))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(VP (VBD (induced))(NP (NN (hepatocarcinogenesis))(NN (rat)))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 415:F01.658.500 554:D02.654.442.200 1162:B01.650.940.800.575.100.087.500  |ES| 10:1 14:1 19:1 74:1 131:1 399:1 412:1 691:1 849:1 900:1 1634:1 1875:1 1946:1 1952:1 2496:1 2916:1 4014:1 4015:1 4016:1  |EV| 
4.3916130581683914257951073523145  |BT| (SINV (ADVP (RB (Furthermore)))(, (,))(NP (NN (exposure))(JJ (colorectal))(NN (cancer))(NN (cell))(JJ (anti-periostin))(NN (antibody)))(VP (VBZ (activates))(NP (NN (apoptosis))))(VP (VBZ (potentiates))(NP (NN (effect))(NN (5-fluorouracil))(NN (chemotherapy))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 151:E02.319 560:D03.383.742.698.875.404 727:D12.776.124.486.485.114.071  |ES| 2:1 17:1 18:1 19:1 75:1 89:1 94:1 301:1 334:1 495:1 1953:1 2307:1 2499:1 2610:1 2611:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (N-acetyl-L-cysteine)))(VP (VBD (blocked))(SBAR (S (NP (NN (EGFR))(NN (activation)))(VP (VBD (reduced))(NP (JJ (N-nitrosodiethylamine-initiated))(NN (hepatocarcinogenesis))(NN (level))(NNP (Cre-Ctrl))(NN (mouse)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259  |ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (VBN (Combined))(NN (lapatinib))(NN (panobinostat))(NN (treatment)))(VP (VBD (interacted))(ADVP (RB (synergistically)))(VP (VB (inhibit))(NP (NP (NN (proliferation))(NN (colony))(NN (formation))(NN (CRC))(NN (cell))(NN (line)))(VP (VBN (tested))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383  |ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (PP (IN (On))(NP (NN (basis))(NN (finding))(, (,))(NN (development))(NN (2-aryl))(NN (benzimidazole))(NN (derivative))))(, (,))(NP (NP (JJ (new))(NN (class))(JJ (multitarget))(JJ (anticancer))(NN (agent)))(, (,))(VP (VBD (warranted))(VP (VBZ (represents))(NP (NP (JJ (novel))(NN (strategy)))(VP (VBG (improving))(NP (NN (breast))(NN (cancer))(NN (treatment))))))))) |ET|  |BS| 52:E02 259:D12.776.395.240.150.500 660:D27.505.954.248 798:D03.438.103  |ES| 2:1 18:1 19:1 23:1 35:1 546:1 712:1 728:1 891:1 927:1 1114:1 1140:1 1880:1 2363:1 2516:1 2810:1 2811:1 2812:1 2813:1 2814:1 2815:1 2816:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Nitric))(JJ (oxide-releasing))(NN (aspirin))(NN (indomethacin))(JJ (potent))(NN (inhibitor))(NN (colon))(NN (cancer))(JJ (azoxymethane-treated))(NN (rat)))(: (:))(NP (NN (effect))(JJ (molecular))(NN (target))))) |ET|  |BS| 52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420  |ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Ursodeoxycholic))(NN (acid)))(VP (VBZ (inhibits))(NP (NP (NN (Ras))(NN (mutation)))(, (,))(NP (NP (JJ (wild-type))(NN (Ras)))(NN (activation)))(, (,))(NP (NN (cyclooxygenase-2))(NN (expression))(NN (colon))(NN (cancer)))))) |ET|  |BS| 1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962  |ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Roxithromycin)))(VP (VBZ (inhibits))(S (NP (NP (JJ (constitutive))(NN (activation))(JJ (nuclear))(NN (factor)))(-LRB- (-LCB-))(NN (kappa))(-RRB- (-RCB-))(NN (B)))(VP (VBG (diminishing))(NP (JJ (oxidative))(NN (stress))(NN (rat))(NN (model))(JJ (hepatocellular))(NN (carcinoma))))))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 843:D02.540.576.500.992.630  |ES| 19:1 72:1 185:1 225:1 303:1 304:1 604:1 615:1 763:1 849:1 1256:1 2522:1 2583:1 3748:1 3749:1 3750:1 3751:1 3752:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNP (Prevention))(JJ (upper))(JJ (aerodigestive))(NN (tract))(NN (cancer))(JJ (zinc-deficient))(JJ (rodent)))(: (:))(NP (NN (inefficacy))(JJ (genetic))(JJ (pharmacological))(NN (disruption))(NN (COX-2)))) |ET|  |BS| 514:B01.050.150.900.649.865 874:D01.268.556.940 1059:H01.158.703  |ES| 18:1 19:1 76:1 104:1 864:1 1602:1 2173:1 2898:1 3101:1 3703:1 3704:1 3705:1 3706:1 3707:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (IN (After))(NP (JJ (2-week))(NN (treatment))))(, (,))(NP (NN (animal)))(VP (VBN (subjected))(SBAR (`` (``))(S (NP (NP (JJ (resistant))(NN (hepatocyte))('' (''))(NN (model))(NN (hepatocarcinogenesis)))(PRN (-LRB- (-LRB-))(NP (NP (NN (initiation))(NN (diethylnitrosamine)))(, (,))(NP (NN (selection/promotion))(JJ (2-acetylaminofluorene))(JJ (partial))(NN (hepatectomy))))(-RRB- (-RRB-))))(VP (VBD (euthanized))(NP (ADJP (CD (8))(NN (week)))(NN (treatment)))))))) |ET|  |BS| 19:B01.050 52:E02 262:A11.436.348 554:D02.654.442.200 812:G05.355.800 881:D02.065.064.150 927:E02.760.905.850 928:E04.210.556  |ES| 2:1 10:1 14:1 19:1 46:1 72:1 427:1 546:1 637:1 781:1 783:1 900:1 1909:1 1952:1 3265:1 3266:1 3267:1 3268:1 3269:1 3270:1 3271:1 3272:1 3273:1 3274:1  |EV| 
-0.65913099177952183538309327559546  |BT| (S (NP (NN (Resveratrol)))(VP (VBZ (induces))(NP (NP (NN (chemosensitization))(NN (5-fluorouracil))(NN (up-regulation))(JJ (intercellular))(NN (junction)))(, (,))(NP (JJ (Epithelial-to-mesenchymal))(NN (transition))(NN (apoptosis))(JJ (colorectal))(NN (cancer)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 142:I01.880.604 495:G04.299.335.500 560:D03.383.742.698.875.404 1054:A11.284.149.165.420  |ES| 2:1 17:1 18:1 19:1 89:1 214:1 552:1 896:1 2307:1 2946:1 3679:1 3680:1 3740:1 3741:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Inflexinol)))(VP (VBZ (inhibits))(NP (NN (colon))(NN (cancer))(NN (cell))(NN (growth))(NN (inhibition))(JJ (nuclear))(NN (factor-kappaB))(NN (activity)))(PP (IN (via))(NP (JJ (direct))(NN (interaction))(NN (p50)))))) |ET|  |BS| 41:A11 43:F01.145.544 45:G07.700.320.249 122:C14.280.383 210:D12.776.260.600  |ES| 18:1 19:1 94:1 102:1 103:1 113:1 399:1 596:1 615:1 618:1 1256:1 1891:1 2377:1 2701:1 2702:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(ADVP (RB (previously)))(VP (VBD (demonstrated))(SBAR (S (NP (NN (simvastatin)))(VP (VBZ (inhibits))(NP (NP (NN (NF-kappaB)))(SBAR (S (NP (NN (signaling))(JJ (human))(JJ (intestinal))(JJ (epithelial))(NN (cell)))(VP (VBZ (ameliorates))(NP (JJ (acute))(JJ (murine))(NN (colitis)))))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 122:C14.280.383 210:D12.776.260.600 754:D02.455.426.559.847.638.400.900  |ES| 19:1 36:1 90:1 94:1 109:1 127:1 143:1 195:1 615:1 627:1 714:1 843:1 1175:1 1527:1 2679:1 2877:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (BACKGROUND))(: (:)))(NP (NP (NNP (Drug))(NN (combination))(NN (therapy)))(VP (VBG (using))(NP (NP (NN (cisplatin))(JJ (natural))(NN (product)))(JJ (common))(NN (practice))(NN (treatment))(JJ (human))(NN (lung))(NN (cancer)))))) |ET|  |BS| 52:E02 55:B01.050.150.900.649.801.400.112.400.400 498:D01.210.375 793:D20.215 939:E02.319.310  |ES| 18:1 19:1 36:1 104:1 130:1 328:1 350:1 530:1 546:1 655:1 675:1 1046:1 1761:1 2333:1 2345:1 3296:1  |EV| 
-0.76347793337959046766627579927444  |BT| (SINV (ADVP (RB (Here)))(, (,))(VP (VBN (examined))(NP (NP (NP (JJ (chemopreventive))(JJ (potential))(NN (Acteoside)))(PRN (-LRB- (-LRB-))(NP (NN (ACT)))(-RRB- (-RRB-))))(, (,))(NP (NP (NN (plant)))(VP (VBN (derived))(NP (NP (JJ (phenylethanoid))(NN (glycoside))(JJ (environmental))(JJ (dietary))(NN (carcinogen)))(, (,))(NP (NP (NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-))))(S (: (-))(VP (VBN (induced))(NP (NN (rat))(NN (hepatocarcinogenesis))))))))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 328:B01.650 554:D02.654.442.200 595:G07.203.650.240 1199:D04.808.155.580 1200:G16.500.275 1201:D09.408  |ES| 2:1 10:1 14:1 19:1 324:1 400:1 409:1 827:1 849:1 900:1 1098:1 1721:1 1875:1 1946:1 1952:1 2125:1 2594:1 3446:1 4195:1 4196:1 4197:1 4198:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NNS (data))(NN (pterostilbene)))(VP (VBG (suppressing))(NP (NP (NN (colon))(NN (tumorigenesis)))(, (,))(NP (NN (cell))(NN (proliferation)))(NP (ADJP (RB (well))(JJ (key)))(JJ (inflammatory))(NN (marker))))(ADVP (FW (vivo))(FW (vitro)))(VP (VBP (suggest))(NP (JJ (potential))(NN (use))(NN (pterostilbene))(NN (colon))(NN (cancer))(NN (prevention)))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 158:D23.101 183:G04.299.233.750  |ES| 2:1 18:1 19:1 78:1 94:1 113:1 159:1 216:1 299:1 378:1 534:1 658:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Overall))(NN (finding)))(VP (VBP (substantiate))(SBAR (S (NP (NN (artesunate)))(VP (VBZ (promotes))(SBAR (S (NP (JJ (anti-tumour))(, (,))(JJ (anti-proliferation))(NN (apoptosis))(NN (nitrosodiethylamine)))(VP (VBD (mediated))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))) |ET|  |BS| 8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500  |ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NNP (Bortezomib)))(ADVP (RB (also)))(VP (VBD (prevented))(SBAR (S (NP (NN (activation))(JJ (hepatic))(JJ (stellate))(NN (cell)))(VP (VBD (inhibited))(NP (NN (liver))(NN (fibrosis))(NN (DEN/CDAA))(NN (model)))))))) |ET|  |BS| 122:C14.280.383 675:D01.029.260.110.500 676:C06.552.630 677:A11.561  |ES| 5:1 19:1 72:1 94:1 225:1 365:1 836:1 838:1 949:1 1944:1 2460:1 2461:1 2462:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NNP (Gefitinib)))(, (,))(NP (NN (EGFR))(NN (inhibitor)))(, (,)))(VP (VBZ (prevents))(NP (JJ (hepatocellular))(NN (carcinoma))(NN (development))(NN (rat))(NN (liver))(NN (cirrhosis))))) |ET|  |BS| 104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355  |ES| 2:1 19:1 35:1 187:1 303:1 304:1 380:1 836:1 849:1 1199:1 2718:1 3024:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (S (NP (JJ (Low))(NN (level))(NN (Caspase-3)))(VP (VBP (predict))(SBAR (S (NP (JJ (favourable))(NN (response))(JJ (5FU-based))(NN (chemotherapy)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer))))))))(: (:))(S (NP (NN (Caspase-3))(NN (inhibition))(JJ (therapeutic))(NN (approach))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404 906:D08.811.277.656.262.500.126.350.300  |ES| 17:1 18:1 19:1 103:1 104:1 249:1 494:1 495:1 541:1 911:1 997:1 1302:1 2232:1 3190:1 3615:1 3616:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNS (CONCLUSIONS))(: (:)))(S (NP (DT (The))(NN (absence))(JJ (retinoid-containing))(NN (HSC))(NN (lipid))(NN (droplet)))(VP (VBP (promote))(SBAR (S (NP (NN (HSC))(NN (activation)))(VP (VBZ (reduces))(NP (NN (hepatocarcinogenesis))))))))) |ET|  |BS| 711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393  |ES| 19:1 104:1 142:1 225:1 239:1 679:1 691:1 900:1 1534:1 2401:1 3381:1 3382:1 3383:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Combination))(NN (aspirin))(NN (sorafenib)))(VP (MD (may))(NP (JJ (effective))(NN (regimen))(NN (treat))(NN (HCC))(NN (colon))(NN (cancer))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 532:E02.183 670:D02.455.426.559.389.657.410.595.176  |ES| 18:1 19:1 113:1 441:1 491:1 1090:1 1639:1 1881:1 2063:1 2486:1 2487:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Inhibition))(JJ (retinoic))(NN (acid))(NN (hepatocarcinogenesis)))(VP (VBD (induced))(NP (NN (N-nitrosomorpholine))(NN (expression))(NN (myc))(NN (oncogene))(NN (protein))(JJ (Sprague-Dawley))(NN (rat))))) |ET|  |BS| 43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500  |ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1  |EV| 
-4.3916130581683914257951073523145  |BT| (SINV (S (VP (VBN (Taken))(ADVP (RB (together)))))(, (,))(S (VP (VBG (finding))(VP (VBP (demonstrate))(SBAR (S (NP (NN (pectolinarigenin)))(VP (MD (may))(NP (NP (NN (candidate))(NN (osteosarcoma))(NN (intervention)))(VP (VBN (linked))(NP (NP (NN (STAT3)))(NN (signaling))(JJ (inhibitory))(NN (activity)))))))))))) |ET|  |BS| 69:G02.111.087.800 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650  |ES| 2:1 19:1 106:1 195:1 251:1 399:1 491:1 502:1 927:1 1243:1 1363:1 1537:1 1538:1 1562:1 2429:1 2785:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (ADVP (RB (Herein)))(, (,))(JJ (first))(NN (time)))(, (,))(VP (VBP (investigate))(NP (FW (vivo))(NN (efficacy))(NN (silibinin))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis))(NN (A/J))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910  |ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Considerable))(NN (attention)))(VP (VBD (focused))(NP (NP (JJ (peroxisome))(JJ (proliferator-induced))(JJ (hepatocellular))(NN (carcinoma)))(, (,))(SBAR (S (NP (NN (phenomenon)))(VP (VBD (noted))(NP (NN (man)))))))(, (,))(SBAR (IN (whereas))(S (NP (JJ (limited))(NN (study)))(VP (VBP (examine))(VP (VBZ (fibrates))(SBAR (S (NP (JJ (therapeutic))(NN (drug)))(VP (VBP (induce))(NP (NP (NN (cholestasis)))(, (,))(NP (JJ (common))(NN (finding))(JJ (human))))))))))))) |ET|  |BS| 52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 104:C04.557.470.200.025.255 275:C23.888 879:C06.130.120.135 905:F02.830.104.214 912:D27.888.569.100.675 1188:D02.241.081.114.968.500 1189:M01.390  |ES| 2:1 19:1 36:1 131:1 191:1 243:1 303:1 304:1 372:1 541:1 655:1 927:1 960:1 1887:1 2131:1 2310:1 3198:1 4125:1 4126:1 4127:1 4128:1 4129:1 4130:1 4131:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (ADVP (RB (Moreover)))(, (,))(S (VP (VBG (using))(NP (NP (NN (mouse))(NN (xenograft))(NN (model)))(, (,))(NP (NN (show))(NN (treatment))(JJ (specific))(NNP (PPOX))(NN (inhibitor))(NN (acifluorfen))))))(ADVP (RB (significantly)))(VP (VBD (reduced))(NP (NP (NP (NP (NN (growth))(CD (three))(CD (seven)))(PRN (-LRB- (-LRB-))(NP (CD (42.8))(NN (%)))(-RRB- (-RRB-))))(NN (colon))(NN (cancer))(NN (line)))(NP (VBN (investigated)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875  |ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 102:1 113:1 124:1 264:1 265:1 350:1 369:1 380:1 403:1 429:1 452:1 482:1 540:1 546:1 622:1 1733:1 2770:1 2771:1 2772:1  |EV| 
-2.4802568273811971266695763915777  |BT| (S (NP (ADVP (RB (Herein)))(, (,))(JJ (first))(NN (time)))(, (,))(VP (VBP (investigate))(NP (FW (vivo))(NN (efficacy))(NN (silibinin))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis))(NN (A/J))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910  |ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NNS (data)))(ADVP (RB (thus)))(VP (VBP (establish))(SBAR (S (NP (NN (EPLE))(JJ (novel))(NN (inhibitor))(NN (Wnt))(NN (signaling)))(VP (VBP (hold))(NP (JJ (great))(NN (promise))(JJ (potential))(NN (candidate))(JJ (preclinical))(NN (evaluation))(NN (CRC))(NN (treatment)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 69:G02.111.087.800 225:E05.337 259:D12.776.395.240.150.500  |ES| 19:1 195:1 220:1 245:1 380:1 546:1 658:1 793:1 827:1 877:1 891:1 1243:1 1334:1 1494:1 2489:1 2503:1 2825:1 2826:1 2827:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (ADVP (RB (Notably)))(, (,))(NP (NN (colon))(NN (tumor))(NN (prevention))(NN (activity))(NN (sulindac)))(VP (VP (VBN (accompanied))(NP (NP (JJ (marked))(NN (induction))(JJ (lymphoid))(NN (aggregate)))(NP (JJ (proximal))(JJ (colonic))(JJ (inflammatory))(NN (mass))(NN (lesion)))))(, (,))(VP (S (NP (JJ (side))(NN (effect)))(VP (VBN (seen))(NP (JJR (lesser))(NN (degree))(NN (celecoxib)))))(, (,))(NP (NN (aspirin)))))) |ET|  |BS| 51:C04.588.274.476.411.307.180 213:F02.830.816.964 251:D02.455.426.559.847.486.875 670:D02.455.426.559.389.657.410.595.176 684:D02.065.884.247 797:A10.549.600  |ES| 2:1 7:1 19:1 75:1 113:1 399:1 677:1 724:1 736:1 869:1 871:1 1070:1 1131:1 1474:1 1967:1 2430:1 2487:1 2798:1 2801:1 2802:1 2803:1 2804:1 2805:1 2806:1 2807:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Evaluation))(JJ (chemopreventive))(NN (effect)))(NP (NNP (Fumaria))(NN (indica))(NN (N-nitrosodiethylamine))(JJ (CCl4-induced))(JJ (hepatocellular))(NN (carcinoma))(NNP (Wistar))(NN (rat))))) |ET|  |BS| 104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750  |ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (Aspirin))(NN (use))(NN (survival))(NN (diagnosis))(JJ (colorectal))(NN (cancer)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 96:I03.784 263:E01 670:D02.455.426.559.389.657.410.595.176  |ES| 17:1 18:1 19:1 274:1 1037:1 1659:1 2449:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (NNP (Alternol)))(, (,))(NP (JJ (natural))(NN (compound)))(, (,)))(VP (VBZ (exerts))(NP (NP (JJ (anti-tumour))(NN (effect))(NN (osteosarcoma)))(VP (VBG (modulating))(NP (NN (STAT3))(NN (ROS/MAPK))(NN (signalling))(NN (pathway))))))) |ET|  |BS| 12:Z01.542.049 38:Z01.058.290.120.180 40:Z01.542.248.700 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650 666:G02.111.087.800.560  |ES| 2:1 19:1 75:1 251:1 383:1 1562:1 1977:1 2333:1 2432:1 2433:1 2434:1 2435:1 2436:1 2437:1  |EV| 
-1.7418983771210889699432300403714  |BT| (FRAG (UCP (NP (JJ (Insulin-independent))(NN (promotion)))(ADVP (RB (chemically)))(NP (VBN (induced))(JJ (hepatocellular))(NN (tumor))(NN (development)))(NP (ADJP (RB (genetically))(JJ (diabetic)))(NN (mouse))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 637:D06.472.699.587.200.500.625  |ES| 7:1 19:1 35:1 52:1 303:1 412:1 898:1 2337:1 2581:1 2964:1 3596:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (S (NP (JJ (Ursolic))(NN (acid)))(VP (VBZ (inhibits))(NP (NP (NN (growth))(NN (metastasis))(JJ (human))(JJ (colorectal))(NN (cancer))(JJ (orthotopic))(JJ (nude))(NN (mouse))(NN (model)))(VP (VBG (targeting))(NP (JJ (multiple))(NN (cell))(NN (signaling))(NN (pathway)))))))(: (:))(NP (NN (chemosensitization))(NN (capecitabine)))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 113:C04.697.650 122:C14.280.383 126:G02.111.087.800 810:D03.383.742.680.245.500.425  |ES| 17:1 18:1 19:1 36:1 52:1 72:1 94:1 102:1 104:1 195:1 266:1 383:1 615:1 616:1 649:1 806:1 1275:1 2873:1 3740:1 3883:1 3884:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (VP (VBG (Combining))(NP (NN (kallistatin))(NN (gene))(NN (therapy))(NN (meloxicam))(NN (treat))(JJ (hepatocellular))(NN (carcinoma))(NN (mouse))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255  |ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Protein))(NN (kinase))(NN (Cbeta)))(NP (JJ (effective))(NN (target))(NN (chemoprevention))(NN (colon))(NN (cancer))))) |ET|  |BS| 12:Z01.542.049 253:E02.319.162 867:D08.811.913.696.620.682.700.725.049  |ES| 18:1 19:1 113:1 160:1 470:1 870:1 1639:1 2911:1 3721:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (JJ (Combined))(NN (treatment))(NN (EPLE))(NN (5-fluorouracil)))(, (,))(NP (JJ (first-line))(NN (chemotherapy))(NN (CRC))(NN (patient)))(, (,)))(VP (VBD (achieved))(NP (JJ (synergistic))(NN (effect))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 151:E02.319 560:D03.383.742.698.875.404 618:E02.186  |ES| 2:1 19:1 75:1 120:1 245:1 495:1 546:1 2012:1 2307:1 2488:1 2489:1 2490:1 2491:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (JJ (Interferon-gamma-mediated))(NN (hepatocarcinogenesis))(NN (mouse)))(VP (VBN (treated))(NP (NN (diethylnitrosamine)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 52:E02 554:D02.654.442.200 1033:D12.644.276.374.440.893  |ES| 19:1 52:1 900:1 1099:1 1952:1 3600:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (AZD6244))(NN (doxorubicin)))(VP (VBP (induce))(NP (NN (growth))(NN (suppression))(NN (apoptosis))(NN (mouse))(NN (model))(JJ (hepatocellular))(NN (carcinoma))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 45:G07.700.320.249 104:C04.557.470.200.025.255 136:D02.455.426.559.847.562.050.200.175  |ES| 19:1 52:1 72:1 89:1 102:1 243:1 303:1 304:1 599:1 2452:1 2453:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (DT (The))(NN (result)))(VP (VBP (demonstrate))(NP (NP (JJ (growth-promoting))(NN (property))(NN (periostin)))(, (,))(NP (NP (JJ (possible))(NN (role)))(VP (VBG (targeting))(NP (NN (protein))(JJ (therapeutic))(NN (option))(JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 15:F01.829.316.616 45:G07.700.320.249 52:E02 112:D12.776.097.820  |ES| 2:1 4:1 17:1 18:1 19:1 31:1 101:1 502:1 541:1 616:1 691:1 841:1 1359:1 3512:1 3832:1 3833:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Polyenephosphatidylcholine)))(VP (VBZ (prevents))(NP (NP (JJ (alcoholic))(NN (liver))(NN (disease))(NN (PPARalpha-null))(NN (mouse))(NN (attenuation))(NN (increase)))(JJ (oxidative))(NN (stress))))) |ET|  |BS| 29:B01.050.050.136.500.500 536:D12.776.826.239.500 716:G03.495.710 814:C06.552.645  |ES| 19:1 40:1 52:1 836:1 998:1 2522:1 2583:1 2718:1 2879:1 2880:1 2881:1 2882:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Colon))(NN (cancer))(NN (cell))(JJ (treated))(NNS (SDs)))(VP (VBD (exhibited))(NP (VBN (reduced))(NN (Wnt))(JJ (transcriptional))(NN (activity)))(, (,))(VP (ADVP (RB (well)))(VBN (reduced)))(NP (JJ (nuclear))(NN (beta-catenin))(NN (localization))(JJ (subsequent))(NN (reduction))(NN (active-beta-catenin))(NN (level))))) |ET|  |BS| 23:D12.776.091.249 41:A11 52:E02 175:J01.897.280.500.269 209:G02.111.087.847  |ES| 2:1 18:1 19:1 60:1 94:1 249:1 370:1 399:1 452:1 559:1 609:1 787:1 877:1 1099:1 1256:1 1319:1 2482:1 2483:1 2484:1 2485:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Beta-ionone)))(, (,))(NP (JJ (end-ring))(NN (analogue))(NN (beta-carotenoid)))(, (,))(NP (NN (constituent))(NN (vegetable))(NN (fruit)))(, (,)))(NP (VBN (analyzed))(NN (colon))(NN (cancer))(NN (chemoprevention))(NN (treatment)))) |ET|  |BS| 12:Z01.542.049 52:E02 253:E02.319.162 672:D02.455.326.271.665.202 673:A18.024.500 674:B01.650.510.956  |ES| 2:1 18:1 19:1 113:1 546:1 870:1 1168:1 1380:1 2454:1 2455:1 2456:1 2457:1 2458:1 2459:1  |EV| 
-1.6940464679419164895080029964447  |BT| (NP (NP (JJ (High-saturate-fat))(NN (diet))(NN (delay))(NN (initiation))(JJ (diethylnitrosamine-induced))(JJ (hepatocellular))(NN (carcinoma)))) |ET|  |BS| 104:C04.557.470.200.025.255 554:D02.654.442.200 694:G07.203.650.240.267  |ES| 19:1 136:1 303:1 304:1 637:1 2191:1 2732:1 4211:1  |EV| 
-3.7366058993193291826173663139343  |BT| (S (ADVP (RB (Herein)))(VP (VBP (show))(SBAR (S (NP (JJ (global))(NN (loss))(NN (ERRalpha)))(VP (VBZ (accelerates))(NP (NP (NN (development))(NN (diethylnitrosamine)))(PRN (-LRB- (-LRB-))(NP (NN (DEN)))(-RRB- (-RRB-)))))))(: (-))(S (VP (VBN (induced))(NP (JJ (hepatocellular))(NN (carcinoma))))))) |ET|  |BS| 104:C04.557.470.200.025.255 197:A01.456.505.420 554:D02.654.442.200  |ES| 10:1 14:1 19:1 32:1 35:1 303:1 304:1 409:1 428:1 429:1 529:1 660:1 1875:1 1952:1 4209:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Anthocyanin-containing))(JJ (purple-fleshed))(NN (potato)))(VP (VBP (suppress))(NP (NP (NN (colon))(NN (tumorigenesis)))(PP (IN (via))(NP (NN (elimination))(NN (colon))(NN (cancer))(NN (stem))(NN (cell))))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 308:A11.872 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087  |ES| 18:1 19:1 78:1 94:1 113:1 156:1 596:1 1106:1 2438:1 2439:1 2440:1 2441:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NP (JJ (Pre-operative))(NN (5-fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(: (-))(NP (VBN (based))(NN (chemoradiotherapy)))(ADVP (RB (locally)))(VP (VBD (advanced))(SBAR (S (NP (NP (JJ (rectal))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (UICC-II/III)))(-RRB- (-RRB-))))(VP (MD (may))(ADVP (RB (significantly)))(VP (VB (reduce))(NP (JJ (local))(NN (tumour))(NN (mass))))))))) |ET|  |BS| 8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404  |ES| 10:1 14:1 18:1 19:1 124:1 491:1 997:1 1011:1 1985:1 1986:1 1989:1 2307:1 2308:1 2361:1 2804:1 2894:1 2895:1 2896:1 2897:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NNS (OBJECTIVES)))(: (:))(NP (NP (NP (NP (DT (The))(JJ (chemopreventive))(JJ (potential))(NN (Tephrosia))(NN (purpurea))(NN (extract)))(PRN (-LRB- (-LRB-))(NP (NN (TPE)))(-RRB- (-RRB-))))(NN (N-nitrosodiethylamine))(-LRB- (-LRB-))(NN (NDEA))(-RRB- (-RRB-))(: (-)))(VP (VBN (induced))(NP (NP (NP (JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(SBAR (S (NP (JJ (Wistar))(NN (rat)))(VP (VBN (assessed)))))))))) |ET|  |BS| 104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890  |ES| 10:1 14:1 19:1 104:1 303:1 304:1 409:1 441:1 691:1 827:1 849:1 1946:1 2496:1 2602:1 2603:1 3823:1 3993:1 3994:1 3995:1 3996:1 3997:1  |EV| 
-3.675416336012290230428334325552  |BT| (S (ADVP (RB (Importantly)))(, (,))(NP (NN (GEN-27)))(VP (VBD (protected))(FRAG (NP (NP (NN (mouse))(NN (azoxymethane)))(PRN (-LRB- (-LRB-))(NP (NN (AOM)))(-RRB- (-RRB-))))(: (/))(FRAG (NP (NP (NN (dextran))(NN (sodium))(NN (sulfate)))(PRN (-LRB- (-LRB-))(NP (NN (DSS)))(-RRB- (-RRB-))))(: (-))(NP (NP (VBN (induced))(NN (colon))(NN (carcinogenesis)))(, (,))(NP (VBD (reduced))(NN (mortality)))(, (,))(NP (NN (tumor))(NN (number))(NN (tumor))(NN (volume)))))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 695:E05.318.308.985.550 1203:E05.041.124.892  |ES| 2:1 7:1 10:1 14:1 19:1 52:1 113:1 207:1 406:1 407:1 409:1 452:1 646:1 1993:1 1994:1 2413:1 2511:1 2651:1 3305:1 3306:1 3589:1 4214:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Synergistic))(JJ (chemopreventive))(NN (effect))(NN (nobiletin))(NN (atorvastatin))(NN (colon))(NN (carcinogenesis)))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 624:D27.505.696.706.018  |ES| 19:1 75:1 113:1 207:1 1946:1 3782:1 3783:1 3784:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Inhibitory))(NN (effect))(NN (silibinin))(JJ (azoxymethane-induced))(NN (colon))(NN (tumorigenesis))(NN (A/J))(NN (mouse)))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080  |ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (PP (VBG (Following))(NP (NP (JJ (initial))(CD (14))(NN (day)))(JJ (dietary))(NN (dose))(NN (range-finding))(NN (study))(JJ (male))(NN (mouse))))(, (,))(ADJP (NP (NP (JJ (mechanistic))(NN (study)))(PRN (-LRB- (-LRB-))(NP (NP (CD (0))(, (,))(CD (3))(, (,))(CD (32))(, (,))(CD (320))(NN (ppm))(NN (toxaphene))(NN (diet))(CD (7)))(, (,))(NP (CD (14)))(, (,))(NP (ADJP (CD (28))(NN (day)))(NN (treatment))))(-RRB- (-RRB-))))(VBN (performed)))(VP (VBP (examine))(SBAR (S (NP (JJ (potential))(NN (mechanism))(NN (toxaphene)))(VP (VBD (induced))(NP (NN (mouse))(NN (liver))(NN (tumor)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 275:C23.888 515:C04.588.274.623 595:G07.203.650.240 596:E02.642.249 1149:D02.455.526.439.913  |ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 162:1 412:1 458:1 546:1 827:1 836:1 862:1 960:1 988:1 1401:1 1402:1 1440:1 1890:1 2191:1 2301:1 2546:1 2594:1 3233:1 3985:1 4078:1 4160:1 4161:1 4162:1 4163:1 4164:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (Cyclooxygenase-2))(NN (inhibitor)))(VP (VBP (down-regulate))(NP (NN (osteopontin))(NN (Nr4A2-new))(JJ (therapeutic))(NN (target))(JJ (colorectal))(NN (cancer))))) |ET|  |BS| 4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360  |ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1  |EV| 
-3.5154872701554040759219788014889  |BT| (NP (NP (NN (Correlation))(NN (Wnt-2))(NN (expression))(NN (beta-catenin))(JJ (intracellular))(NN (accumulation))(JJ (Chinese))(JJ (gastric))(NN (cancer)))(: (:))(NP (NN (relevance))(NN (tumour))(NN (dissemination)))) |ET|  |BS| 8:C04 23:D12.776.091.249 924:A11.284.430.214  |ES| 18:1 19:1 60:1 86:1 104:1 115:1 795:1 1011:1 2120:1 2763:1 3252:1 3324:1 3413:1 3414:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (NN (HTHQ)))(ADVP (RB (also)))(VP (VBD (inhibited))(NP (NP (NP (JJ (2-amino-1-methyl-6-phenylimidazo))(-LRB- (-LSB-))(JJ (4,5-b))(-RRB- (-RSB-))(NN (pyridine)))(PRN (-LRB- (-LRB-))(NP (NN (PhIP)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (colon))(NN (carcinogenesis))(CD (two))(NN (stage))(NN (colon))(NN (carcinogenesis))(NN (model)))(S (VP (VBG (using))(NP (NP (NP (NN (1,2-dimethylhydrazine)))(PRN (-LRB- (-LRB-))(NP (NN (DMH)))(-RRB- (-RRB-))))(NN (initiator)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725  |ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1  |EV| 
-0.088420410676349092682357877492905  |BT| (NP (NP (JJ (Chronic))(JJ (excessive))(NN (alcohol))(NN (consumption))(NN (lead))(NN (development)))(NP (NP (JJ (alcoholic))(NN (liver))(NN (disease)))(PRN (-LRB- (-LRB-))(NP (NN (ALD)))(-RRB- (-RRB-))))(S (VP (ADVP (RB (greatly)))(VB (increase))(NP (NN (risk))(NN (liver))(NN (cancer)))))) |ET|  |BS| 61:E05.318.740.600.800 86:D01.268.556.435 650:C06.552 904:F01.145.317.269 1148:M01.066  |ES| 10:1 14:1 18:1 19:1 35:1 40:1 171:1 254:1 836:1 998:1 2387:1 2880:1 3710:1 3967:1 3982:1 3983:1 3984:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (EX (There)))(VP (VBG (increasing))(NP (NN (interest))(NP (NP (NNS (phytoestrogens))(JJ (potential))(JJ (alternative))(JJ (synthetic))(JJ (selective))(NN (estrogen))(NN (receptor))(NNS (modulators)))(PRN (-LRB- (-LRB-))(NP (NNS (SERMs)))(-RRB- (-RRB-))))(NN (prevention))(NN (therapy))(NN (breast))(NN (cancer))))) |ET|  |BS| 52:E02 375:Z01.639.100 831:D27.505.696.399.472.277.540.500 915:D06.347.360.827  |ES| 10:1 14:1 18:1 19:1 23:1 130:1 186:1 715:1 827:1 1474:1 1749:1 2311:1 2671:1 2955:1 3168:1 3217:1 3218:1 3219:1 3220:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (NP (NP (JJ (Immunohistochemical))(NN (analysis)))(JJ (late))(NN (stage))(NN (tumor))(NN (promotion))(NN (oxfendazole))(NN (rat))(NN (hepatocarcinogenesis))(NN (model)))) |ET|  |BS| 8:C04 38:Z01.058.290.120.180 40:Z01.542.248.700 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700  |ES| 7:1 19:1 72:1 661:1 849:1 900:1 1129:1 2337:1 2648:1 2649:1 2650:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (Breast))(NN (cancer)))(VP (VBG (expressing))(NP (VBN (activated))(NN (HER2/neu))(JJ (sensitive))(FW (gefitinib))(FW (vitro))(FW (vivo)))))(VP (VBZ (acquires))(NP (NN (resistance))(JJ (novel))(NN (point))(NN (mutation))(NN (HER2/neu))))) |ET|  |BS| 63:G05.360.340.024.340.375.500.791.295.305 259:D12.776.395.240.150.500 438:G05.365.590.675  |ES| 18:1 19:1 34:1 163:1 216:1 378:1 810:1 891:1 901:1 1094:1 2121:1 3308:1 3309:1 3310:1 3311:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NP (NN (5-Fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NP (NP (CD (one))(ADJP (RB (commonly))(VBN (used)))(JJ (chemotherapeutic))(NN (agent))(NN (colon))(NN (cancer))(NN (treatment)))(, (,))(NP (JJ (narrow))(JJ (therapeutic))(NN (index))(JJ (limited))(NN (toxicity)))))) |ET|  |BS| 46:A03.556.124.526.356 52:E02 560:D03.383.742.698.875.404 660:D27.505.954.248  |ES| 2:1 10:1 14:1 15:1 18:1 19:1 113:1 476:1 541:1 546:1 721:1 728:1 1010:1 1762:1 2131:1 2308:1 2404:1 2405:1 2406:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (DT (The))(NN (neurotensin))(NN (receptor-1)))(VP (VBZ (promotes))(NP (NN (tumor))(NN (development))(JJ (sporadic))(JJ (inflammation-associated))(NN (mouse))(NN (model))(NN (colon))(NN (cancer))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 53:C06.405.205.265 525:C23.550.470 1048:D12.776.543.750.100.550  |ES| 7:1 18:1 19:1 35:1 52:1 72:1 113:1 298:1 691:1 725:1 1849:1 3657:1 3820:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NP (NN (5-Fluorouracil)))(PRN (-LRB- (-LRB-))(NP (NN (5-FU)))(-RRB- (-RRB-))))(NP (NP (CD (one))(JJ (common))(JJ (chemotherapeutic))(NN (agent)))(VP (VBN (used))(NP (NP (NN (treatment))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-)))))))) |ET|  |BS| 52:E02 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 660:D27.505.954.248  |ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 655:1 728:1 1010:1 1762:1 2308:1 2404:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Preclinical))(JJ (clinical))(NN (investigation)))(VP (VBP (demonstrate))(SBAR (S (NP (NN (aspirin)))(VP (VBP (inhibit))(NP (NP (JJ (several))(NN (type))(NN (cancer))(JJ (colorectal))(NN (adenoma))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))))))) |ET|  |BS| 17:C04.557.470.035 104:C04.557.470.200.025.255 122:C14.280.383 225:E05.337 670:D02.455.426.559.389.657.410.595.176  |ES| 10:1 14:1 17:1 18:1 19:1 42:1 84:1 262:1 303:1 304:1 441:1 502:1 543:1 1370:1 1497:1 2487:1 2893:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (JJ (2-Nitrobenzo))(-LRB- (-LSB-))(-RRB- (-RSB-))(NN (pyrene))(NN (6-nitrochrysene)))(VP (VBD (induced))(NP (NP (JJ (high))(NN (incidence))(NN (liver))(NN (tumor)))(PRN (-LRB- (-LRB-))(NP (CD (91-100))(NN (%)))(-RRB- (-RRB-))))(, (,))(PP (VBG (remaining))(NP (NN (test))(NN (compound))))))(VP (VBP (induce))(NP (NN (tumor))(NN (rate)))(NP (RB (significantly))(JJR (higher))(JJ (solvent))(NN (control))))) |ET|  |BS| 8:C04 434:E05.318.308.985.525.375 515:C04.588.274.623 1173:D02.455.426.559.847.799 1174:D27.720.844  |ES| 2:1 7:1 10:1 14:1 19:1 41:1 124:1 170:1 178:1 243:1 289:1 369:1 412:1 836:1 1373:1 1378:1 1418:1 1511:1 2433:1 4062:1 4063:1 4064:1 4065:1 4066:1 4067:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NP (NP (NP (NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-))))(-RRB- (-RRB-))(NN (mouse))(JJ (susceptible))(JJ (DMH-induced))(NN (colon))(NN (carcinogenesis))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-))))(NP (NN (mouse))))(, (,))(S (NP (NN (embelin)))(ADVP (RB (significantly)))(VP (VBD (reduced))(NP (NP (NP (NN (incidence))(NN (colon))(NN (cancer))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(NP (NP (CC (+))(: (/))(CC (+))(-RRB- (-RRB-))(NN (mouse))(NN (PPARgamma)))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(: (-))))(-RRB- (-RRB-))))(NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 434:E05.318.308.985.525.375 719:D12.776.826.239.588  |ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 124:1 207:1 452:1 899:1 1511:1 2588:1 2888:1 2889:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (HTHQ)))(ADVP (RB (also)))(VP (VBD (inhibited))(NP (NP (NP (JJ (2-amino-1-methyl-6-phenylimidazo))(-LRB- (-LSB-))(JJ (4,5-b))(-RRB- (-RSB-))(NN (pyridine)))(PRN (-LRB- (-LRB-))(NP (NN (PhIP)))(-RRB- (-RRB-))))(: (-))(NP (VBN (induced))(NN (colon))(NN (carcinogenesis))(CD (two))(NN (stage))(NN (colon))(NN (carcinogenesis))(NN (model)))(S (VP (VBG (using))(NP (NP (NP (NN (1,2-dimethylhydrazine)))(PRN (-LRB- (-LRB-))(NP (NN (DMH)))(-RRB- (-RRB-))))(NN (initiator)))))))) |ET|  |BS| 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725  |ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NNS (METHODS))(: (:)))(NP (NP (JJ (UVB-induced))(NN (skin))(NN (carcinogenesis))(NN (model))(NN (SKH-1))(NN (mouse)))(VP (VBN (used))(S (VP (VBG (determining))(NP (JJ (preventive))(NN (effect))(NN (magnolol))(NN (skin))(NN (cancer))(NN (development)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 168:E05.581 785:A17.815  |ES| 18:1 19:1 35:1 52:1 72:1 75:1 104:1 207:1 476:1 565:1 1883:1 2319:1 2526:1 2750:1 2751:1 2752:1  |EV| 
-0.32512152401318417105358093976974  |BT| (S (NP (NN (Protein))(NN (kinase))(NN (D1)))(VP (VBZ (attenuates))(NP (NP (NN (tumorigenesis))(NN (colon))(NN (cancer)))(VP (VBG (modulating))(NP (NN (beta-catenin/T))(NN (cell))(NN (factor))(NN (activity))))))) |ET|  |BS| 23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 68:A11.118.637.555.567.569 1063:D08.811.913.696.620.682  |ES| 18:1 19:1 78:1 94:1 113:1 185:1 399:1 470:1 744:1 2423:1 2435:1 2911:1 3724:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (PP (IN (In))(NP (NN (addition))))(, (,))(NP (NN (alpha-mangostin)))(VP (MD (may))(VP (VB (chemopreventive))(NP (NP (NN (benefit)))(CC (and/or))(VP (VB (prove))(NP (NP (JJ (useful))(JJ (adjuvant))(NN (therapy)))(, (,))(NP (JJ (complementary))(NN (alternative))(NN (medicine))(NN (treatment))(NN (breast))(NN (cancer))))))))) |ET|  |BS| 52:E02 685:D27.505.696.477.067 687:D26.650.064 750:E02.190  |ES| 2:1 18:1 19:1 23:1 130:1 149:1 244:1 468:1 491:1 546:1 1036:1 1946:1 2246:1 2327:1 2479:1 2619:1 2669:1 2670:1 2671:1  |EV| 
-0.9047045395922452826198423281312  |BT| (S (VP (PRP$ (Our))(S (VP (VBP (result))(VP (VBP (demonstrate))(S (NP (JJ (potential))(JJ (therapeutic))(NN (role))(NN (panobinostat)))(VP (VBG (targeting))(NP (JJ (aggressive))(JJ (triple-negative))(NN (breast))(NN (cancer))(NN (cell))(NN (type)))))))))) |ET|  |BS| 15:F01.829.316.616 41:A11 52:E02 160:C04.588.180.788 162:F01.145.126.125  |ES| 18:1 19:1 23:1 26:1 31:1 94:1 101:1 502:1 538:1 541:1 543:1 616:1 658:1 827:1 3348:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Exenatide)))(PRN (-LRB- (-LRB-))(NP (NN (Ex-4)))(-RRB- (-RRB-))))(, (,))(NP (NP (JJ (potent))(NN (diabetes))(NN (drug)))(VP (VBG (targeting))(NP (NP (JJ (glucagon-like))(NN (peptide-1))(NN (receptor)))(PRN (-LRB- (-LRB-))(NP (NN (GLP-1R)))(-RRB- (-RRB-))))))(, (,))(NP (NP (JJ (protective))(JJ (non-alcoholic))(NN (fatty))(NN (liver))(NN (disease)))(PRN (-LRB- (-LRB-))(NP (NN (NAFLD)))(-RRB- (-RRB-))))) |ET|  |BS| 369:E02.319.300 577:C06.552.241.519 725:D12.776.543.750.100.021.500 726:C18.452.394.750  |ES| 2:1 10:1 14:1 19:1 22:1 186:1 191:1 493:1 616:1 836:1 998:1 2009:1 2069:1 2070:1 2604:1 2605:1 2606:1 2607:1 2608:1 2609:1  |EV| 
-3.1811798235205515084089711308479  |BT| (NP (NP (NN (PURPOSE))(: (:)))(NP (NP (NP (NP (JJ (Fatty))(NN (acid))(NN (synthase)))(PRN (-LRB- (-LRB-))(NP (NN (FAS)))(-RRB- (-RRB-))))(NP (JJ (overexpressed))(NN (lung))(NN (cancer))))(, (,))(VP (VBD (investigated))(NP (JJ (potential))(NN (use))(NN (FAS))(NN (inhibitor))(NN (chemoprevention))(NN (lung))(NN (cancer)))))) |ET|  |BS| 253:E02.319.162 921:D08.811.682.664.500.772 922:D10.251  |ES| 2:1 10:1 14:1 18:1 19:1 25:1 66:1 104:1 328:1 380:1 403:1 687:1 827:1 870:1 1275:1 1659:1 3725:1 3726:1  |EV| 
4.3916130581683914257951073523145  |BT| (FRAG (NP (NNS (CONCLUSIONS))(: (:)))(PP (DT (These))(S (VP (VBG (finding))(S (VP (VBP (suggest))(NP (NP (NN (MPT0E028))(NN (combination))(NN (sorafenib))(JJ (significant))(JJ (anti-hepatocellular))(NN (carcinoma))(NN (activity))(JJ (preclinical))(NN (model)))(, (,))(S (ADVP (RB (potentially)))(VP (VBG (suggesting))(SBAR (S (NP (JJ (novel))(JJ (therapeutic))(NN (strategy))(NN (patient)))(VP (VBD (advanced))(NP (JJ (hepatocellular))(NN (carcinoma))))))))))))))) |ET|  |BS| 50:M01.643 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500  |ES| 2:1 19:1 72:1 104:1 120:1 135:1 239:1 303:1 304:1 399:1 530:1 541:1 773:1 792:1 796:1 891:1 927:1 997:1 1009:1 1114:1 1494:1 2063:1 2539:1 2540:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Forkhead))(NN (box))(NN (transcription))(NN (factor))(NN (FOXO3a)))(VP (VBZ (suppresses))(NP (JJ (estrogen-dependent))(NN (breast))(NN (cancer))(NN (cell))(NN (proliferation))(NN (tumorigenesis))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 166:D12.776.930 183:G04.299.233.750 889:D27.505.696.399.472.277  |ES| 18:1 19:1 23:1 78:1 94:1 185:1 299:1 487:1 686:1 1918:1 3361:1 3363:1 3494:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(ADVP (RB (previously)))(VP (VBD (showed))(SBAR (S (NP (NN (embelin)))(VP (VBZ (inhibits))(NP (NN (growth))(NN (colon))(NN (cancer))(NN (cell))(NN (vitro))))))(, (,))(VP (ADVP (RB (effectively)))(VBZ (suppresses))(NP (JJ (1,2-dimethylhydrazine))(JJ (dihydrochloride-induced))(NN (colon))(NN (carcinogenesis))(NN (mouse)))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383  |ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1  |EV| 
-0.60802945243040085188113152980804  |BT| (SINV (NP (DT (These)))(VBG (finding))(ADVP (RB (strongly)))(VBP (suggest))(NP (NP (NP (NN (estrogen))(NN (play))(JJ (critical))(NN (role)))(NP (JJ (female))(NN (hepatocarcinogenesis)))))) |ET|  |BS| 15:F01.829.316.616 79:I03.450.642.693 642:M01.975 889:D27.505.696.399.472.277  |ES| 19:1 31:1 238:1 635:1 792:1 796:1 825:1 900:1 927:1 1404:1 3168:1  |EV| 
4.3916130581683914257951073523145  |BT| (S (NP (JJ (Nuclear))(NN (Maspin))(NN (expression)))(NP (ADJP (RB (highly))(JJ (predictive)))(NN (5-FU))(NN (chemotherapy))(NN (response))(NN (patient)))(VP (VBD (advanced))(NP (NN (stage))(NN (colon))(NN (cancer))))) |ET|  |BS| 50:M01.643 151:E02.319 560:D03.383.742.698.875.404  |ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1  |EV| 
4.3916130581683914257951073523145  |BT| (NP (NP (JJ (Non-steroidal))(JJ (anti-inflammatory))(NN (drug))(NN (sulindac))(JJ (promising))(NN (chemoprevention))(NN (agent))(NN (colon))(NN (cancer)))(, (,))(NP (JJ (weak))(NN (potency))(NN (side))(NN (effect))(NN (limit))(NN (use))(NN (chemoprevention))(NN (chemotherapy)))) |ET|  |BS| 151:E02.319 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500  |ES| 2:1 18:1 19:1 75:1 113:1 191:1 338:1 495:1 728:1 869:1 870:1 871:1 1517:1 1659:1 2794:1 2795:1 2796:1 2797:1  |EV| 
-4.3916130581683914257951073523145  |BT| (FRAG (ADVP (RB (Overall)))(, (,))(NP (NP (JJ (2-SeCD))(NNS (sensitises))(JJ (resistant))(NN (breast))(NN (cancer))(NN (cell))(JJ (TRAIL-based))(NN (apoptosis)))(ADVP (FW (vitro))(FW (vivo))))) |ET|  |BS| 39:G04.299.139.160 41:A11 333:D01.045 696:V02.270.500  |ES| 2:1 18:1 19:1 23:1 89:1 94:1 216:1 378:1 427:1 2858:1 3681:1 3682:1 3683:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NNS (METHODS))(: (:)))(S (NP (JJ (Male))(ADJP (ADJP (NN (C57BL/6))(NN (mouse))(NN (fed))(NN (methionine))(JJ (choline-deficient)))(PRN (-LRB- (-LRB-))(NP (NN (MCD)))(-RRB- (-RRB-))))(NN (diet)))(VP (VBP (induce))(NP (NN (steatohepatitis)))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 508:C06.552.241 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676  |ES| 10:1 14:1 19:1 52:1 104:1 243:1 565:1 1791:1 2050:1 2188:1 2191:1 2192:1 2426:1 2524:1 3635:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Evaluation))(JJ (chemopreventive))(NN (effect)))(NP (NNP (Fumaria))(NN (indica))(NN (N-nitrosodiethylamine))(JJ (CCl4-induced))(JJ (hepatocellular))(NN (carcinoma))(NNP (Wistar))(NN (rat))))) |ET|  |BS| 104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750  |ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NP (NN (PURPOSE))(: (:)))(NP (NP (NP (NN (Signal))(NN (transducer))(NN (activator))(NN (transcription-3)))(PRN (-LRB- (-LRB-))(NP (NN (STAT3)))(-RRB- (-RRB-))))(NP (JJ (downstream))(NN (growth))(NN (factor))(NN (cytokine))(NN (receptor))))(, (,)))(VP (VBZ (regulates))(NP (NP (JJ (key))(JJ (oncogenic))(NN (pathway))(JJ (non-small))(NN (cell))(NN (lung))(NN (cancer)))(PRN (-LRB- (-LRB-))(NP (NN (NSCLC)))(-RRB- (-RRB-)))))) |ET|  |BS| 82:D12.644.360.024.342.300 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 279:D27.888.569.100 897:Z01.252.245.500.375 1066:D12.776.543.750.705.852  |ES| 2:1 10:1 14:1 18:1 19:1 94:1 102:1 104:1 159:1 185:1 186:1 251:1 328:1 329:1 383:1 560:1 603:1 687:1 694:1 860:1 861:1 953:1 2676:1 2960:1 3731:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (VBN (Enhanced))(NN (liver))(NN (tumor))(NN (promotion))(NN (liver))(NN (initiation))(NN (activity)))(NP (NN (rat))(VBN (subjected))(JJ (combined))(NN (administration))(NN (omeprazole))(NN (beta-naphthoflavone))))) |ET|  |BS| 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 983:D03.383.663.283.266.450.175.100 984:D02.886.640.074.500  |ES| 7:1 19:1 164:1 399:1 637:1 836:1 849:1 2337:1 2575:1 3267:1 3466:1 3467:1 3468:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Hepatocarcinogenesis)))(VP (VBD (induced))(NP (NP (JJ (male))(NP (NP (JJ (Sprague-Dawley))(NN (rat))(JJ (chronic))(NN (feeding))(NN (2-acetylaminofluorene)))(PRN (-LRB- (-LRB-))(NP (NN (2-AAF)))(-RRB- (-RRB-))))(NN (dose))(ADJP (CD (0.05))(NN (%)))(JJ (basal))(NN (diet)))(NP (JJ (daily))(CD (5))(NN (day))(NN (week)))))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 595:G07.203.650.240 596:E02.642.249 767:D02.065.064.150 769:B01.050.150.900.649.865.635.505.700.750 881:D02.065.064.150  |ES| 10:1 14:1 19:1 369:1 412:1 578:1 783:1 849:1 1402:1 1790:1 1959:1 2191:1 2301:1 2696:1 2707:1 2942:1 3271:1 3849:1 4078:1 4184:1 4185:1  |EV| 
-0.71638334885028598364442586898804  |BT| (NP (NP (NN (Cross-talk))(NN (aryl))(NN (hydrocarbon))(NN (receptor))(JJ (mitogen-activated))(NN (protein))(NN (kinase))(NN (signaling))(NN (pathway))(NN (liver))(NN (cancer))(NN (c-raf))(JJ (transcriptional))(NN (regulation)))) |ET|  |BS| 69:G02.111.087.800 126:G02.111.087.800 142:I01.880.604 148:G12.425.143.281 209:G02.111.087.847 478:D08.811.913.696.620.682.700.567 969:D12.776.260.643.715  |ES| 4:1 18:1 19:1 186:1 195:1 383:1 438:1 470:1 559:1 836:1 3295:1 3416:1 3417:1 3418:1 3419:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNP (Nestin))(NN (silencing)))(VP (ADVP (RB (also)))(VP (VBD (upregulated))(NP (NP (NN (Axin))(, (,))(NP (NP (NN (glycogen))(NN (synthase))(NN (kinase-3))(NN (beta)))(PRN (-LRB- (-LRB-))(NP (NN (GSK-3beta)))(-RRB- (-RRB-))))(, (,))(NP (JJ (adenomatous))(NN (polyposis))(NN (coli))(PRN (-LRB- (-LRB-))(NP (NN (APC)))(-RRB- (-RRB-))))(, (,)))(NP (NP (NN (peroxisome))(JJ (proliferator-activated))(NN (receptor))(NN (alpha)))(PRN (-LRB- (-LRB-))(NP (NN (PPARa)))(-RRB- (-RRB-))))))(, (,))(VP (VBD (downregulated))(NP (NP (NN (beta-catenin)))(, (,))(NP (NN (c-Myc)))(, (,))(NP (NP (NN (cyclin))(NN (D)))(NN (MMP-7))(NN (expression))(NNP (CSC))))))) |ET|  |BS| 3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540  |ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NN (Inhibition))(NN (licorice))(NN (flavonoid))(NN (oil))(NN (glutathione))(JJ (S-transferase-positive))(NN (focus))(JJ (medium-term))(NN (rat))(NN (hepatocarcinogenesis))(NN (bioassay)))) |ET|  |BS| 43:F01.145.544 106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 534:D03.383.663.283.266.450 780:D08.811.913.225.500 849:G08.686.785.760.769.490.500 914:L01.178 1027:B01.650.940.800.575.100.401.300 1028:B01.650.940.800.575.100.401.300 1029:D10.627.700 1030:D10.627  |ES| 19:1 849:1 900:1 1431:1 1886:1 2614:1 2703:1 2744:1 2931:1 3215:1 3590:1 3591:1  |EV| 
-0.85916459194299932278227061033249  |BT| (NP (NP (NN (DESIGN))(: (:)))(NP (NP (NP (JJ (Spontaneous))(JJ (experimental))(NN (fibrogenesis)))(SBAR (S (NP (ADJP (RB (well))(JJ (diethylnitrosamine-induced)))(NN (hepatocarcinogenesis)))(VP (VBD (investigated))(NP (NP (JJ (lecithin-retinol))(NN (acyltransferase)))(PRN (-LRB- (-LRB-))(NP (NN (LRAT)))(-RRB- (-RRB-))))))))(: (-))(NP (JJ (deficient))(NN (mouse))(NN (lack))(JJ (retinoid-containing))(NN (lipid))(NN (droplet))(NNS (HSCs))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393  |ES| 10:1 14:1 19:1 52:1 104:1 263:1 403:1 690:1 787:1 900:1 2401:1 2732:1 3381:1 3383:1 3937:1 4136:1 4137:1 4138:1 4139:1 4140:1 4141:1 4142:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (JJ (Suppressive))(NN (effect))(NN (liver))(JJ (tumor-promoting))(NN (activity))(NN (rat)))(VP (VBN (subjected))(NP (JJ (combined))(NN (administration))(JJ (phenobarbital))(NN (piperonyl))(NN (butoxide))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1077:D03.383.246.118.600  |ES| 19:1 75:1 164:1 399:1 836:1 849:1 2575:1 2685:1 3267:1 3772:1 3776:1 3777:1 3778:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(VP (VBD (investigated))(NP (NP (NP (NN (expression))(NN (leptin))(NN (receptor))(CD (171))(JJ (consecutive))(NN (patient)))(PRN (-LRB- (-LRB-))(NP (NP (CD (78))(JJ (female))(CD (93))(NN (male)))(: (;))(NP (CD (71))(NN (year))))(-RRB- (-RRB-))))(NN (CRC))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 642:M01.975 1124:D06.472.699.042.500  |ES| 10:1 14:1 19:1 115:1 120:1 186:1 217:1 245:1 403:1 843:1 1402:1 1404:1 1452:1 3206:1 3930:1 3931:1 3932:1 3933:1 3934:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Simvastatin)))(VP (VP (VBZ (induces))(NP (NN (apoptosis))(JJ (human))(NN (colon))(NN (cancer))(NN (cell))(NN (tumor))(NN (xenograft))))(, (,))(VP (VBZ (attenuates))(NP (JJ (colitis-associated))(NN (colon))(NN (cancer))(NN (mouse)))))) |ET|  |BS| 8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900  |ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1  |EV| 
-2.2986266599909868091344833374023  |BT| (FRAG (PP (IN (In))(NP (NN (mouse))(NN (fed))(NN (bezafibrate))(CD (1))(NN (year))))(, (,))(NP (NP (JJ (preneoplastic))(NN (focus)))(, (,))(NP (NP (NP (NN (adenoma))(JJ (hepatocellular))(NN (carcinoma)))(VP (VBN (found))))(PRN (-LRB- (-LRB-))(CC (+))(: (/))(CC (+))(-RRB- (-RRB-))))(NP (NN (mouse)))(, (,))(NP (NP (JJ (single))(JJ (microscopic))(NN (adenoma)))(VP (VBD (found))(S (NP (NP (CD (one)))(PRN (-LRB- (-LRB-))(: (-))(: (/))(: (-))(-RRB- (-RRB-))))(NP (NN (mouse)))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 104:C04.557.470.200.025.255 426:E01.370.350.515 663:C16.320.565.398.500.330.500 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 909:D02.065.277.067  |ES| 2:1 10:1 14:1 19:1 37:1 42:1 45:1 51:1 52:1 98:1 244:1 303:1 304:1 1010:1 1431:1 1438:1 1452:1 2426:1 2846:1 3201:1 4071:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP (We)))(ADVP (RB (recently)))(VP (VBN (shown))(NP (NP (NN (I3C))(JJ (cyclic))(JJ (tetrameric))(JJ (derivative))(NN (CTet)))(VP (VBN (formulated))(NP (NP (NN (gamma-cyclodextrin)))(PRN (-LRB- (-LRB-))(NP (NN (gamma-CD)))(-RRB- (-RRB-))))(ADVP (RB (efficiently)))(VP (VBD (inhibited))(NP (JJ (cellular))(NN (proliferation))(NN (breast))(NN (cancer))(NN (cell))(NN (line)))))))) |ET|  |BS| 41:A11 122:C14.280.383 776:G01.910.645 1122:B01.050.500.500.294.700.750.700.680  |ES| 10:1 14:1 18:1 19:1 23:1 94:1 237:1 264:1 299:1 365:1 772:1 843:1 2813:1 3074:1 3916:1 3917:1 3918:1 3919:1 3920:1 3921:1 3922:1 3923:1  |EV| 
-0.65017432248487239121459424495697  |BT| (S (NP (NNP (Methylenetetrahydrofolate))(NN (reductase))(NN (gene))(NN (polymorphism))(NN (response))(JJ (fluorouracil-based))(NN (treatment)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer))(NN (patient))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 50:M01.643 52:E02 307:G05.365.795 333:D01.045 560:D03.383.742.698.875.404 606:D08.811.682.662.290  |ES| 9:1 17:1 18:1 19:1 96:1 120:1 494:1 546:1 997:1 1060:1 3636:1 3637:1  |EV| 
-2.8283210674755991931306198239326  |BT| (S (ADVP (RB (Herein)))(NP (ADJP (NN (report))(JJ (concurrent)))(NP (NN (increase))(NN (liver))(NN (progenitor))(NN (cell)))(PRN (-LRB- (-LRB-))(NP (NNS (LPCs)))(-RRB- (-RRB-))))(NP (NP (VBG (transforming))(NN (growth))(NN (factor-beta)))(PRN (-LRB- (-LRB-))(NP (NN (TGF-beta)))(-RRB- (-RRB-))))(VP (NN (diethylnitrosamine))(S (-LRB- (-LRB-))(NP (NN (DEN))(-RRB- (-RRB-))(: (-)))(VP (VBN (induced))(NP (NN (rat))(NN (hepatocarcinogenesis))(JJ (cirrhotic))(NN (liver))(NN (HCC))(NN (patient))))))) |ET|  |BS| 50:M01.643 104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 503:D12.644.276.374.687 554:D02.654.442.200  |ES| 10:1 14:1 19:1 40:1 94:1 102:1 120:1 409:1 417:1 428:1 441:1 836:1 849:1 900:1 1772:1 1773:1 1774:1 1875:1 1952:1 2968:1 4206:1 4207:1 4208:1  |EV| 
-3.5017861844116264791182402404957  |BT| (NP (NP (NNP (Hepatitis))(NN (B))(NN (virus))(-LRB- (-LRB-))(NN (HBV))(-RRB- (-RRB-))(: (-)))(NP (VBN (induced))(NN (hepatitis))(NP (NP (JJ (carcinogen-induced))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NP (JJ (associated))(NN (serum))(NN (androgen))(NN (concentration))))) |ET|  |BS| 104:C04.557.470.200.025.255 279:D27.888.569.100 782:A12.207.152.846 863:B04.280.375.650.425 892:D27.505.696.399.472.161 905:F02.830.104.214  |ES| 10:1 14:1 19:1 169:1 303:1 304:1 409:1 441:1 763:1 1422:1 1954:1 2048:1 2421:1 2741:1 3154:1 3188:1 3189:1  |EV| 
-3.1036576572999479139980394393206  |BT| (S (NP (NN (Cooperativity))(NN (E-cadherin))(NN (Smad4))(NN (loss)))(VP (VBP (promote))(NP (JJ (diffuse-type))(JJ (gastric))(NN (adenocarcinoma))(NN (metastasis))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115  |ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (VBN (Enhanced))(NP (NN (liver)))(NN (tumor))(NN (promotion))(NN (activity))(NN (rat)))(VP (VBN (subjected))(NP (JJ (combined))(NN (administration))(JJ (phenobarbital))(NN (orphenadrine))))) |ET|  |BS| 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1159:D02.092.471.600  |ES| 7:1 19:1 164:1 399:1 836:1 849:1 2337:1 2575:1 2685:1 3267:1 3466:1 4005:1  |EV| 
-2.853322271956017175398301333189  |BT| (S (VP (NP (NNP (Digital)))(VBG (karyotyping))(VP (VBZ (identifies))(NP (NN (thymidylate))(NN (synthase))(NN (amplification))(NN (mechanism))(NN (resistance))(NN (5-fluorouracil))(JJ (metastatic))(JJ (colorectal))(NN (cancer))(NN (patient)))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430  |ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (PRP$ (Our))(NN (observation)))(VP (VBP (suggest))(NP (NP (JJ (chemoprotective))(NN (effect))(NN (isorhamnetin))(NN (colon))(NN (cancer)))(VP (VBN (linked))(NP (NP (JJ (anti-inflammatory))(NN (activity))(NN (inhibition))(JJ (oncogenic))(NN (Src))(NN (activity))(JJ (consequential))(NN (loss)))(VP (JJ (nuclear))(NP (NP (NN (beta-catenin)))(, (,))(NP (NN (activity)))(NP (JJ (dependent))(NN (CSK))(NN (expression)))))))))) |ET|  |BS| 23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158  |ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NNS (Thiazolidinediones)))(VP (VBP (inhibit))(NP (NN (hepatocarcinogenesis))(NN (hepatitis))(NN (B))(JJ (virus-transgenic))(NN (mouse))(NN (peroxisome))(JJ (proliferator-activated))(NN (receptor))(JJ (gamma-independent))(NN (regulation))(NN (nucleophosmin))))) |ET|  |BS| 38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425  |ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (VP (DT (These))(VBG (finding))(VP (VBP (suggest))(S (ADVP (RB (aberrantly)))(VP (VBN (expressed))(SBAR (S (NP (NN (CARM1))(NN (tumor))(JJ (marker-positive))(NN (cell)))(VP (VBZ (promotes))(NP (NN (tumorigenesis))(JJ (early))(NN (stage))(NN (hepatocarcinogenesis))))))))))) |ET|  |BS| 32:C04.697.098.500 33:C04.697.098 41:A11 376:D23.101.140  |ES| 6:1 7:1 19:1 78:1 94:1 298:1 792:1 796:1 900:1 927:1 1128:1 1129:1 2657:1 3856:1 3857:1  |EV| 
-1.8182500579737279622349888086319  |BT| (S (NP (NN (Tandutinib)))(VP (VBZ (inhibits))(S (NP (NN (Akt/mTOR))(NN (signaling))(NN (pathway)))(VP (VBP (inhibit))(NP (NN (colon))(NN (cancer))(NN (growth))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 378:D08.811.913.696.620.682.700.755  |ES| 18:1 19:1 102:1 113:1 195:1 383:1 615:1 1370:1 2819:1 3787:1  |EV| 
-3.4800380382000639656325802206993  |BT| (NP (NP (NP (NN (Mouse))(JJ (nongenotoxic))(NNS (hepatocarcinogens)))(SBAR (S (NP (JJ (phenobarbital))(PRN (-LRB- (-LRB-))(NP (NN (PB)))(-RRB- (-RRB-)))(NN (chlordane)))(VP (VBP (induce))(ADVP (RB (hepatomegaly)))(VP (VBN (characterized))(NP (NN (hypertrophy))(NN (hyperplasia))))))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 510:C23.550.444 756:D03.383.742.698.253.650 1150:D02.455.526.439.180 1151:C06.552.416 1152:C23.300.775  |ES| 10:1 14:1 19:1 243:1 985:1 1795:1 2127:1 2685:1 3340:1 3496:1 3989:1 3990:1 3991:1 3992:1  |EV| 
-4.3916130581683914257951073523145  |BT| (NP (NP (NP (NN (Targeting))(NN (cyclooxygenase-2))(JJ (epidermal))(NN (growth))(NN (factor))(NN (receptor))(NN (prevention))(NN (treatment)))(JJ (intestinal))(NP (NN (cancer))))) |ET|  |BS| 24:D08.811.600.720.750 52:E02 64:D08.811.913.696.620.682.725.400.009.300 101:C04.588.274.476.411  |ES| 18:1 19:1 61:1 102:1 109:1 184:1 185:1 186:1 546:1 1474:1 2100:1  |EV| 
-4.3916130581683914257951073523145  |BT| (S (NP (NN (Caveolin-1)))(VP (VBZ (enhances))(NP (JJ (resveratrol-mediated))(NN (cytotoxicity))(NN (transport))(JJ (hepatocellular))(NN (carcinoma))(NN (model))))) |ET|  |BS| 104:C04.557.470.200.025.255 945:D12.644.360.024.264 946:D27.888.569.213 947:G03.495.166  |ES| 19:1 72:1 303:1 304:1 1356:1 3315:1 3316:1 3317:1 3318:1  |EV| 
-2.2172956623710291523821069858968  |BT| (FRAG (NP (NP (DT (The))(JJ (angiogenic))(NN (inducer))(NN (CYR61)))(PP (RB (differentially))(NP (NP (NP (JJ (overexpressed))(NN (breast))(NN (cancer))(NN (cell)))(VP (VBG (exhibiting))(NP (NP (JJ (high))(NN (level))(NN (Heregulin)))(PRN (-LRB- (-LRB-))(NP (NN (HRG)))(-RRB- (-RRB-))))))(, (,))(NP (NN (growth))(NN (factor)))(NP (ADVP (RB (closely)))(NP (VBN (associated))(JJ (metastatic))(NN (breast))(NN (cancer))(NN (phenotype)))))))) |ET|  |BS| 10:A01.236 41:A11 80:G05.695 113:C04.697.650 175:J01.897.280.500.269 1080:D12.644.276.860.550.750 1081:D12.644.276.860.550  |ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 102:1 169:1 178:1 185:1 236:1 249:1 337:1 691:1 855:1 1139:1 3790:1 3791:1 3792:1 3793:1 3794:1 3795:1  |EV| 
-0.80202366403313618548054364509881  |BT| (S (S (ADVP (RB (Here)))(, (,))(VP (VBD (identified))(SBAR (S (NP (JJ (novel))(NN (mechanism))(NN (alcohol)))(VP (VBZ (accelerates))(NP (NN (liver))(NN (fibrosis))))))))(: (:))(NP (NP (NN (inhibition))(JJ (antifibrotic))(NN (effect)))(SBAR (S (NP (NP (JJ (natural))(NN (killer)))(PRN (-LRB- (-LRB-))(NP (NN (NK)))(-RRB- (-RRB-))))(VP (NN (cell))(NP (NP (NN (interferon-gamma)))(PRN (-LRB- (-LRB-))(NP (NN (IFN-gamma)))(-RRB- (-RRB-))))))))) |ET|  |BS| 43:F01.145.544 259:D12.776.395.240.150.500 676:C06.552.630 751:D02.033.375 822:D02.033 1033:D12.644.276.374.440.893 1202:A11.118.637.555.567.537  |ES| 2:1 10:1 14:1 19:1 75:1 94:1 103:1 104:1 162:1 400:1 529:1 623:1 836:1 891:1 949:1 2333:1 2885:1 3710:1 4199:1 4200:1 4201:1 4202:1  |EV| 
-0.46485318172600642583347507752478  |BT| (S (S (NP (NN (Expression))(NN (retinoid))(NN (X))(NN (receptor))(NN (alpha)))(VP (VBD (decreased))(NP (CD (3))('' (')))))(: (-))(FRAG (NP (JJ (methyl-4-dimethylaminoazobenzene-induced))(JJ (hepatocellular))(NN (carcinoma))(NN (rat))))) |ET|  |BS| 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 941:D12.776.826.701.500.500 1193:D02.092.146.325  |ES| 19:1 186:1 202:1 303:1 304:1 316:1 849:1 929:1 1836:1 2573:1 4159:1  |EV| 
-0.96580867108684742561308667063713  |BT| (S (PP (IN (In))(NP (JJ (present))(NN (study))))(, (,))(VP (VBD (sought))(VP (VB (examine))(SBAR (S (NP (NN (effectiveness))(NN (honokiol))(VBG (inhibiting))(NP (NN (migration))(NN (invasion))(NN (breast))(NN (cancer))(NN (cell))))(VP (VBP (elucidate))(S (VP (VBG (underlying))(NP (JJ (molecular))(NN (mechanism))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 122:C14.280.383  |ES| 2:1 18:1 19:1 23:1 94:1 131:1 161:1 162:1 219:1 244:1 435:1 514:1 620:1 880:1 960:1 1307:1 1697:1 3573:1 3574:1  |EV| 
-0.1161147490296254858321844949387  |BT| (S (NP (DT (The))(NN (result)))(VP (VBP (suggest))(SBAR (S (NP (NN (MTHFR))(NN (genotype))(JJ (relevant))(JJ (independent))(NN (factor))(NN (patient))(NN (outcome))(JJ (5FU-based))(NN (treatment)))(VP (VBD (advanced))(NP (JJ (colorectal))(NN (cancer)))))))) |ET|  |BS| 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290  |ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1  |EV| 
-0.10986151363377416600997094064951  |BT| (NP (NP (NP (NNP (UNLABELLED))(: (:))(NN (Activation))(NN (beta-catenin)))(, (,))(NP (NP (JJ (central))(NN (effector))(JJ (canonical))(NN (Wnt))(NN (pathway)))(VP (VBD (recognized))(NP (NP (NN (oncogene)))(, (,))(NP (VBN (implicated))(JJ (hepatocellular))(NN (carcinoma)))))))) |ET|  |BS| 9:G05.360.340.024.340.375.500 23:D12.776.091.249 104:C04.557.470.200.025.255 105:G02.149.115.800.925  |ES| 2:1 19:1 24:1 60:1 87:1 104:1 303:1 304:1 383:1 570:1 877:1 977:1 2266:1 3235:1 3236:1 3237:1  |EV| 
-0.29848010625130427797557786107063  |BT| (NP (NP (NN (CONCLUSION)))(: (:))(S (NP (NP (PRP$ (Our))(NNS (data)))(VP (VBP (indicate))(SBAR (S (NP (JJ (sustained))(NN (LPS))(NN (accumulation)))(VP (VBZ (represents))(NP (JJ (pathological))(NN (mediator))(NP (NP (JJ (inflammation-associated))(JJ (hepatocellular))(NN (carcinoma)))(PRN (-LRB- (-LRB-))(NP (NN (HCC)))(-RRB- (-RRB-))))(NN (manipulation))(NN (gut))(NN (flora))))))))(VP (VBP (prevent))(SBAR (S (NP (JJ (pathogenic))(JJ (bacterial))(NN (translocation))(NN (endotoxin))(NN (absorption)))(VP (MD (may))(ADVP (RB (favorably)))(VP (VB (influence))(NP (NP (NN (liver))(NN (function))(NN (patient))(NN (cirrhosis))(NN (risk)))(VP (VBG (developing))(NP (NNP (HCC)))))))))))) |ET|  |BS| 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 327:G06.930 357:C06.552.630 417:H02.403.650 662:C23.550.355 954:G06.755.375 955:G06.755.375 956:D09.400.500 957:G06.099.112.105 958:G01.595.014 959:D23.946.123.329 960:D23.469  |ES| 10:1 14:1 19:1 33:1 104:1 120:1 171:1 303:1 304:1 441:1 491:1 590:1 658:1 733:1 793:1 836:1 867:1 1199:1 1426:1 1479:1 1618:1 1698:1 1847:1 1849:1 1882:1 2120:1 2516:1 3350:1 3351:1 3352:1 3353:1 3354:1 3355:1 3356:1 3357:1 3358:1  |EV| 
-0.077607162717697519838111475110054  |BT| (S (NP (VBN (Accelerated))(NN (liver))(NN (regeneration))(NN (hepatocarcinogenesis))(NN (mouse)))(VP (VBG (overexpressing))(NP (NN (serine-45))(JJ (mutant))(NN (beta-catenin))))) |ET|  |BS| 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 925:G10.261.326.520 926:D12.125.154.800  |ES| 19:1 52:1 60:1 811:1 836:1 900:1 3259:1 3260:1 3261:1 3262:1  |EV| 
